

<!DOCTYPE html>
<html lang="en-US">
<head>
<meta charset="UTF-8">
<script type="text/javascript">
/* <![CDATA[ */
var gform;gform||(document.addEventListener("gform_main_scripts_loaded",function(){gform.scriptsLoaded=!0}),document.addEventListener("gform/theme/scripts_loaded",function(){gform.themeScriptsLoaded=!0}),window.addEventListener("DOMContentLoaded",function(){gform.domLoaded=!0}),gform={domLoaded:!1,scriptsLoaded:!1,themeScriptsLoaded:!1,isFormEditor:()=>"function"==typeof InitializeEditor,callIfLoaded:function(o){return!(!gform.domLoaded||!gform.scriptsLoaded||!gform.themeScriptsLoaded&&!gform.isFormEditor()||(gform.isFormEditor()&&console.warn("The use of gform.initializeOnLoaded() is deprecated in the form editor context and will be removed in Gravity Forms 3.1."),o(),0))},initializeOnLoaded:function(o){gform.callIfLoaded(o)||(document.addEventListener("gform_main_scripts_loaded",()=>{gform.scriptsLoaded=!0,gform.callIfLoaded(o)}),document.addEventListener("gform/theme/scripts_loaded",()=>{gform.themeScriptsLoaded=!0,gform.callIfLoaded(o)}),window.addEventListener("DOMContentLoaded",()=>{gform.domLoaded=!0,gform.callIfLoaded(o)}))},hooks:{action:{},filter:{}},addAction:function(o,r,e,t){gform.addHook("action",o,r,e,t)},addFilter:function(o,r,e,t){gform.addHook("filter",o,r,e,t)},doAction:function(o){gform.doHook("action",o,arguments)},applyFilters:function(o){return gform.doHook("filter",o,arguments)},removeAction:function(o,r){gform.removeHook("action",o,r)},removeFilter:function(o,r,e){gform.removeHook("filter",o,r,e)},addHook:function(o,r,e,t,n){null==gform.hooks[o][r]&&(gform.hooks[o][r]=[]);var d=gform.hooks[o][r];null==n&&(n=r+"_"+d.length),gform.hooks[o][r].push({tag:n,callable:e,priority:t=null==t?10:t})},doHook:function(r,o,e){var t;if(e=Array.prototype.slice.call(e,1),null!=gform.hooks[r][o]&&((o=gform.hooks[r][o]).sort(function(o,r){return o.priority-r.priority}),o.forEach(function(o){"function"!=typeof(t=o.callable)&&(t=window[t]),"action"==r?t.apply(null,e):e[0]=t.apply(null,e)})),"filter"==r)return e[0]},removeHook:function(o,r,t,n){var e;null!=gform.hooks[o][r]&&(e=(e=gform.hooks[o][r]).filter(function(o,r,e){return!!(null!=n&&n!=o.tag||null!=t&&t!=o.priority)}),gform.hooks[o][r]=e)}});
/* ]]> */
</script>

<meta name="viewport" content="width=device-width, initial-scale=1">
<meta property="fb:app_id" content="1663747670592702">
<meta name="facebook-domain-verification" content="cgmveqx8aik93eq5j9pdshpzignquh" />
<link rel="profile" href="http://gmpg.org/xfn/11">
<link rel="pingback" href="https://xtalks.com/xmlrpc.php">
<script type="text/javascript">
/* <![CDATA[ */
window.JetpackScriptData = {"site":{"icon":"https://i0.wp.com/xtalks.com/wp-content/uploads/2017/06/cropped-Xtalks-Favicon.png?w=64\u0026ssl=1","title":"Xtalks","host":"unknown","is_wpcom_platform":false}};
/* ]]> */
</script>
<meta name='robots' content='index, follow, max-image-preview:large, max-snippet:-1, max-video-preview:-1' />
	<style>img:is([sizes="auto" i], [sizes^="auto," i]) { contain-intrinsic-size: 3000px 1500px }</style>
	<!-- Jetpack Site Verification Tags -->
<meta name="google-site-verification" content="PcIglNOqO69tgfn6O1IWZCCf3nGrDK_iTZvAsGfJDoc" />
<meta name="msvalidate.01" content="6E8EDC691FACBC78AC59792D9AE3465E" />
<script>window._wca = window._wca || [];</script>

	<!-- This site is optimized with the Yoast SEO Premium plugin v25.4 (Yoast SEO v25.4) - https://yoast.com/wordpress/plugins/seo/ -->
	<title>Biotech IPOs in 2024: Navigating the New Wave of Innovation - Xtalks</title>
<link crossorigin data-rocket-preconnect href="https://www.google-analytics.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://www.gstatic.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://s.ytimg.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://snap.licdn.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://www.googletagmanager.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://connect.facebook.net" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://ajax.googleapis.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://stats.wp.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://googleads.g.doubleclick.net" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://trackcmp.net" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://a.omappapi.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://www.linkedin.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://www.youtube.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://www.tradingview-widget.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://platform.linkedin.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://xtalks.activehosted.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://www.google.com" rel="preconnect">
<link crossorigin data-rocket-preconnect href="https://widget.tagembed.com" rel="preconnect"><link rel="preload" data-rocket-preload as="image" href="https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-1024x683.jpg" imagesrcset="https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-1024x683.jpg 1024w, https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-scaled-e1707165831193-600x400.jpg 600w, https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-300x200.jpg 300w, https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-768x512.jpg 768w, https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-1536x1024.jpg 1536w, https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-2048x1365.jpg 2048w, https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-scaled-e1707165831193.jpg 1200w" imagesizes="(max-width: 892px) 100vw, 892px" fetchpriority="high">
	<meta name="description" content="Biotech IPOs in 2024 present enticing prospects for investors. Here are 29 biotechs that went public in 2024 so far." />
	<link rel="canonical" href="https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/" />
	<meta property="og:locale" content="en_US" />
	<meta property="og:type" content="article" />
	<meta property="og:title" content="Biotech IPOs in 2024: Navigating the New Wave of Innovation" />
	<meta property="og:description" content="Biotech IPOs in 2024 present enticing prospects for investors. Here are 29 biotechs that went public in 2024 so far." />
	<meta property="og:url" content="https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/" />
	<meta property="og:site_name" content="Xtalks" />
	<meta property="article:publisher" content="https://www.facebook.com/Xtalks.Webinars" />
	<meta property="article:published_time" content="2024-12-06T00:02:14+00:00" />
	<meta property="article:modified_time" content="2025-02-20T15:11:56+00:00" />
	<meta property="og:image" content="https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-scaled-e1707165831193.jpg" />
	<meta property="og:image:width" content="1200" />
	<meta property="og:image:height" content="800" />
	<meta property="og:image:type" content="image/jpeg" />
	<meta name="author" content="Vincent Xie, MSc, Soumya Shashikumar, MBiotech" />
	<meta name="twitter:card" content="summary_large_image" />
	<meta name="twitter:creator" content="@xtalks" />
	<meta name="twitter:site" content="@xtalks" />
	<meta name="twitter:label1" content="Written by" />
	<meta name="twitter:data1" content="Vincent Xie, MSc, Soumya Shashikumar, MBiotech" />
	<meta name="twitter:label2" content="Est. reading time" />
	<meta name="twitter:data2" content="44 minutes" />
	<script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"Article","@id":"https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/#article","isPartOf":{"@id":"https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/"},"author":[{"@id":"https://xtalks.com/#/schema/person/image/bee43312968e8b7ae92ae51b1e829bbf"},{"@id":"https://xtalks.com/#/schema/person/a310e01086a4fb76f68a66b0f116b088"}],"headline":"Biotech IPOs in 2024: Navigating the New Wave of Innovation","datePublished":"2024-12-06T00:02:14+00:00","dateModified":"2025-02-20T15:11:56+00:00","mainEntityOfPage":{"@id":"https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/"},"wordCount":8768,"commentCount":0,"publisher":{"@id":"https://xtalks.com/#organization"},"image":{"@id":"https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/#primaryimage"},"thumbnailUrl":"https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-scaled-e1707165831193.jpg","keywords":["Biotech","Featured","Highlight","Initial Public Offering","IPO"],"articleSection":["Biotech Blogs","Biotech News","Biotech Videos","Blogs","Life Science Blogs","Life Science News","Life Science Videos","News","Pharma Blogs","Pharma Videos","Videos"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/#respond"]}]},{"@type":"WebPage","@id":"https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/","url":"https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/","name":"Biotech IPOs in 2024: Navigating the New Wave of Innovation - Xtalks","isPartOf":{"@id":"https://xtalks.com/#website"},"primaryImageOfPage":{"@id":"https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/#primaryimage"},"image":{"@id":"https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/#primaryimage"},"thumbnailUrl":"https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-scaled-e1707165831193.jpg","datePublished":"2024-12-06T00:02:14+00:00","dateModified":"2025-02-20T15:11:56+00:00","description":"Biotech IPOs in 2024 present enticing prospects for investors. Here are 29 biotechs that went public in 2024 so far.","breadcrumb":{"@id":"https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/#primaryimage","url":"https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-scaled-e1707165831193.jpg","contentUrl":"https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-scaled-e1707165831193.jpg","width":1200,"height":800,"caption":"Biotech IPOs present enticing prospects for investors."},{"@type":"BreadcrumbList","@id":"https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://xtalks.com/"},{"@type":"ListItem","position":2,"name":"Vitals","item":"https://xtalks.com/vitals/"},{"@type":"ListItem","position":3,"name":"Biotech IPOs in 2024: Navigating the New Wave of Innovation"}]},{"@type":"WebSite","@id":"https://xtalks.com/#website","url":"https://xtalks.com/","name":"Xtalks","description":"","publisher":{"@id":"https://xtalks.com/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://xtalks.com/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https://xtalks.com/#organization","name":"Xtalks","url":"https://xtalks.com/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://xtalks.com/#/schema/logo/image/","url":"https://xtalks.com/wp-content/uploads/2021/02/New-Logo-transparent-with-registered-trademark.png","contentUrl":"https://xtalks.com/wp-content/uploads/2021/02/New-Logo-transparent-with-registered-trademark.png","width":753,"height":275,"caption":"Xtalks"},"image":{"@id":"https://xtalks.com/#/schema/logo/image/"},"sameAs":["https://www.facebook.com/Xtalks.Webinars","https://x.com/xtalks","https://www.instagram.com/xtalks/","https://www.linkedin.com/company/xtalks-webconferences/","https://www.pinterest.ca/xtalkswebinars/","https://www.youtube.com/user/XtalksWebinars"]},{"@type":"Person","@id":"https://xtalks.com/#/schema/person/image/bee43312968e8b7ae92ae51b1e829bbf","name":"Vincent Xie, MSc","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://xtalks.com/#/schema/person/image/23494c9101089ad44ae88ce9d2f56aac","url":"https://secure.gravatar.com/avatar/?s=96&d=mm&r=g","contentUrl":"https://secure.gravatar.com/avatar/?s=96&d=mm&r=g","caption":"Vincent Xie, MSc"},"description":"Vincent Xie has a MSc in Immunology, with a strong interest and extensive experience in biomedical research. Vincent joined Xtalks as a freelance writer/contributing journalist primarily focusing on the life science industry.","url":"https://xtalks.com/author/vincent-xie-msc/"},{"@type":"Person","@id":"https://xtalks.com/#/schema/person/a310e01086a4fb76f68a66b0f116b088","name":"Soumya Shashikumar, MBiotech","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://xtalks.com/#/schema/person/image/55eb5f3d12e63ce0581b5a907eb3f14a","url":"https://secure.gravatar.com/avatar/cb5fe43d81dd10f43750c86fd7714ba30093e11d453c6f1d97859447beab7efa?s=96&d=mm&r=g","contentUrl":"https://secure.gravatar.com/avatar/cb5fe43d81dd10f43750c86fd7714ba30093e11d453c6f1d97859447beab7efa?s=96&d=mm&r=g","caption":"Soumya Shashikumar, MBiotech"},"url":"https://xtalks.com/author/soumya-shashikumar/"}]}</script>
	<!-- / Yoast SEO Premium plugin. -->


<link rel='dns-prefetch' href='//widget.tagembed.com' />
<link rel='dns-prefetch' href='//stats.wp.com' />
<link rel='dns-prefetch' href='//a.omappapi.com' />
<link rel='dns-prefetch' href='//www.googletagmanager.com' />
<link rel='dns-prefetch' href='//ajax.googleapis.com' />

<link rel="alternate" type="application/rss+xml" title="Xtalks &raquo; Feed" href="https://xtalks.com/feed/" />
<link rel="alternate" type="application/rss+xml" title="Xtalks &raquo; Comments Feed" href="https://xtalks.com/comments/feed/" />
<link rel="alternate" type="application/rss+xml" title="Xtalks &raquo; Biotech IPOs in 2024: Navigating the New Wave of Innovation Comments Feed" href="https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/feed/" />
<link rel='stylesheet' id='wc-blocks-integration-css' href='https://xtalks.com/wp-content/plugins/woocommerce-subscriptions/build/index.css?ver=8.3.0' type='text/css' media='all' />
<link rel='stylesheet' id='wp-block-library-css' href='https://xtalks.com/wp-includes/css/dist/block-library/style.min.css?ver=6.8.3' type='text/css' media='all' />
<style id='co-authors-plus-coauthors-style-inline-css' type='text/css'>
.wp-block-co-authors-plus-coauthors.is-layout-flow [class*=wp-block-co-authors-plus]{display:inline}

</style>
<style id='co-authors-plus-avatar-style-inline-css' type='text/css'>
.wp-block-co-authors-plus-avatar :where(img){height:auto;max-width:100%;vertical-align:bottom}.wp-block-co-authors-plus-coauthors.is-layout-flow .wp-block-co-authors-plus-avatar :where(img){vertical-align:middle}.wp-block-co-authors-plus-avatar:is(.alignleft,.alignright){display:table}.wp-block-co-authors-plus-avatar.aligncenter{display:table;margin-inline:auto}

</style>
<style id='co-authors-plus-image-style-inline-css' type='text/css'>
.wp-block-co-authors-plus-image{margin-bottom:0}.wp-block-co-authors-plus-image :where(img){height:auto;max-width:100%;vertical-align:bottom}.wp-block-co-authors-plus-coauthors.is-layout-flow .wp-block-co-authors-plus-image :where(img){vertical-align:middle}.wp-block-co-authors-plus-image:is(.alignfull,.alignwide) :where(img){width:100%}.wp-block-co-authors-plus-image:is(.alignleft,.alignright){display:table}.wp-block-co-authors-plus-image.aligncenter{display:table;margin-inline:auto}

</style>
<link rel='stylesheet' id='mediaelement-css' href='https://xtalks.com/wp-includes/js/mediaelement/mediaelementplayer-legacy.min.css?ver=4.2.17' type='text/css' media='all' />
<link rel='stylesheet' id='wp-mediaelement-css' href='https://xtalks.com/wp-includes/js/mediaelement/wp-mediaelement.min.css?ver=6.8.3' type='text/css' media='all' />
<style id='jetpack-sharing-buttons-style-inline-css' type='text/css'>
.jetpack-sharing-buttons__services-list{display:flex;flex-direction:row;flex-wrap:wrap;gap:0;list-style-type:none;margin:5px;padding:0}.jetpack-sharing-buttons__services-list.has-small-icon-size{font-size:12px}.jetpack-sharing-buttons__services-list.has-normal-icon-size{font-size:16px}.jetpack-sharing-buttons__services-list.has-large-icon-size{font-size:24px}.jetpack-sharing-buttons__services-list.has-huge-icon-size{font-size:36px}@media print{.jetpack-sharing-buttons__services-list{display:none!important}}.editor-styles-wrapper .wp-block-jetpack-sharing-buttons{gap:0;padding-inline-start:0}ul.jetpack-sharing-buttons__services-list.has-background{padding:1.25em 2.375em}
</style>
<link rel='stylesheet' id='view_editor_gutenberg_frontend_assets-css' href='https://xtalks.com/wp-content/plugins/toolset-blocks/public/css/views-frontend.css?ver=3.6.19' type='text/css' media='all' />
<style id='view_editor_gutenberg_frontend_assets-inline-css' type='text/css'>
.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default > span.wpv-sort-list,.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default .wpv-sort-list-item {border-color: #cdcdcd;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default .wpv-sort-list-item a {color: #444;background-color: #fff;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default a:hover,.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default a:focus {color: #000;background-color: #eee;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default .wpv-sort-list-item.wpv-sort-list-current a {color: #000;background-color: #eee;}
.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default > span.wpv-sort-list,.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default .wpv-sort-list-item {border-color: #cdcdcd;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default .wpv-sort-list-item a {color: #444;background-color: #fff;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default a:hover,.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default a:focus {color: #000;background-color: #eee;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default .wpv-sort-list-item.wpv-sort-list-current a {color: #000;background-color: #eee;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-grey > span.wpv-sort-list,.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-grey .wpv-sort-list-item {border-color: #cdcdcd;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-grey .wpv-sort-list-item a {color: #444;background-color: #eeeeee;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-grey a:hover,.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-grey a:focus {color: #000;background-color: #e5e5e5;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-grey .wpv-sort-list-item.wpv-sort-list-current a {color: #000;background-color: #e5e5e5;}
.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default > span.wpv-sort-list,.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default .wpv-sort-list-item {border-color: #cdcdcd;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default .wpv-sort-list-item a {color: #444;background-color: #fff;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default a:hover,.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default a:focus {color: #000;background-color: #eee;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-default .wpv-sort-list-item.wpv-sort-list-current a {color: #000;background-color: #eee;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-grey > span.wpv-sort-list,.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-grey .wpv-sort-list-item {border-color: #cdcdcd;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-grey .wpv-sort-list-item a {color: #444;background-color: #eeeeee;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-grey a:hover,.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-grey a:focus {color: #000;background-color: #e5e5e5;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-grey .wpv-sort-list-item.wpv-sort-list-current a {color: #000;background-color: #e5e5e5;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-blue > span.wpv-sort-list,.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-blue .wpv-sort-list-item {border-color: #0099cc;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-blue .wpv-sort-list-item a {color: #444;background-color: #cbddeb;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-blue a:hover,.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-blue a:focus {color: #000;background-color: #95bedd;}.wpv-sort-list-dropdown.wpv-sort-list-dropdown-style-blue .wpv-sort-list-item.wpv-sort-list-current a {color: #000;background-color: #95bedd;}
</style>
<style id='global-styles-inline-css' type='text/css'>
:root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--color--base: #FFFFFF;--wp--preset--color--contrast: #111111;--wp--preset--color--accent-1: #FFEE58;--wp--preset--color--accent-2: #F6CFF4;--wp--preset--color--accent-3: #503AA8;--wp--preset--color--accent-4: #686868;--wp--preset--color--accent-5: #FBFAF3;--wp--preset--color--accent-6: color-mix(in srgb, currentColor 20%, transparent);--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--font-family--system-fonts: -apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;--wp--preset--font-family--geneva-verdana: Geneva, Tahoma, Verdana, sans-serif;--wp--preset--font-family--cambria-georgia: Cambria, Georgia, serif;--wp--preset--spacing--20: 10px;--wp--preset--spacing--30: 20px;--wp--preset--spacing--40: 30px;--wp--preset--spacing--50: clamp(30px, 5vw, 50px);--wp--preset--spacing--60: clamp(30px, 7vw, 70px);--wp--preset--spacing--70: clamp(50px, 7vw, 90px);--wp--preset--spacing--80: clamp(70px, 10vw, 140px);--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:root { --wp--style--global--content-size: 850px;--wp--style--global--wide-size: calc( var(--wp--style--global--content-size) + 7% ); }:where(body) { margin: 0; }.wp-site-blocks { padding-top: var(--wp--style--root--padding-top); padding-bottom: var(--wp--style--root--padding-bottom); }.has-global-padding { padding-right: var(--wp--style--root--padding-right); padding-left: var(--wp--style--root--padding-left); }.has-global-padding > .alignfull { margin-right: calc(var(--wp--style--root--padding-right) * -1); margin-left: calc(var(--wp--style--root--padding-left) * -1); }.has-global-padding :where(:not(.alignfull.is-layout-flow) > .has-global-padding:not(.wp-block-block, .alignfull)) { padding-right: 0; padding-left: 0; }.has-global-padding :where(:not(.alignfull.is-layout-flow) > .has-global-padding:not(.wp-block-block, .alignfull)) > .alignfull { margin-left: 0; margin-right: 0; }.wp-site-blocks > .alignleft { float: left; margin-right: 2em; }.wp-site-blocks > .alignright { float: right; margin-left: 2em; }.wp-site-blocks > .aligncenter { justify-content: center; margin-left: auto; margin-right: auto; }:where(.wp-site-blocks) > * { margin-block-start: 24px; margin-block-end: 0; }:where(.wp-site-blocks) > :first-child { margin-block-start: 0; }:where(.wp-site-blocks) > :last-child { margin-block-end: 0; }:root { --wp--style--block-gap: 24px; }:root :where(.is-layout-flow) > :first-child{margin-block-start: 0;}:root :where(.is-layout-flow) > :last-child{margin-block-end: 0;}:root :where(.is-layout-flow) > *{margin-block-start: 24px;margin-block-end: 0;}:root :where(.is-layout-constrained) > :first-child{margin-block-start: 0;}:root :where(.is-layout-constrained) > :last-child{margin-block-end: 0;}:root :where(.is-layout-constrained) > *{margin-block-start: 24px;margin-block-end: 0;}:root :where(.is-layout-flex){gap: 24px;}:root :where(.is-layout-grid){gap: 24px;}.is-layout-flow > .alignleft{float: left;margin-inline-start: 0;margin-inline-end: 2em;}.is-layout-flow > .alignright{float: right;margin-inline-start: 2em;margin-inline-end: 0;}.is-layout-flow > .aligncenter{margin-left: auto !important;margin-right: auto !important;}.is-layout-constrained > .alignleft{float: left;margin-inline-start: 0;margin-inline-end: 2em;}.is-layout-constrained > .alignright{float: right;margin-inline-start: 2em;margin-inline-end: 0;}.is-layout-constrained > .aligncenter{margin-left: auto !important;margin-right: auto !important;}.is-layout-constrained > :where(:not(.alignleft):not(.alignright):not(.alignfull)){max-width: var(--wp--style--global--content-size);margin-left: auto !important;margin-right: auto !important;}.is-layout-constrained > .alignwide{max-width: var(--wp--style--global--wide-size);}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}body{font-family: var(--wp--preset--font-family--system-fonts);--wp--style--root--padding-top: 0px;--wp--style--root--padding-right: 0px;--wp--style--root--padding-bottom: 0px;--wp--style--root--padding-left: 0px;}a:where(:not(.wp-element-button)){text-decoration: underline;}:root :where(.wp-element-button, .wp-block-button__link){background-color: #32373c;border-width: 0;color: #fff;font-family: inherit;font-size: inherit;line-height: inherit;padding: calc(0.667em + 2px) calc(1.333em + 2px);text-decoration: none;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-base-color{color: var(--wp--preset--color--base) !important;}.has-contrast-color{color: var(--wp--preset--color--contrast) !important;}.has-accent-1-color{color: var(--wp--preset--color--accent-1) !important;}.has-accent-2-color{color: var(--wp--preset--color--accent-2) !important;}.has-accent-3-color{color: var(--wp--preset--color--accent-3) !important;}.has-accent-4-color{color: var(--wp--preset--color--accent-4) !important;}.has-accent-5-color{color: var(--wp--preset--color--accent-5) !important;}.has-accent-6-color{color: var(--wp--preset--color--accent-6) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-base-background-color{background-color: var(--wp--preset--color--base) !important;}.has-contrast-background-color{background-color: var(--wp--preset--color--contrast) !important;}.has-accent-1-background-color{background-color: var(--wp--preset--color--accent-1) !important;}.has-accent-2-background-color{background-color: var(--wp--preset--color--accent-2) !important;}.has-accent-3-background-color{background-color: var(--wp--preset--color--accent-3) !important;}.has-accent-4-background-color{background-color: var(--wp--preset--color--accent-4) !important;}.has-accent-5-background-color{background-color: var(--wp--preset--color--accent-5) !important;}.has-accent-6-background-color{background-color: var(--wp--preset--color--accent-6) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-base-border-color{border-color: var(--wp--preset--color--base) !important;}.has-contrast-border-color{border-color: var(--wp--preset--color--contrast) !important;}.has-accent-1-border-color{border-color: var(--wp--preset--color--accent-1) !important;}.has-accent-2-border-color{border-color: var(--wp--preset--color--accent-2) !important;}.has-accent-3-border-color{border-color: var(--wp--preset--color--accent-3) !important;}.has-accent-4-border-color{border-color: var(--wp--preset--color--accent-4) !important;}.has-accent-5-border-color{border-color: var(--wp--preset--color--accent-5) !important;}.has-accent-6-border-color{border-color: var(--wp--preset--color--accent-6) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}.has-system-fonts-font-family{font-family: var(--wp--preset--font-family--system-fonts) !important;}.has-geneva-verdana-font-family{font-family: var(--wp--preset--font-family--geneva-verdana) !important;}.has-cambria-georgia-font-family{font-family: var(--wp--preset--font-family--cambria-georgia) !important;}
:root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;}
</style>
<link rel='stylesheet' id='wscsd-front-style-css' href='https://xtalks.com/wp-content/plugins/custom-start-date-for-woocommerce-subscriptions/css/style.css?ver=1770573771' type='text/css' media='all' />
<link rel='stylesheet' id='jquery-ui-datepicker-style-css' href='//ajax.googleapis.com/ajax/libs/jqueryui/1.10.4/themes/smoothness/jquery-ui.css?ver=1.10.4' type='text/css' media='all' />
<link rel='stylesheet' id='gdpr-css' href='https://xtalks.com/wp-content/plugins/gdpr/dist/css/public.css?ver=2.1.4' type='text/css' media='all' />
<link rel='stylesheet' id='woocommerce-layout-css' href='https://xtalks.com/wp-content/plugins/woocommerce/assets/css/woocommerce-layout.css?ver=9.9.5' type='text/css' media='all' />
<style id='woocommerce-layout-inline-css' type='text/css'>

	.infinite-scroll .woocommerce-pagination {
		display: none;
	}
</style>
<link rel='stylesheet' id='woocommerce-smallscreen-css' href='https://xtalks.com/wp-content/plugins/woocommerce/assets/css/woocommerce-smallscreen.css?ver=9.9.5' type='text/css' media='only screen and (max-width: 768px)' />
<link rel='stylesheet' id='woocommerce-general-css' href='https://xtalks.com/wp-content/plugins/woocommerce/assets/css/woocommerce.css?ver=9.9.5' type='text/css' media='all' />
<style id='woocommerce-inline-inline-css' type='text/css'>
.woocommerce form .form-row .required { visibility: visible; }
</style>
<link rel='stylesheet' id='wsl-widget-css' href='https://xtalks.com/wp-content/plugins/wordpress-social-login/assets/css/style.css?ver=6.8.3' type='text/css' media='all' />
<link rel='stylesheet' id='citring-integration-css-css' href='https://xtalks.com/wp-content/plugins/wp-citrix-api/includes/assets/css/tk-citrix-integration.css?ver=1768247156' type='text/css' media='all' />
<link rel='stylesheet' id='brands-styles-css' href='https://xtalks.com/wp-content/plugins/woocommerce/assets/css/brands.css?ver=9.9.5' type='text/css' media='all' />
<link rel='stylesheet' id='xtk-style-css' href='https://xtalks.com/wp-content/themes/xtalks/style.css?ver=6.8.3' type='text/css' media='all' />
<link rel='stylesheet' id='xtk-appcss-css' href='https://xtalks.com/wp-content/themes/xtalks/assets/css/app.css?ver=1768247156' type='text/css' media='all' />
<link rel='stylesheet' id='tablepress-default-css' href='https://xtalks.com/wp-content/plugins/tablepress/css/build/default.css?ver=3.1.3' type='text/css' media='all' />
<link rel='stylesheet' id='algolia-autocomplete-css' href='https://xtalks.com/wp-content/plugins/wp-search-with-algolia/css/algolia-autocomplete.css?ver=2.10.1' type='text/css' media='all' />
<link rel='stylesheet' id='sharedaddy-css' href='https://xtalks.com/wp-content/plugins/jetpack/modules/sharedaddy/sharing.css?ver=14.8' type='text/css' media='all' />
<link rel='stylesheet' id='social-logos-css' href='https://xtalks.com/wp-content/plugins/jetpack/_inc/social-logos/social-logos.min.css?ver=14.8' type='text/css' media='all' />
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/toolset-blocks/vendor/toolset/common-es/public/toolset-common-es-frontend.js?ver=175000" id="toolset-common-es-frontend-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-includes/js/jquery/jquery.min.js?ver=3.7.1" id="jquery-core-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=3.4.1" id="jquery-migrate-js"></script>
<script type="text/javascript" id="gdpr-js-extra">
/* <![CDATA[ */
var GDPR = {"ajaxurl":"https:\/\/xtalks.com\/wp-admin\/admin-ajax.php","logouturl":"","i18n":{"aborting":"Aborting","logging_out":"You are being logged out.","continue":"Continue","cancel":"Cancel","ok":"OK","close_account":"Close your account?","close_account_warning":"Your account will be closed and all data will be permanently deleted and cannot be recovered. Are you sure?","are_you_sure":"Are you sure?","policy_disagree":"By disagreeing you will no longer have access to our site and will be logged out."},"is_user_logged_in":"","refresh":"1"};
/* ]]> */
</script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/gdpr/dist/js/public.js?ver=2.1.4" id="gdpr-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/woocommerce/assets/js/jquery-blockui/jquery.blockUI.min.js?ver=2.7.0-wc.9.9.5" id="jquery-blockui-js" defer="defer" data-wp-strategy="defer"></script>
<script type="text/javascript" id="wc-add-to-cart-js-extra">
/* <![CDATA[ */
var wc_add_to_cart_params = {"ajax_url":"\/wp-admin\/admin-ajax.php","wc_ajax_url":"\/?wc-ajax=%%endpoint%%","i18n_view_cart":"View cart","cart_url":"https:\/\/xtalks.com\/cart\/","is_cart":"","cart_redirect_after_add":"no"};
/* ]]> */
</script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/woocommerce/assets/js/frontend/add-to-cart.min.js?ver=9.9.5" id="wc-add-to-cart-js" defer="defer" data-wp-strategy="defer"></script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/woocommerce/assets/js/js-cookie/js.cookie.min.js?ver=2.1.4-wc.9.9.5" id="js-cookie-js" defer="defer" data-wp-strategy="defer"></script>
<script type="text/javascript" id="woocommerce-js-extra">
/* <![CDATA[ */
var woocommerce_params = {"ajax_url":"\/wp-admin\/admin-ajax.php","wc_ajax_url":"\/?wc-ajax=%%endpoint%%","i18n_password_show":"Show password","i18n_password_hide":"Hide password"};
/* ]]> */
</script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/woocommerce/assets/js/frontend/woocommerce.min.js?ver=9.9.5" id="woocommerce-js" defer="defer" data-wp-strategy="defer"></script>
<script type="text/javascript" src="https://stats.wp.com/s-202606.js" id="woocommerce-analytics-js" defer="defer" data-wp-strategy="defer"></script>

<!-- Google tag (gtag.js) snippet added by Site Kit -->
<!-- Google Analytics snippet added by Site Kit -->
<script type="text/javascript" src="https://www.googletagmanager.com/gtag/js?id=G-5XXFSWKDKQ" id="google_gtagjs-js" async></script>
<script type="text/javascript" id="google_gtagjs-js-after">
/* <![CDATA[ */
window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);}
gtag("set","linker",{"domains":["xtalks.com"]});
gtag("js", new Date());
gtag("set", "developer_id.dZTNiMT", true);
gtag("config", "G-5XXFSWKDKQ");
/* ]]> */
</script>
<meta name="generator" content="Site Kit by Google 1.159.0" />	<style>img#wpstats{display:none}</style>
			<noscript><style>.woocommerce-product-gallery{ opacity: 1 !important; }</style></noscript>
	
<!-- Meta Pixel Code -->
<script type='text/javascript'>
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,'script','https://connect.facebook.net/en_US/fbevents.js?v=next');
</script>
<!-- End Meta Pixel Code -->
<script type='text/javascript'>var url = window.location.origin + '?ob=open-bridge';
            fbq('set', 'openbridge', '863144310740549', url);
fbq('init', '863144310740549', {}, {
    "agent": "wordpress-6.8.3-4.1.4"
})</script><script type='text/javascript'>
    fbq('track', 'PageView', []);
  </script><style type="text/css">.recentcomments a{display:inline !important;padding:0 !important;margin:0 !important;}</style> <script> window.addEventListener("load",function(){ var c={script:false,link:false}; function ls(s) { if(!['script','link'].includes(s)||c[s]){return;}c[s]=true; var d=document,f=d.getElementsByTagName(s)[0],j=d.createElement(s); if(s==='script'){j.async=true;j.src='https://xtalks.com/wp-content/plugins/toolset-blocks/vendor/toolset/blocks/public/js/frontend.js?v=1.6.15';}else{ j.rel='stylesheet';j.href='https://xtalks.com/wp-content/plugins/toolset-blocks/vendor/toolset/blocks/public/css/style.css?v=1.6.15';} f.parentNode.insertBefore(j, f); }; function ex(){ls('script');ls('link')} window.addEventListener("scroll", ex, {once: true}); if (('IntersectionObserver' in window) && ('IntersectionObserverEntry' in window) && ('intersectionRatio' in window.IntersectionObserverEntry.prototype)) { var i = 0, fb = document.querySelectorAll("[class^='tb-']"), o = new IntersectionObserver(es => { es.forEach(e => { o.unobserve(e.target); if (e.intersectionRatio > 0) { ex();o.disconnect();}else{ i++;if(fb.length>i){o.observe(fb[i])}} }) }); if (fb.length) { o.observe(fb[i]) } } }) </script>
	<noscript>
		<link rel="stylesheet" href="https://xtalks.com/wp-content/plugins/toolset-blocks/vendor/toolset/blocks/public/css/style.css">
	</noscript>		<style>
			.algolia-search-highlight {
				background-color: #fffbcc;
				border-radius: 2px;
				font-style: normal;
			}
		</style>
		<link rel="icon" href="https://xtalks.com/wp-content/uploads/2017/06/cropped-Xtalks-Favicon-32x32.png" sizes="32x32" />
<link rel="icon" href="https://xtalks.com/wp-content/uploads/2017/06/cropped-Xtalks-Favicon-192x192.png" sizes="192x192" />
<link rel="apple-touch-icon" href="https://xtalks.com/wp-content/uploads/2017/06/cropped-Xtalks-Favicon-180x180.png" />
<meta name="msapplication-TileImage" content="https://xtalks.com/wp-content/uploads/2017/06/cropped-Xtalks-Favicon-270x270.png" />

<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-WV398W');</script>
<!-- End Google Tag Manager -->
<meta name="generator" content="WP Rocket 3.19.1.2" data-wpr-features="wpr_preconnect_external_domains wpr_oci wpr_desktop" /></head>

<body class="wp-singular post-template-default single single-post postid-130798 single-format-standard wp-theme-xtalks notice-bar-open theme-xtalks woocommerce-no-js">

	<!-- Google Tag Manager (noscript) -->
	<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WV398W"
	height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
	<!-- End Google Tag Manager (noscript) -->

			<div  class="notice-bar">
			<div  class="row">
				<div  class="small-11 columns">
					<p>Tuesday, February 10, 2026 | 11am EST: <a href="https://xtalks.com/webinars/centralize-to-modernize-a-stepwise-path-to-agile-clinical-operations/">Centralize to Modernize: A Stepwise Path to Agile Clinical Operations</a></p>
				</div>
				<div  class="small-1 columns">
					<p class="close"><a href="#" class="close-notice">X</a></p>
				</div>
			</div>
		</div>
	
<div  id="page" class="site">
	<a class="skip-link screen-reader-text" href="#content">Skip to content</a>

	<header  id="masthead" class="site-header" role="banner">
		<div  class="topbar">
			<div  class="row">
				<div class="columns">
					<form role="search" method="get" id="searchform"
    class="searchform" action="https://xtalks.com/">
    <div>
        <label class="screen-reader-text" for="s"></label>
        <input type="text" placeholder="Enter Keyword..." value="" name="s" id="s" />
    </div>
</form>
					<ul>
						
						
						<li class="search-toggle"><i class="fa fa-search"></i></li>

													<li class="highlight-item"><a class="login" href="https://xtalks.com/login/">LOGIN</a></li>
						
																				<li class="highlight-item highlighted">
								<a class="join" href="https://xtalks.com/register/" class="xtk_btn orange">
									JOIN								</a>
							</li>
																		</ul>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="columns small-12">
				<div class="header-navigation">
					<div class="site-branding">
													<a href="https://xtalks.com/" rel="home">
								<img src="https://xtalks.com/wp-content/themes/xtalks/assets/img/xtalks_logo.png" width="200" height="73" alt="Xtalks" />							</a>
											</div><!-- .site-branding -->
					<button>
						<i class="fa fa-bars" aria-hidden="true"></i>
					</button>
					<nav class="main-navigation" role="navigation">
						<div class="menu-primary-menu-container"><ul id="menu-primary-menu" class="menu"><li id="menu-item-222" class="menu-item menu-item-type-post_type_archive menu-item-object-webinars menu-item-222"><a href="https://xtalks.com/webinars/">Webinars</a></li>
<li id="menu-item-10013" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-10013"><a href="https://xtalks.com/webinars/">Industries</a>
<ul class="sub-menu">
	<li id="menu-item-10016" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-10016"><a href="https://xtalks.com/life-sciences/">All Life Sciences</a></li>
	<li id="menu-item-188832" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188832"><a href="https://xtalks.com/pharma/">Pharma</a></li>
	<li id="menu-item-188828" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188828"><a href="https://xtalks.com/biotech/">Biotech</a></li>
	<li id="menu-item-10014" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-10014"><a href="https://xtalks.com/medtech/">Medtech</a></li>
	<li id="menu-item-124860" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-124860"><a href="https://xtalks.com/healthcare/">Healthcare</a></li>
	<li id="menu-item-188831" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188831"><a href="https://xtalks.com/research/">Research</a></li>
	<li id="menu-item-10015" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-10015"><a href="https://xtalks.com/food-industry/">Food</a></li>
</ul>
</li>
<li id="menu-item-225" class="menu-item menu-item-type-post_type menu-item-object-page current_page_parent menu-item-has-children menu-item-225"><a href="https://xtalks.com/vitals/">News &#038; Features</a>
<ul class="sub-menu">
	<li id="menu-item-11815" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-11815"><a href="https://xtalks.com/vitals/">All Xtalks Editorial</a></li>
	<li id="menu-item-10980" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-10980"><a href="https://xtalks.com/category/news/">News</a></li>
	<li id="menu-item-10981" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-10981"><a href="https://xtalks.com/category/blogs/">Blogs</a></li>
	<li id="menu-item-10983" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-10983"><a href="https://xtalks.com/category/videos/">Videos</a></li>
	<li id="menu-item-11814" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-11814"><a href="https://xtalks.com/category/quizzes-polls/">Quizzes &#038; Polls</a></li>
	<li id="menu-item-165997" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-165997"><a href="https://xtalks.com/category/pharmaville/">Pharmaville</a></li>
	<li id="menu-item-123069" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-123069"><a href="https://xtalks.com/category/spotlight/">Xtalks Spotlight</a></li>
	<li id="menu-item-90060" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-90060"><a href="https://xtalks.com/category/life-science-podcast/">Life Science Podcast</a></li>
	<li id="menu-item-128922" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-128922"><a href="https://clinicaledge.xtalks.com/magazine/resource-hub/">Xtalks Clinical Edge</a></li>
	<li id="menu-item-188812" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188812"><a href="https://xtalks.com/category/blogs/life-science-blogs/xtalks-community-blogs/">Community Features</a></li>
	<li id="menu-item-111258" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-111258"><a href="https://xtalks.com/peer-circles/">Peer Circles</a></li>
</ul>
</li>
<li id="menu-item-73271" class="hide-jobs menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-73271"><a href="https://xtalks.com/life-science-jobs/">Industry Jobs</a>
<ul class="sub-menu">
	<li id="menu-item-73274" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-73274"><a href="https://xtalks.com/job/">Search Jobs</a></li>
	<li id="menu-item-73275" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-73275"><a href="https://xtalks.com/create-job/">Post Job</a></li>
	<li id="menu-item-129282" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-129282"><a href="https://xtalks.com/xtalks-talent-acquisition-branding-bundle-position-your-organization-to-attract-elite-talent/">Talent Acquisition &#038; Branding Bundle</a></li>
</ul>
</li>
<li id="menu-item-9013" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-9013"><a href="https://xtalks.com/why-host-a-webinar/">Partner With Us</a>
<ul class="sub-menu">
	<li id="menu-item-178258" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-178258"><a href="https://xtalks.com/partner-with-us/">All Services</a></li>
	<li id="menu-item-178259" class="menu-item menu-item-type-post_type menu-item-object-product menu-item-178259"><a href="https://xtalks.com/product/xtalks-webinars/">Host a Webinar</a></li>
	<li id="menu-item-178264" class="menu-item menu-item-type-post_type menu-item-object-product menu-item-178264"><a href="https://xtalks.com/product/xtalks-spotlight/">Spotlight Videos</a></li>
	<li id="menu-item-178265" class="menu-item menu-item-type-post_type menu-item-object-product menu-item-178265"><a href="https://xtalks.com/product/xtalks-editorial-feature/">Editorial Features</a></li>
	<li id="menu-item-178266" class="menu-item menu-item-type-post_type menu-item-object-product menu-item-178266"><a href="https://xtalks.com/product/xtalks-clinical-edge-digital-magazine/">Xtalks Clinical Edge Magazine</a></li>
	<li id="menu-item-178267" class="menu-item menu-item-type-post_type menu-item-object-product menu-item-178267"><a href="https://xtalks.com/product/xtalks-life-science-podcast/">Life Science Podcast</a></li>
	<li id="menu-item-178270" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-178270"><a href="https://xtalks.com/partner-with-us/#h-email-marketing-land-your-message-in-the-right-inboxes">Email Marketing</a></li>
	<li id="menu-item-59552" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-59552"><a href="https://xtalks.com/category/blogs/xtalks-marketing-insights/">Marketing Insights Blog</a></li>
</ul>
</li>
<li id="menu-item-238" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-238"><a href="https://xtalks.com/about/">About</a>
<ul class="sub-menu">
	<li id="menu-item-188850" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188850"><a href="https://xtalks.com/about/">About Us</a></li>
	<li id="menu-item-9770" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-9770"><a href="https://xtalks.com/frequently-asked-questions/">Frequently Asked Questions</a></li>
	<li id="menu-item-9771" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-9771"><a href="https://xtalks.com/team/">Xtalks Team</a></li>
	<li id="menu-item-9772" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-9772"><a href="https://xtalks.com/register/">Join The Community</a></li>
</ul>
</li>
<li id="menu-item-237" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-237"><a href="https://xtalks.com/contact/">Contact</a></li>
</ul></div>					</nav>
				</div>
			</div>
		</div>
		<div  class="flyout-nav">
			<form role="search" method="get" id="searchform"
    class="searchform" action="https://xtalks.com/">
    <div>
        <label class="screen-reader-text" for="s"></label>
        <input type="text" placeholder="Enter Keyword..." value="" name="s" id="s" />
    </div>
</form>
			<div class="menu-primary-menu-container"><ul id="menu-primary-menu-1" class="menu"><li class="menu-item menu-item-type-post_type_archive menu-item-object-webinars menu-item-222"><a href="https://xtalks.com/webinars/">Webinars</a></li>
<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-has-children menu-item-10013"><a href="https://xtalks.com/webinars/">Industries</a>
<ul class="sub-menu">
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-10016"><a href="https://xtalks.com/life-sciences/">All Life Sciences</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188832"><a href="https://xtalks.com/pharma/">Pharma</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188828"><a href="https://xtalks.com/biotech/">Biotech</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-10014"><a href="https://xtalks.com/medtech/">Medtech</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-124860"><a href="https://xtalks.com/healthcare/">Healthcare</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188831"><a href="https://xtalks.com/research/">Research</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-10015"><a href="https://xtalks.com/food-industry/">Food</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page current_page_parent menu-item-has-children menu-item-225"><a href="https://xtalks.com/vitals/">News &#038; Features</a>
<ul class="sub-menu">
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-11815"><a href="https://xtalks.com/vitals/">All Xtalks Editorial</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-10980"><a href="https://xtalks.com/category/news/">News</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-10981"><a href="https://xtalks.com/category/blogs/">Blogs</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-10983"><a href="https://xtalks.com/category/videos/">Videos</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-11814"><a href="https://xtalks.com/category/quizzes-polls/">Quizzes &#038; Polls</a></li>
	<li class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-165997"><a href="https://xtalks.com/category/pharmaville/">Pharmaville</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-123069"><a href="https://xtalks.com/category/spotlight/">Xtalks Spotlight</a></li>
	<li class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-90060"><a href="https://xtalks.com/category/life-science-podcast/">Life Science Podcast</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-128922"><a href="https://clinicaledge.xtalks.com/magazine/resource-hub/">Xtalks Clinical Edge</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188812"><a href="https://xtalks.com/category/blogs/life-science-blogs/xtalks-community-blogs/">Community Features</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-111258"><a href="https://xtalks.com/peer-circles/">Peer Circles</a></li>
</ul>
</li>
<li class="hide-jobs menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-73271"><a href="https://xtalks.com/life-science-jobs/">Industry Jobs</a>
<ul class="sub-menu">
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-73274"><a href="https://xtalks.com/job/">Search Jobs</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-73275"><a href="https://xtalks.com/create-job/">Post Job</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-129282"><a href="https://xtalks.com/xtalks-talent-acquisition-branding-bundle-position-your-organization-to-attract-elite-talent/">Talent Acquisition &#038; Branding Bundle</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-9013"><a href="https://xtalks.com/why-host-a-webinar/">Partner With Us</a>
<ul class="sub-menu">
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-178258"><a href="https://xtalks.com/partner-with-us/">All Services</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-product menu-item-178259"><a href="https://xtalks.com/product/xtalks-webinars/">Host a Webinar</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-product menu-item-178264"><a href="https://xtalks.com/product/xtalks-spotlight/">Spotlight Videos</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-product menu-item-178265"><a href="https://xtalks.com/product/xtalks-editorial-feature/">Editorial Features</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-product menu-item-178266"><a href="https://xtalks.com/product/xtalks-clinical-edge-digital-magazine/">Xtalks Clinical Edge Magazine</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-product menu-item-178267"><a href="https://xtalks.com/product/xtalks-life-science-podcast/">Life Science Podcast</a></li>
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-178270"><a href="https://xtalks.com/partner-with-us/#h-email-marketing-land-your-message-in-the-right-inboxes">Email Marketing</a></li>
	<li class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-59552"><a href="https://xtalks.com/category/blogs/xtalks-marketing-insights/">Marketing Insights Blog</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-238"><a href="https://xtalks.com/about/">About</a>
<ul class="sub-menu">
	<li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188850"><a href="https://xtalks.com/about/">About Us</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-9770"><a href="https://xtalks.com/frequently-asked-questions/">Frequently Asked Questions</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-9771"><a href="https://xtalks.com/team/">Xtalks Team</a></li>
	<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-9772"><a href="https://xtalks.com/register/">Join The Community</a></li>
</ul>
</li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-237"><a href="https://xtalks.com/contact/">Contact</a></li>
</ul></div>		</div>
	</header><!-- #masthead -->

	<div  id="content" class="site-content">

	<div  id="primary" class="content-area">
		<main id="main" class="site-main" role="main">

				
		<article id="post-130798" class="single-post post-130798 post type-post status-publish format-standard has-post-thumbnail hentry category-biotech-blogs category-biotech-news category-biotech-videos category-blogs category-life-science-blogs category-life-science-news category-life-science-videos category-news category-pharma-blogs category-pharma-videos category-videos tag-biotech tag-featured tag-highlight tag-initial-public-offering tag-ipo webinar-topics-life-science">
			<div class="row">
				<!-- <div class="small-12 medium-1 columns show-for-medium"> -->
				<!-- </div> -->
				<div class="small-12 small-centered medium-9 columns">
					<header class="entry-header">
						<h1>Biotech IPOs in 2024: Navigating the New Wave of Innovation</h1>

						
						<div class="entry-meta">
							<span class="posted-on">
								<strong>Posted on:</strong> <time class="entry-date published" datetime="2024-12-05T19:02:14-05:00">December 5, 2024</time> in <a href="https://xtalks.com/category/news/">News</a> | <a href="https://xtalks.com/category/blogs/life-science-blogs/biotech-blogs/">Biotech Blogs</a> | <a href="https://xtalks.com/category/news/life-science-news/biotech-news/">Biotech News</a> | <a href="https://xtalks.com/category/videos/life-science-videos/biotech-videos/">Biotech Videos</a> | <a href="https://xtalks.com/category/blogs/">Blogs</a> | <a href="https://xtalks.com/category/blogs/life-science-blogs/">Life Science Blogs</a> | <a href="https://xtalks.com/category/news/life-science-news/">Life Science News</a> | <a href="https://xtalks.com/category/videos/life-science-videos/">Life Science Videos</a> | <a href="https://xtalks.com/category/blogs/life-science-blogs/pharma-blogs/">Pharma Blogs</a> | <a href="https://xtalks.com/category/videos/life-science-videos/pharma-videos/">Pharma Videos</a> | <a href="https://xtalks.com/category/videos/">Videos</a>								<br>
								<strong>By: </strong> <a href="https://xtalks.com/author/vincent-xie-msc/" title="Posts by Vincent Xie, MSc" class="author url fn" rel="author">Vincent Xie, MSc</a> and <a href="https://xtalks.com/author/soumya-shashikumar/" title="Posts by Soumya Shashikumar, MBiotech" class="author url fn" rel="author">Soumya Shashikumar, MBiotech</a>							</span>

							<div class="sharedaddy sd-sharing-enabled"><div class="robots-nocontent sd-block sd-social sd-social-icon sd-sharing"><h3 class="sd-title">Share this:</h3><div class="sd-content"><ul><li class="share-linkedin"><a rel="nofollow noopener noreferrer"
				data-shared="sharing-linkedin-130798"
				class="share-linkedin sd-button share-icon no-text"
				href="https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/?share=linkedin"
				target="_blank"
				aria-labelledby="sharing-linkedin-130798"
				>
				<span id="sharing-linkedin-130798" hidden>Click to share on LinkedIn (Opens in new window)</span>
				<span>LinkedIn</span>
			</a></li><li class="share-facebook"><a rel="nofollow noopener noreferrer"
				data-shared="sharing-facebook-130798"
				class="share-facebook sd-button share-icon no-text"
				href="https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/?share=facebook"
				target="_blank"
				aria-labelledby="sharing-facebook-130798"
				>
				<span id="sharing-facebook-130798" hidden>Click to share on Facebook (Opens in new window)</span>
				<span>Facebook</span>
			</a></li><li class="share-x"><a rel="nofollow noopener noreferrer"
				data-shared="sharing-x-130798"
				class="share-x sd-button share-icon no-text"
				href="https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/?share=x"
				target="_blank"
				aria-labelledby="sharing-x-130798"
				>
				<span id="sharing-x-130798" hidden>Click to share on X (Opens in new window)</span>
				<span>X</span>
			</a></li><li class="share-reddit"><a rel="nofollow noopener noreferrer"
				data-shared="sharing-reddit-130798"
				class="share-reddit sd-button share-icon no-text"
				href="https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/?share=reddit"
				target="_blank"
				aria-labelledby="sharing-reddit-130798"
				>
				<span id="sharing-reddit-130798" hidden>Click to share on Reddit (Opens in new window)</span>
				<span>Reddit</span>
			</a></li><li class="share-email"><a rel="nofollow noopener noreferrer" data-shared="sharing-email-130798" class="share-email sd-button share-icon no-text" href="/cdn-cgi/l/email-protection#2c135f594e46494f581109196e7f444d5e4948091e1c7c435f58091968091e1c6e454358494f44091e1c657c635f091e1c4542091e1c1e1c1e18091f6d091e1c624d5a454b4d5845424b091e1c584449091e1c62495b091e1c7b4d5a49091e1c434a091e1c654242435a4d584543420a0f1c1f14174e434855114458585c5f091f6d091e6a091e6a54584d40475f024f4341091e6a4e454358494f4401455c435f014542011e1c1e1801424d5a454b4d5845424b015844490142495b015b4d5a4901434a01454242435a4d58454342011f1b1c15091e6a0a0f1c1f14175f444d5e491149414d4540" target="_blank" aria-labelledby="sharing-email-130798" data-email-share-error-title="Do you have email set up?" data-email-share-error-text="If you&#039;re having problems sharing via email, you might not have email set up for your browser. You may need to create a new email yourself." data-email-share-nonce="de280edd36" data-email-share-track-url="https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/?share=email">
				<span id="sharing-email-130798" hidden>Click to email a link to a friend (Opens in new window)</span>
				<span>Email</span>
			</a></li><li class="share-end"></li></ul></div></div></div>
							<a class="xtk_btn orange subscribe scroll" href="#subscribe">Subscribe</a>
						</div>
						<div class="hero-image">
							<img width="892" height="595" src="https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-1024x683.jpg" class="attachment-large size-large wp-post-image" alt="Biotech IPOs in 2024" decoding="async" fetchpriority="high" srcset="https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-1024x683.jpg 1024w, https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-scaled-e1707165831193-600x400.jpg 600w, https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-300x200.jpg 300w, https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-768x512.jpg 768w, https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-1536x1024.jpg 1536w, https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-2048x1365.jpg 2048w, https://xtalks.com/wp-content/uploads/2024/02/Biotech-IPOs-in-2024-scaled-e1707165831193.jpg 1200w" sizes="(max-width: 892px) 100vw, 892px" />												</div>

						
						<p class="image-caption"><strong>Biotech IPOs present enticing prospects for investors.</strong></p>					</header>
					<div class="entry-content">
						<p>An initial public offering (IPO) is the process by which a privately held company offers its shares to the public for the first time, allowing it to become a publicly traded company. In the biotech industry, a biotech IPO refers to a specific case where a biotechnology company goes public and lists its shares on a stock exchange. This enables the company to raise funds from public investors. Successful biotech IPOs in 2024 have the potential to generate substantial returns for early investors and provide the crucial capital required for biotech firms to sustain and advance their research and development endeavors.</p>
<hr />
<p>Related: <a href="https://xtalks.com/biotech-ipos-in-2023-shaping-the-future-of-innovation-3392/" target="_blank" rel="noopener">Biotech IPOs in 2023: Shaping the Future of Innovation</a></p>
<hr />
<div class="jetpack-video-wrapper"><iframe title="New Biotech IPOs in 2024" width="892" height="502" src="https://www.youtube.com/embed/JUjMomWFSpI?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe></div>
<p>Here are the 29 biotech IPOs in 2024 that have made it to Wall Street so far:</p>
<p><img decoding="async" class="aligncenter size-full wp-image-148817" src="https://xtalks.com/wp-content/uploads/2024/12/Jupiter-Neurosciences-biotech-IPO-e1733442123114.png" alt="Jupiter Neurosciences biotech IPO" width="1200" height="276" srcset="https://xtalks.com/wp-content/uploads/2024/12/Jupiter-Neurosciences-biotech-IPO-e1733442123114.png 1200w, https://xtalks.com/wp-content/uploads/2024/12/Jupiter-Neurosciences-biotech-IPO-e1733442123114-600x138.png 600w" sizes="(max-width: 1200px) 100vw, 1200px" /></p>
<h2><strong>Jupiter Neurosciences</strong></h2>
<p><strong>IPO Date:</strong> December 3, 2024</p>
<p><strong>Initial IPO Price:</strong> $4.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:JUNS",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Jupiter Neurosciences, a clinical-stage pharmaceutical company focused on neuroinflammation, recently launched its IPO on the Nasdaq Capital Market under the ticker symbol &#8220;JUNS.&#8221; The IPO offered 2,750,000 shares of common stock priced at $4.00 per share, aiming to raise $11 million in gross proceeds. Trading began on December 3, 2024, and <a href="https://www.globenewswire.com/news-release/2024/12/04/2991956/0/en/Jupiter-Neurosciences-Inc-Announces-Closing-of-11-million-Initial-Public-Offering.html" target="_blank" rel="noopener">the offering closed the following day</a>.</p>
<p>At the core of <a href="https://www.sec.gov/Archives/edgar/data/1679628/000149315224048322/form424b3.htm" target="_blank" rel="noopener">Jupiter&#8217;s platform is Jotrol</a>, a novel formulation of resveratrol, a plant-based compound recognized for its anti-inflammatory and neuroprotective effects. Unlike traditional resveratrol products, which often suffer from poor absorption and gastrointestinal side effects, Jotrol leverages patented micellar technology to improve bioavailability, enabling effective therapeutic dosing.</p>
<p>Jotrol is being developed as a treatment for central nervous system (CNS) disorders, including Parkinsons disease, Alzheimers disease and rare conditions such as Friedreichs ataxia and mucopolysaccharidosis type 1. The company has received Orphan Drug designation for Friedreichs ataxia, granting it advantages like market exclusivity and eligibility for Priority Review vouchers.</p>
<p>Preclinical research conducted at the University of Miami demonstrated Jotrol&#8217;s potential in a Parkinsons disease mouse model, addressing key symptoms such as dopamine deficits and the loss of nigral cells.</p>
<p>Funds raised from the IPO will support the advancement of Jotrols development, including a Phase II clinical trial for Parkinsons disease and a proof-of-concept study targeting biomarkers for mild cognitive impairment and Alzheimers disease.</p>
<p>Jupiter has also established strategic partnerships in the Asia-Pacific region with Sichuan Kelun and Tianjin Pharmaceuticals, integrating Jotrol into traditional Chinese medicine practices. With international patents secured until 2036, the company is well-positioned to accelerate commercialization and out-licensing opportunities in this high-growth market.</p>
<p>Despite financial challenges and the complexities of scaling operations in a competitive landscape, Jupiter is committed to pursuing grant funding to support proof-of-concept trials. The companys innovative approach to addressing neuroinflammation and mitochondrial dysfunction positions it to tackle unmet needs in neurodegenerative and rare diseases.</p>
<p>By combining resveratrols scientific and traditional medicinal roots, Jupiter aims to carve a distinctive niche in the pharmaceutical industry, focusing on innovative solutions for critical therapeutic areas.</p>
<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-148816" src="https://xtalks.com/wp-content/uploads/2024/12/Invizyne-Technologies-biotech-IPO-e1733441611491.png" alt="" width="1200" height="236" srcset="https://xtalks.com/wp-content/uploads/2024/12/Invizyne-Technologies-biotech-IPO-e1733441611491.png 1200w, https://xtalks.com/wp-content/uploads/2024/12/Invizyne-Technologies-biotech-IPO-e1733441611491-600x118.png 600w" sizes="auto, (max-width: 1200px) 100vw, 1200px" /></p>
<h2><strong>Invizyne Technologies</strong></h2>
<p><strong>IPO Date:</strong> November 13, 2024</p>
<p><strong>Initial IPO Price:</strong> $8.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:IZTC",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Invizyne Technologies has entered the biomanufacturing sector with the successful <a href="https://investors.invizyne.com/pr/invizyne-technologies-announces-closing-of-initial-public-offering" target="_blank" rel="noopener">completion of its IPO</a> on November 14, 2024. The IPO raised $15 million in gross proceeds through the sale of 1,875,000 shares priced at $8.00 each. Trading under the ticker symbol IZTC, <a href="https://investors.invizyne.com/pr/invizyne-technologies-announces-pricing-of-15-million-initial-public-offering-4e011c98-14db3a41-ef37b14d-2a3495e5-60795e84" target="_blank" rel="noopener">the companys shares debuted</a> on the Nasdaq Capital Market on November 13, 2024.</p>
<p>Invizynes innovative cell-free enzymatic system operates by leveraging enzymes to precisely assemble complex molecules, bypassing the limitations of traditional cellular processes. This approach allows the company to produce a wide range of commercially valuable chemicals  including active pharmaceutical ingredients, biofuels, food flavors and cosmetics  in a more efficient and sustainable manner than conventional synthetic biology methods.</p>
<p>At the heart of Invizynes innovation is its proprietary platform, SimplePath, which transforms renewable resources into complex molecules. The platform addresses inefficiencies and high costs associated with traditional methods such as chemical synthesis and natural extraction. SimplePath uses cascades of enzymatic reactions to efficiently convert raw materials into target compounds, offering a scalable and environmentally friendly alternative to legacy production methods.</p>
<p>Since its inception in 2019, Invizyne has concentrated on using SimplePath to produce key chemicals. Current projects include cannabigerolic acid, a precursor to cannabinoids with therapeutic potential, and isobutanol, an essential biofuel component.</p>
<p>SimplePaths near-theoretical yields enable the majority of input materials to be converted into the desired products with minimal waste.</p>
<p>A <a href="https://www.nature.com/articles/s41467-020-18124-1" target="_blank" rel="noopener">study published in <em>Nature Communications</em></a> highlighted that Invizyne achieved exceptional metrics in isobutanol production, reaching titers of up to 275 g/L with a 95 percent yield in multi-day runs using glucose as the input.</p>
<p>The companys efforts have been bolstered by a <a href="https://investors.invizyne.com/pr/invizyne-technologies-selected-for-2-million-project-to-advance-sustainable-aviation-fuel-capabilities" target="_blank" rel="noopener">$2 million project</a> under the Department of Defenses (DoD) <a href="https://www.biomade.org/about-biomade" target="_blank" rel="noopener">BioMADE initiative</a>, which supports enzyme production for cell-free biomanufacturing of sustainable aviation fuel (SAF). This initiative is a critical milestone for scaling production at a 100L pilot facility and aligns with the growing SAF market, projected to reach $27.4 billion by 2032. The partnership also reinforces SimplePaths potential in renewable fuel production.</p>
<p>BioMADE is a US initiative aimed at advancing industrial biomanufacturing innovations and workforce development to maintain global leadership in biotechnology. Invizynes SAF project, conducted in collaboration with the University of Georgia, builds on previous funding from the US Department of Energys Bioenergy Technologies Office (BETO), which awarded $5.85 million for isobutanol production development.</p>
<p>Through these projects, Invizyne continues to demonstrate the flexibility of its SimplePath platform, which can be applied across industries to create pharmaceuticals, biofuels, food additives and sustainable industrial chemicals. With its groundbreaking enzyme-based systems, Invizyne is paving the way for a greener and more efficient future in biomanufacturing.</p>
<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-147707" src="https://xtalks.com/wp-content/uploads/2024/11/Gelteq.png" alt="gelteq ipo, biotech ipo" width="779" height="116" srcset="https://xtalks.com/wp-content/uploads/2024/11/Gelteq.png 779w, https://xtalks.com/wp-content/uploads/2024/11/Gelteq-600x89.png 600w, https://xtalks.com/wp-content/uploads/2024/11/Gelteq-300x45.png 300w, https://xtalks.com/wp-content/uploads/2024/11/Gelteq-768x114.png 768w" sizes="auto, (max-width: 779px) 100vw, 779px" /></p>
<h2><strong>Gelteq</strong></h2>
<p><strong>IPO Date:</strong> October 29, 2024</p>
<p><strong>Initial IPO Price:</strong> $4.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:GELS",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Gelteq Limited, a biotech company specializing in ingestible gel delivery technologies, <a href="https://www.globenewswire.com/news-release/2024/10/30/2971815/0/en/Gelteq-Limited-Closes-US-5-2-Million-Initial-Public-Offering.html" target="_blank" rel="noopener">recently launched its IPO</a>, generating $5.2 million in gross proceeds. The IPO was priced at $4.00 per share, comprising 1,300,000 shares, which began trading on the Nasdaq Global Market under the ticker &#8220;GELS&#8221; on October 29, 2024.</p>
<p>Gelteqs core technology is a <a href="https://www.gelteq.com/the-gel-technology" target="_blank" rel="noopener">proprietary gel platform</a> that offers tailored drug delivery solutions for applications across pharmaceuticals, nutraceuticals, pet care, and sports supplements. The platforms stable gel matrix can encapsulate various ingredients, supporting controlled release, improved bioavailability, and an enhanced user experience.</p>
<p>The company&#8217;s formulations enable delivery of active compounds like branched-chain amino acids, protein, caffeine, and essential minerals, which makes them suitable for uses in sports performance, nutrition, and therapeutic settings.</p>
<p>Gelteq&#8217;s gels address common challenges in medication adherence, improving taste, lowering choking hazards, and making swallowing easier  particularly beneficial for individuals with dysphagia, children, and older adults with specific dietary or swallowing requirements.</p>
<p>Further, Gelteqs technology customizes ingredient release profiles along the gastrointestinal tract, optimizing absorption and targeting specific areas based on each ingredient&#8217;s properties.</p>
<p>To meet increasing demand, <a href="https://www.sec.gov/Archives/edgar/data/1920092/000121390024089716/ea0209219-07.htm#T19" target="_blank" rel="noopener">Gelteq is enhancing</a> its production capabilities with a Good Manufacturing Practice (GMP)-certified facility, anticipated to be fully operational by 2025.</p>
<p>In the pharmaceutical sector, Gelteq is progressing its lead product  a gel-based pain management solution  through the US Food and Drug Administration&#8217;s (FDA) 505(b)(2) pathway, utilizing bioequivalence studies for quicker approval and positioning the gel as an alternative to conventional oral dosage forms. The platforms flexibility allows for multi-ingredient and high-dosage formulations, accommodating both lipid and non-lipid components in a user-friendly format.</p>
<p>Backed by a growing patent portfolio and collaborations in human and animal health, Gelteq is advancing its goal of improving therapeutic outcomes and patient compliance across various health markets.</p>
<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-147706" src="https://xtalks.com/wp-content/uploads/2024/11/Polyrizon-IPO-1.png" alt="polyrizon IPO" width="978" height="101" srcset="https://xtalks.com/wp-content/uploads/2024/11/Polyrizon-IPO-1.png 978w, https://xtalks.com/wp-content/uploads/2024/11/Polyrizon-IPO-1-600x62.png 600w, https://xtalks.com/wp-content/uploads/2024/11/Polyrizon-IPO-1-300x31.png 300w, https://xtalks.com/wp-content/uploads/2024/11/Polyrizon-IPO-1-768x79.png 768w" sizes="auto, (max-width: 978px) 100vw, 978px" /></p>
<h2><strong>Polyrizon</strong></h2>
<p><strong>IPO Date:</strong> October 29, 2024</p>
<p><strong>Initial IPO Price:</strong> $4.38</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:PLRZ",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
<p>&nbsp;</p>
<p>Biotech company Polyrizon Ltd., known for its expertise in medical device hydrogels, <a href="https://www.globenewswire.com/news-release/2024/10/30/2971841/0/en/Polyrizon-Announces-Closing-of-4-2-Million-Initial-Public-Offering.html" target="_blank" rel="noopener">recently completed</a> its IPO, securing $4.2 million in gross proceeds. The IPO was priced at $4.38 per unit, comprising 958,903 units, each containing one ordinary share and three warrants for additional share purchases at a per-share exercise price of $4.38. Trading began on October 29, 2024, on the Nasdaq Capital Market, under the ticker symbol &#8220;PLRZ.&#8221;</p>
<p>The funds raised from the IPO will support the preclinical and clinical advancement of Polyrizons novel hydrogel product candidates, facilitating research and development (R&amp;D) activities. Additional allocations include working capital, possible future acquisitions, and repayment of specific outstanding debts.</p>
<p>Polyrizon Ltd. is pioneering innovative <a href="https://www.sec.gov/Archives/edgar/data/1893645/000121390024091968/ea021895002-424b4_polyrizon.htm" target="_blank" rel="noopener">nasal spray-based hydrogel technologies</a> through two unique platforms: Capture and Contain (C&amp;C) and Trap and Target (T&amp;T).</p>
<p>The C&amp;C platform functions as a &#8220;biological mask,&#8221; forming a protective hydrogel barrier in the nasal passage to block viruses and allergens. Its primary candidate, PL-14, which addresses nasal allergies, is slated for FDA submission via the 510(k) pathway. Preclinical trials are projected to start in the second quarter of 2025, followed by pivotal trials toward the end of the year.</p>
<p>Two additional C&amp;C candidates, PL-15 and PL-16, are focused on COVID-19 and influenza prevention and are expected to proceed toward De Novo classification, with clinical trials projected beyond 2025.</p>
<p>Polyrizons T&amp;T platform offers a different solution, aiming at the intranasal delivery of active pharmaceutical ingredients (APIs) with extended release, targeting potential uses in central nervous system (CNS) treatments, opioid overdose response, and allergic rhinitis. Early testing for this platform is planned from late 2024 to early 2026, with further preclinical and Phase I trials contingent on additional funding.</p>
<p>Polyrizons R&amp;D initiatives are bolstered by strategic partnerships. Its agreement with SciSparc grants Polyrizon exclusive rights to the SCI-160 platform, enabling non-opioid pain treatment development with milestone-linked royalties. Additionally, a collaboration with NurExone supports the development of an intranasal delivery system for exosome-based therapies aimed at treating spinal cord injuries, with potential expansion to other neurological applications.</p>
<h2><img loading="lazy" decoding="async" class="aligncenter wp-image-147577" src="https://xtalks.com/wp-content/uploads/2024/10/Septerna-1024x220.png" alt="Septerna IPO biotech IPO" width="600" height="129" /></h2>
<h2><strong>Septerna</strong></h2>
<p><strong>IPO Date:</strong> October 25, 2024</p>
<p><strong>Initial IPO Price:</strong> $18.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:SEPN",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Septerna, Inc., a clinical-stage biotech company focused on developing therapies based on G protein-coupled receptors (GPCRs), has reached a major milestone by <a href="https://www.globenewswire.com/news-release/2024/10/25/2969214/0/en/Septerna-Prices-Upsized-Initial-Public-Offering.html" target="_blank" rel="noopener">completing its IPO</a>. The South San Francisco company is known for its cutting-edge approach to GPCR drug discovery, utilizing its proprietary Native Complex Platform to build a strong portfolio targeting key areas like endocrinology, immunology, inflammation and metabolic diseases.</p>
<p>Septernas IPO led to the issuance of 18.4 million shares at $18.00 each, including an additional 2.4 million shares acquired by underwriters exercising their option in full. The IPO raised $331.2 million in gross proceeds before deducting underwriting discounts, commissions and other related expenses. Shares of Septerna began trading on the Nasdaq Global Market (under the ticker SEPN) on October 25, 2024, with the <a href="https://www.globenewswire.com/news-release/2024/10/30/2972144/0/en/Septerna-Announces-Closing-of-331-2-Million-Upsized-Initial-Public-Offering.html" target="_blank" rel="noopener">IPO officially closing</a> on October 30, 2024.</p>
<p>This funding boost will help drive <a href="https://www.sec.gov/Archives/edgar/data/1984086/000119312524244123/d762905d424b4.htm" target="_blank" rel="noopener">Septernas pipeline</a> forward and support clinical studies in its primary therapeutic areas. With GPCR-targeted therapies addressing critical medical challenges, Septerna is strategically positioned for impact in the industry.</p>
<p>The companys leading program, SEP-786, addresses hypoparathyroidism, a rare disorder affecting roughly 70,000 people in the US that can lead to severe issues such as seizures and heart complications. SEP-786 is an oral parathyroid hormone 1 receptor (PTH1R) agonist aiming to restore mineral balance, with Phase I trial results expected by mid-2025.</p>
<p>Septerna&#8217;s SEP-631 is being developed for chronic spontaneous urticaria, a painful inflammatory skin condition impacting 1.5 million people in the U.S. This selective mas-related G-protein coupled receptor member X2 (MRGPRX2) inhibitor works by modulating mast cell activity, with regulatory submissions for trial initiation expected soon.</p>
<p>Septernas thyroid-stimulating hormone receptor (TSHR) modulators target Graves disease and thyroid eye disease, both of which require significant treatment. The companys TSHR modulators could offer a disease-modifying oral therapy, with lead compounds advancing toward clinical candidate selection.</p>
<p>Septernas pipeline also includes incretin programs aimed at addressing obesity and type 2 diabetes, which affect over 800 million people globally. Through oral agonists for glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and glucagon receptors, Septernas approach may overcome some limitations of current injectable treatments, with key compounds nearing the development candidate stage.</p>
<p>Septernas IPO success underscores investor confidence in its scientific vision and potential to innovate small molecule therapeutics, advancing treatments for complex medical conditions.</p>
<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-145869" src="https://xtalks.com/wp-content/uploads/2024/10/Upstream-Bio-1.png" alt="Upstream Bio biotech IPO 2024" width="4000" height="363" /></p>
<h2><strong>Upstream Bio</strong></h2>
<p><strong>IPO Date:</strong> October 11, 2024</p>
<p><strong>Initial IPO Price:</strong> $17.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:UPB",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Upstream Bio recently <a href="https://www.globenewswire.com/news-release/2024/10/15/2963649/0/en/Upstream-Bio-Announces-Closing-of-293-Million-Upsized-Initial-Public-Offering-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html" target="_blank" rel="noopener">closed</a> its upsized <a href="https://www.globenewswire.com/news-release/2024/10/10/2961765/0/en/Upstream-Bio-Announces-Pricing-of-Upsized-Initial-Public-Offering.html" target="_blank" rel="noopener">IPO</a>, raising approximately $293 million after the underwriters exercised their option to purchase an additional 2,250,000 shares. The offering comprised 17,250,000 shares of common stock at $17 per share, and the stock began trading on the Nasdaq Global Select Market on October 11, 2024, under the ticker UPB. Proceeds from the IPO will support Upstream Bios development of innovative therapies for inflammatory diseases, particularly severe respiratory disorders.</p>
<p>Upstream Bio is <a href="https://www.sec.gov/Archives/edgar/data/2022626/000119312524236714/d843142d424b4.htm" target="_blank" rel="noopener">advancing</a> verekitug, its lead monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), into clinical trials for severe respiratory disorders. Verekitug is the only known TSLP receptor antagonist in clinical development, designed to inhibit TSLP&#8217;s upstream inflammatory effects. The company has already completed three Phase I trials, showing promising pharmacokinetics and safety data. Verekitug&#8217;s Phase Ib results demonstrated rapid, sustained receptor occupancy and significant reductions in key biomarkers like fractional exhaled nitric oxide and eosinophil levels in asthma patients.</p>
<p>Currently, two Phase II trials are underway  one for severe asthma and the other for chronic rhinosinusitis with nasal polyps (CRSwNP). Both trials aim to evaluate 12- and 24-week dosing intervals, potentially allowing for less frequent dosing compared to current biologics. Results from the CRSwNP trial are expected in late 2025, with asthma trial data anticipated in the second half of 2026. Additionally, Upstream plans to initiate a Phase II clinical trial for chronic obstructive pulmonary disease (COPD) in late 2025.</p>
<p>Beyond these, Upstream plans to leverage verekitugs attributes for other TSLP-driven diseases, exploring its potential across multiple inflammatory conditions. Strategic collaborations and potential acquisitions are expected to position the company to address unmet needs in respiratory care.</p>
<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-145870" src="https://xtalks.com/wp-content/uploads/2024/10/CAMP4-Therapeutics-Corporation-biotech-IPO.png" alt="CAMP4 Therapeutics Corporation biotech IPO" width="4000" height="783" /></p>
<h2><strong>CAMP4 Therapeutics Corporation</strong></h2>
<p><strong>IPO Date:</strong> October 10, 2024</p>
<p><strong>Initial IPO Price:</strong> $11.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:CAMP",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>CAMP4 Therapeutics, a clinical-stage biopharmaceutical company, <a href="https://www.globenewswire.com/news-release/2024/10/10/2961761/0/en/CAMP4-Announces-Pricing-of-Initial-Public-Offering.html" target="_blank" rel="noopener">recently priced</a> its IPO at $11.00 per share, generating approximately $75 million in gross proceeds. CAMP4 is focused on developing regulatory <a href="https://www.sec.gov/Archives/edgar/data/1736730/000110465924108067/tm2415452-18_424b4.htm#tPRSU" target="_blank" rel="noopener">RNA-based therapeutics</a> that upregulate gene expression to restore healthy protein levels. Their RNA Actuating Platform (RAP) identifies regulatory RNA sequences that control protein-coding genes, allowing CAMP4 to create antisense oligonucleotide therapeutics to modulate gene expression.</p>
<p>On October 1, 2024, CAMP4 entered into a strategic research <a href="https://www.camp4tx.com/camp4-enters-strategic-research-collaboration-to-advance-novel-regulatory-rna-targeting-medicines-for-rare-genetic-conditions/" target="_blank" rel="noopener">collaboration</a> with BioMarin Pharmaceutical Inc. to advance novel therapeutics for rare genetic conditions. This collaboration combines CAMP4s target discovery capabilities with BioMarins expertise in genetic medicines, with BioMarin having the right to select two targets from CAMP4s RAP platform to move into clinical development.</p>
<p>The companys lead product candidate, CMP-CPS-001, is designed to treat urea cycle disorders by increasing the expression of CPS1, a key enzyme in the urea cycle. It is currently undergoing Phase I clinical trials, with data from the single ascending dose (SAD) portion expected in the first quarter of 2025, and multiple ascending dose (MAD) data anticipated in the second half of 2025. CMP-CPS-001 has also received Rare Pediatric Disease and <a href="https://www.globenewswire.com/en/news-release/2024/09/17/2947357/0/en/CAMP4-Therapeutics-Secures-Orphan-Drug-Designation-for-CMP-CPS-001-for-the-Treatment-of-Urea-Cycle-Disorders.html" target="_blank" rel="noopener">Orphan Drug designations</a> from the US Food and Drug Administration (FDA), signaling potential market exclusivity and regulatory support.</p>
<p>In addition to CMP-CPS-001, CAMP4 is advancing its CMP-SYNGAP program targeting SYNGAP1-related neurodevelopmental disorders, which cause cognitive impairment and epilepsy. Preclinical results were promising, and the company plans to initiate Good Laboratory Practice (GLP) toxicology studies in 2025.</p>
<p>Looking ahead, CAMP4 intends to form more strategic partnerships to maximize the value of its RAP platform and expand its pipeline to address metabolic and central nervous system (CNS) diseases. The funds from the IPO will be used to advance clinical trials, expand the RAP platform and support future product development initiatives.</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-144257" src="https://xtalks.com/wp-content/uploads/2024/09/BioAge-300x300.jpg" alt="biotech ipos 2024 biotech ipo 2024 bioage ipo" width="275" height="275" srcset="https://xtalks.com/wp-content/uploads/2024/09/BioAge-300x300.jpg 300w, https://xtalks.com/wp-content/uploads/2024/09/BioAge-100x100.jpg 100w, https://xtalks.com/wp-content/uploads/2024/09/BioAge-600x600.jpg 600w, https://xtalks.com/wp-content/uploads/2024/09/BioAge-150x150.jpg 150w, https://xtalks.com/wp-content/uploads/2024/09/BioAge-768x768.jpg 768w, https://xtalks.com/wp-content/uploads/2024/09/BioAge.jpg 825w" sizes="auto, (max-width: 275px) 100vw, 275px" /></p>
<h2><strong>BioAge Labs, Inc. </strong></h2>
<p><strong>IPO Date:</strong> September 26, 2024</p>
<p><strong>Initial IPO Price:</strong> $18.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:BIOA",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p><a href="https://bioagelabs.com/" target="_blank" rel="noopener">BioAge Labs, Inc.</a>, a clinical-stage biopharmaceutical company, <a href="https://www.globenewswire.com/news-release/2024/09/26/2953430/0/en/BioAge-Labs-Announces-Pricing-of-Upsized-Initial-Public-Offering.html" target="_blank" rel="noopener">recently priced</a> its upsized IPO of 11,000,000 shares at $18.00 each, raising $198.0 million before deducting expenses. Underwriters were granted a 30-day option to buy an additional 1,650,000 shares. The stock began trading on the Nasdaq Global Select Market under the ticker BIOA on September 26, 2024.</p>
<p>On October 1, 2024, BioAge <a href="https://www.globenewswire.com/news-release/2024/10/01/2956605/0/en/BioAge-Labs-Announces-Closing-of-Initial-Public-Offering-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares-and-Closing-of-the-Concurrent-Private-Placement.html" target="_blank" rel="noopener">confirmed the closing</a> of the upsized IPO, including the full exercise of the underwriters&#8217; option, totaling 12,650,000 shares. Additionally, BioAge closed a concurrent private placement on September 27, selling 588,888 shares to an existing stockholder. The combined gross proceeds from the IPO, underwriters&#8217; option and private placement amounted to approximately $238.3 million.</p>
<p>BioAges <a href="https://www.sec.gov/Archives/edgar/data/1709941/000119312524226927/d835745d424b4.htm" target="_blank" rel="noopener">investigational oral drug</a>, azelaprag, is a small molecule agonist of the apelin receptor (APJ), designed to replicate exercise benefits. In preclinical obesity models, azelaprag more than doubled weight loss when combined with glucagon-like peptide-1 (GLP-1) receptor agonists. Phase Ib clinical trials demonstrated reduced muscle atrophy and improved metabolism in older adults.</p>
<p>Currently, BioAge is running two Phase II trials: the ongoing Study to Evaluate the Reduction of Insulin-Related Disorders and Enhance Satiety (STRIDES) trial with tirzepatide, with results expected in the third quarter of 2025, and a trial with semaglutide, set to start in the first half of 2025, with topline results anticipated in the second half of 2026. An insulin sensitivity proof-of-concept trial with azelaprag monotherapy is also planned for the first half of 2025.</p>
<p>The company pipeline also includes brain-penetrating nucleotide-binding domain and leucine-rich repeat protein 3 (NLRP3) inhibitors targeting neuroinflammatory diseases. An Investigational New Drug (IND) application for one such NLRP3 inhibitor has been planned for the second half of 2025 and likely, a Phase I trial in the first half of 2026.</p>
<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-143267" src="https://xtalks.com/wp-content/uploads/2024/07/KAIROS-PHARMA.png" alt="Kairos Pharma IPO, biotech IPO 2024, biotech IPOs 2024" width="4000" height="784" /></p>
<h2><strong>Kairos Pharma</strong></h2>
<p><strong>IPO Date:</strong> September 16, 2024</p>
<p><strong>Initial IPO Price:</strong> $4.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "AMEX:KAPA",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Kairos Pharma successfully <a href="https://www.globenewswire.com/news-release/2024/09/17/2947841/0/en/Kairos-Pharma-Closing-of-6-2-Million-Initial-Public-Offering.html" target="_blank" rel="noopener">closed</a> its <a href="https://www.globenewswire.com/news-release/2024/09/16/2946812/0/en/Kairos-Pharma-Prices-6-2-Million-Initial-Public-Offering.html" target="_blank" rel="noopener">IPO</a> on September 17, 2024, raising $6.2 million through the sale of 1,550,000 shares at $4.00 per share. Trading began on the NYSE American under the symbol &#8220;KAPA&#8221; on September 16, 2024. Underwriters were granted a 45-day option to purchase an additional 232,500 shares. With net proceeds estimated at $5.76 million, the company plans to advance its robust oncology pipeline, which targets immune suppression and drug resistance in cancers.</p>
<p>At the forefront of <a href="https://www.sec.gov/Archives/edgar/data/1962011/000149315224036474/form424b4.htm" target="_blank" rel="noopener">Kairos development efforts</a> is ENV 105, a therapeutic antibody currently in Phase I trials for lung cancer and Phase II trials for prostate cancer. ENV 105 specifically targets CD105, a molecule that becomes upregulated in tumors resistant to standard therapies, including androgen receptor inhibitors and EGFR-targeted drugs. Early trials demonstrated a promising clinical benefit rate of 62 percent in heavily pre-treated prostate cancer patients.</p>
<p>Preclinical candidates include the KROS portfolio, with KROS 101 and 102 targeting glucocorticoid-induced tumor necrosis factor receptor (GITR) ligands to modulate T cell activity and function, and KROS 201, an autologous T cell therapy designed to eliminate glioblastoma cancer stem cells.</p>
<p>Kairos received a $3.2 million grant from the National Cancer Institute to support the development of ENV 105. This funding will be used for companion biomarker research in prostate cancer, helping identify patients most likely to benefit from the therapy.</p>
<p>Other products in development include ENV 205, which targets mitochondrial DNA to reverse chemotherapy resistance, and KROS 301, a small molecule aimed at inhibiting the nuclear factor-kappa B (NF-) pathway, which has been <a href="https://www.frontierspartnerships.org/journals/oncology-reviews/articles/10.3389/or.2022.10568/full" target="_blank" rel="noopener">found to promote</a> tumor growth and resistance to therapies, in triple-negative breast cancer.</p>
<p>The IPO proceeds will support these ongoing trials, pipeline expansions and preclinical studies, solidifying Kairos&#8217; commitment to addressing critical unmet needs in oncology.</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-143270 size-full" src="https://xtalks.com/wp-content/uploads/2024/09/impact-biomedical-inc-logo-1.jpg" alt="Impact Biomedical IPO" width="469" height="185" srcset="https://xtalks.com/wp-content/uploads/2024/09/impact-biomedical-inc-logo-1.jpg 469w, https://xtalks.com/wp-content/uploads/2024/09/impact-biomedical-inc-logo-1-300x118.jpg 300w" sizes="auto, (max-width: 469px) 100vw, 469px" /></p>
<h2><strong>Impact BioMedical</strong></h2>
<p><strong>IPO Date:</strong> September 16, 2024</p>
<p><strong>Initial IPO Price:</strong> $3.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "AMEX:IBO",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Impact BioMedical Inc. <a href="https://www.globenewswire.com/news-release/2024/09/17/2947656/0/en/Impact-BioMedical-Inc-Announces-the-Closing-of-its-Initial-Public-Offering.html" target="_blank" rel="noopener">completed</a> its IPO on September 17, 2024, after <a href="https://www.globenewswire.com/news-release/2024/09/16/2946794/0/en/Impact-BioMedical-Inc-Announces-Pricing-of-Initial-Public-Offering.html" target="_blank" rel="noopener">debuting</a> on the NYSE American the previous day. The company offered 1.5 million shares priced at $3.00 per share, with Revere Securities, LLC as the lead underwriter. The IPO included a 45-day option for underwriters to acquire an additional 225,000 shares. In connection with the offering, Impact issued warrants for the purchase of up to 75,000 shares at an exercise price of $3.75 per share, with the potential to extend to 86,250 shares if the overallotment option is exercised.</p>
<p>Impact BioMedical is advancing an array of cutting-edge technologies through its subsidiaries. At the forefront is its <a href="https://www.sec.gov/Archives/edgar/data/1834105/000149315224036520/form424b4.htm" target="_blank" rel="noopener">Linebacker platform</a>, a series of polyphenol-based compounds designed to target oncology, inflammation and neurological disorders. These compounds, derived from natural sources like berries and nuts, have demonstrated the potential to inhibit PIM kinase, a driver of several cancers. Linebacker-1 and Linebacker-2 have been licensed to ProPhase Laboratories for global development, creating opportunities for future milestone and royalty payments.</p>
<p>Another notable product is Laetose, a sugar substitute that lowers caloric intake and glycemic response while also inhibiting tumor necrosis factor alpha. Impact BioMedical is exploring partnerships to advance Laetoses applications in consumer markets and biopharmaceuticals.</p>
<p>The company also collaborates with Chemia Corporation to develop 3F, a fragrance technology with antimicrobial properties that could be used in insect repellents, detergents and more. Equivir, a blend of polyphenols with antiviral effects, is licensed to ProPhase Laboratories, with potential applications in upper respiratory wellness and beyond.</p>
<p>These innovative offerings, paired with strategic partnerships and licensing agreements, could propel Impact BioMedical&#8217;s efforts to develop next-generation wellness and biopharmaceutical solutions.</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-143262" src="https://xtalks.com/wp-content/uploads/2024/07/Zenas-BioPharma-.png" alt="Zenas BioPharma IPO, biotech IPO 2024, biotech IPOs 2024" width="700" height="244" /></p>
<h2><strong>Zenas BioPharma</strong></h2>
<p><strong>IPO Date:</strong> September 13, 2024</p>
<p><strong>Initial IPO Price:</strong> $17.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:ZBIO",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Zenas BioPharma <a href="https://www.globenewswire.com/news-release/2024/09/13/2945685/0/en/Zenas-BioPharma-Announces-Pricing-of-Upsized-Initial-Public-Offering.html" target="_blank" rel="noopener">launched its IPO</a>, pricing 13,235,294 shares at $17 per share, aiming to raise approximately $225 million in gross proceeds. The company is listed on the Nasdaq Global Select Market under the ticker symbol &#8220;ZBIO,&#8221; with the IPO closing on September 16, 2024. On September 19, 2024, the underwriters fully exercised their option to purchase an additional 1,985,294 shares at the initial offering price, bringing the total to <a href="https://financialpost.com/globe-newswire/zenas-biopharma-announces-closing-of-full-exercise-of-underwriters-option-to-purchase-additional-shares-in-initial-public-offering#:~:text=(%E2%80%9CZenas%E2%80%9D)%2C%20(,of%2013%2C235%2C294%20shares%20of%20its" target="_blank" rel="noopener">15,220,588 shares sold</a> and raising gross proceeds of $258.7 million.</p>
<p>Notably, Zenas&#8217; <a href="https://stockanalysis.com/stocks/zbio/" target="_blank" rel="noopener">current market cap</a> stands at $715 million which could indicate strong investor confidence in its immunology therapies.</p>
<p>As an emerging growth company, the funds will be directed toward advancing its <a href="https://www.sec.gov/Archives/edgar/data/1953926/000110465924099805/tm2332800-18_424b4.htm" target="_blank" rel="noopener">pipeline</a> of transformative immunology therapies. Their lead product, obexelimab, a bifunctional monoclonal antibody, is designed to inhibit B cells without depleting them, holding promise in autoimmune disease treatment.</p>
<p>Zenas is advancing multiple clinical trials, including a Phase III trial for immunoglobulin G4-related disease (IgG4-RD), which is currently enrolling patients globally. Obexelimab is also being tested in a Phase II/III trial for warm autoimmune hemolytic anemia (wAIHA), and Phase II trials are underway for multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Additionally, Zenas is developing two global programs  ZB002 (an anti-TNF monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion)  along with regional programs ZB001 and ZB005, targeting various inflammatory and autoimmune conditions. The IPO will accelerate trial progress and expand Zenas&#8217; pipeline toward commercialization.</p>
<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-143266" src="https://xtalks.com/wp-content/uploads/2024/07/Bicara-Therapeutics-.png" alt="Bicara Therapeutics IPO, biotech IPOs 2024, biotech IPO 2024" width="4000" height="584" /></p>
<h2><strong>Bicara Therapeutics</strong></h2>
<p><strong>IPO Date:</strong> September 12, 2024</p>
<p><strong>Initial IPO Price:</strong> $18.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:BCAX",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company advancing bifunctional therapies for solid tumors, <a href="https://www.globenewswire.com/news-release/2024/09/13/2945680/0/en/Bicara-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html" target="_blank" rel="noopener">announced</a> the pricing of its IPO on September 12, 2024. Offering 17,500,000 shares at $18.00 per share, the company raised approximately $315 million. Following the full exercise of underwriters options, the IPO <a href="https://www.globenewswire.com/news-release/2024/09/16/2947009/0/en/Bicara-Therapeutics-Announces-Closing-of-362-Million-Initial-Public-Offering-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html" target="_blank" rel="noopener">closed</a> on September 16, 2024, with a total of 20,125,000 shares sold, pushing gross proceeds to $362 million.</p>
<p>Bicaras <a href="https://www.sec.gov/Archives/edgar/data/2023658/000119312524218862/d821336d424b4.htm" target="_blank" rel="noopener">lead asset</a>, ficerafusp alfa, is a bifunctional antibody designed to target both epidermal growth factor receptor (EGFR) and transforming growth factor beta (TGF-). This dual mechanism holds promise in treating various solid tumors by inhibiting tumor growth while reducing the immunosuppressive environment in the tumor microenvironment.</p>
<p>Early clinical results have been compelling, particularly in head and neck squamous cell carcinoma (HNSCC), where ficerafusp alfa combined with pembrolizumab achieved a 54 percent overall response rate (ORR), and an even higher 64 percent ORR in human papillomavirus (HPV)-negative patients.</p>
<p>With these promising data, Bicara plans to launch a pivotal Phase II/III trial by late 2024 or early 2025, testing ficerafusp alfa combined with pembrolizumab as a first-line treatment for recurrent/metastatic HNSCC. The company is also exploring the drugs potential in other EGFR-expressing solid tumors like colorectal cancer and cutaneous squamous cell carcinoma.</p>
<p>Bicaras bifunctional approach aims to provide longer-lasting responses and improved survival outcomes for patients with few treatment options. Funds from the IPO will support ongoing clinical trials and future pipeline expansion, helping Bicara potentially bring new treatment options to cancer patients who currently have limited alternatives.</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-143261" src="https://xtalks.com/wp-content/uploads/2024/07/MBX-Biosciences.png" alt="MBX Biosciences, biotech IPOs 2024, biotech IPO 2024" width="750" height="156" /></p>
<h2><strong>MBX Biosciences</strong></h2>
<p><strong>IPO Date:</strong> September 12, 2024</p>
<p><strong>Initial IPO Price:</strong> $16.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:MBX",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>MBX Biosciences <a href="https://mbxbio.com/uncategorized/mbx-biosciences-announces-pricing-of-initial-public-offering/" target="_blank" rel="noopener">announced</a> the pricing of its IPO, selling 10.2 million shares of common stock at $16.00 per share, expecting to raise $163.2 million. The underwriters also have a 30-day option to buy an additional 1.53 million shares. The shares started trading on Nasdaq under the ticker symbol &#8220;MBX.&#8221; On September 16, MBX announced the <a href="https://www.globenewswire.com/news-release/2024/09/16/2947014/0/en/MBX-Biosciences-Announces-Closing-of-Upsized-Initial-Public-Offering-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html" target="_blank" rel="noopener">closing</a> of its upsized IPO, which included the full exercise of the underwriters&#8217; option to purchase additional shares, bringing the total to 11.73 million shares sold. This upsized offering raised approximately $187.7 million in gross proceeds, surpassing the initial estimate of $163.2 million.</p>
<p>The IPO supports the development of MBXs <a href="https://www.sec.gov/Archives/edgar/data/1776111/000119312524218860/d790774d424b5.htm#toc790774_1" target="_blank" rel="noopener">innovative pipeline</a> of precision peptide therapies, driven by its proprietary Precision Endocrine Peptide (PEP) platform. MBX is progressing through critical clinical trials, including Phase II testing for MBX 2109 and Phase I for MBX 1416, with other treatments, like MBX 4291, in the preclinical stage.</p>
<p>MBX 2109, the lead candidate, is a long-acting parathyroid hormone peptide prodrug designed for chronic hypoparathyroidism (HP). Now in Phase II trials, MBX 2109 offers once-weekly dosing with continuous PTH exposure, aiming to improve outcomes by reducing the need for daily supplements. Phase I results indicated that the treatment was well-tolerated and worked for a longer period between doses.</p>
<p>MBX 1416, in Phase I development for post-bariatric hypoglycemia (PBH), is a GLP-1 receptor antagonist intended to reduce hypoglycemic events through once-weekly dosing. MBX 4291, still in preclinical testing, is being developed for obesity, potentially offering once-monthly dosing based on preclinical data.</p>
<p>The IPO positions MBX Biosciences to accelerate its pipeline, addressing unmet needs in endocrine and metabolic disorders with long-acting, novel therapies designed to enhance patient management and improve efficacy.</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-143259" src="https://xtalks.com/wp-content/uploads/2024/07/Actuate-Therapeutics-1-1024x329.png" alt="Actuate Therapeutics IPO biotech IPO 2024 biotech IPOs 2024" width="700" height="225" srcset="https://xtalks.com/wp-content/uploads/2024/07/Actuate-Therapeutics-1-1024x329.png 1024w, https://xtalks.com/wp-content/uploads/2024/07/Actuate-Therapeutics-1-600x193.png 600w, https://xtalks.com/wp-content/uploads/2024/07/Actuate-Therapeutics-1-300x96.png 300w, https://xtalks.com/wp-content/uploads/2024/07/Actuate-Therapeutics-1-768x247.png 768w, https://xtalks.com/wp-content/uploads/2024/07/Actuate-Therapeutics-1-1536x493.png 1536w, https://xtalks.com/wp-content/uploads/2024/07/Actuate-Therapeutics-1-2048x657.png 2048w" sizes="auto, (max-width: 700px) 100vw, 700px" /></p>
<h2><strong>Actuate Therapeutics</strong></h2>
<p><strong>IPO Date:</strong> August 12, 2024</p>
<p><strong>Initial IPO Price:</strong> $8.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:ACTU",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Actuate Therapeutics, a clinical-stage biopharmaceutical company targeting tough-to-treat cancers made an IPO on August 13, 2024. The company priced its <a href="https://www.globenewswire.com/en/news-release/2024/08/13/2928855/0/en/Actuate-Therapeutics-Announces-Pricing-of-Initial-Public-Offering.html" target="_blank" rel="noopener">IPO at $8.00 per share</a>, raising a decent $30 million through the sale of 3.75 million shares. This influx of capital is set to fuel the advancement of their lead compound, elraglusib (formerly 9-ING-41), a small molecule designed to inhibit glycogen synthase kinase-3 beta (GSK-3) in refractory cancers.</p>
<p>Elraglusib is an innovative drug that infiltrates cancer cells and disrupts GSK-3, a key enzyme that orchestrates the survival, growth and spread of tumor cells. By blocking this enzyme, elraglusib not only aims to kill cancer cells but also boosts the bodys immune response against tumors. Actuate is currently putting elraglusib through its paces in a randomized Phase II trial for metastatic pancreatic cancer, where <a href="https://www.sec.gov/Archives/edgar/data/1652935/000110465924065172/tm247121-12_s1.htm#tPRSU" target="_blank" rel="noopener">early data</a> has shown promising survival benefits  12.2 months in the treatment arm versus 7.3 months in the control group.</p>
<p>The IPO officially <a href="https://www.globenewswire.com/en/news-release/2024/08/14/2930464/0/en/Actuate-Therapeutics-Announces-Closing-of-Initial-Public-Offering.html" target="_blank" rel="noopener">closed</a> on August 14, 2024, with Actuates stock debuting on the Nasdaq under the ticker &#8220;ACTU&#8221;. Beyond pancreatic cancer, Actuate is exploring elraglusibs potential in other tough-to-treat cancers within its <a href="https://actuatetherapeutics.com/pipeline/" target="_blank" rel="noopener">pipeline</a> like glioblastoma, lung and colorectal cancers, as well as pediatric cancers, such as Ewing sarcoma, through ongoing Phase I/II studies.</p>
<p>Elraglusibs significance is underscored by its Fast Track and <a href="https://www.globenewswire.com/en/news-release/2023/08/01/2715774/0/en/Actuate-Therapeutics-Receives-FDA-Orphan-Drug-Designation-for-Elraglusib-for-Treatment-of-Pancreatic-Cancer.html" target="_blank" rel="noopener">Orphan Drug</a> Designations from the US Food and Drug Administration (FDA) for pancreatic cancer, signaling its potential to meet critical unmet medical needs. Actuate is also expanding the drugs versatility by developing oral forms, potentially widening its application across multiple cancer types, including melanoma and colorectal cancer.</p>
<p>In a symbolic gesture, Actuate rang the Nasdaq <a href="https://www.globenewswire.com/en/news-release/2024/08/20/2932879/0/en/Actuate-Therapeutics-to-Ring-the-Nasdaq-Opening-Bell-on-Friday-August-23-2024.html" target="_blank" rel="noopener">opening bell</a> on August 23, 2024, marking their official entry as a publicly traded entity.</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-143260" src="https://xtalks.com/wp-content/uploads/2024/07/OS-Therapies-1024x218.png" alt="OS Therapies IPO, biotech IPOs 2024, biotech IPO 2024" width="725" height="154" srcset="https://xtalks.com/wp-content/uploads/2024/07/OS-Therapies-1024x218.png 1024w, https://xtalks.com/wp-content/uploads/2024/07/OS-Therapies-600x127.png 600w, https://xtalks.com/wp-content/uploads/2024/07/OS-Therapies-300x64.png 300w, https://xtalks.com/wp-content/uploads/2024/07/OS-Therapies-768x163.png 768w, https://xtalks.com/wp-content/uploads/2024/07/OS-Therapies-1536x326.png 1536w, https://xtalks.com/wp-content/uploads/2024/07/OS-Therapies-2048x435.png 2048w" sizes="auto, (max-width: 725px) 100vw, 725px" /></p>
<h2><strong>OS Therapies</strong></h2>
<p><strong>IPO Date:</strong> July 31, 2024</p>
<p><strong>Initial IPO Price:</strong> $4.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "AMEX:OSTX",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Amid the 2024 biotech IPO surge, OS Therapeutics Incorporated (OSTX) raised $6.4 million through its <a href="https://www.businesswire.com/news/home/20240731616879/en/OS-Therapies-Announces-Pricing-of-its-Initial-Public-Offering-on-NYSE-American---Company-to-Trade-under-Symbol-%E2%80%9COSTX%E2%80%9D/" target="_blank" rel="noopener">IPO</a>, pricing 1.6 million shares at $4.00 each. Net proceeds, around $6.0 million, will fuel the companys clinical development programs and support corporate operations.</p>
<p>OS Therapeutics&#8217; <a href="https://ir.ostherapies.com/news-events/press-releases/detail/22/os-therapies-reports-second-quarter-2024-financial-results" target="_blank" rel="noopener">second quarter (Q2) 2024 financial results</a> showcased a solid financial foundation, with $11.5 million in cash and cash equivalents as of June 30, 2024. This, combined with IPO proceeds, will fund ongoing and future clinical trials, including the pivotal Phase IIb trial of OST-HER2 in recurrent osteosarcoma, a bone cancer that keeps returning. Operating expenses were primarily driven by R&amp;D activities, with a clear focus on high-impact areas such as immunotherapy and antibody-drug conjugates (ADCs).</p>
<p>In a strategic leap, OS Therapeutics <a href="https://ir.ostherapies.com/news-events/press-releases/detail/23/os-therapies-accepted-into-johnson-johnson-innovation-" target="_blank" rel="noopener">joined Johnson &amp; Johnson Innovation  JLABS</a>, gaining access to cutting-edge research facilities and strategic mentorship. This collaboration is expected to accelerate the development of its key pipeline candidates, OST-HER2 and OST-tADC.</p>
<p>OST-HER2, OS Therapeutics&#8217; flagship product, uses bioengineered <em>Listeria monocytogenes</em> to provoke a potent immune response against HER2 (human epidermal growth factor receptor 2)-expressing cancer cells. With a Phase IIb trial nearing completion and key FDA designations  including Fast Track, Orphan Drug and Rare Pediatric Disease, and actively seeking Breakthrough Therapy  the company is poised for a potential Biologics License Application (BLA) soon.</p>
<p>OS Therapeutics is also pioneering the OST-tADC platform, using SiLinkers technology to precisely target cancer cells with minimal damage to healthy tissues. The <a href="https://www.marketsandmarkets.com/Market-Reports/antibody-drug-conjugates-market-122857391.html" target="_blank" rel="noopener">ADC market</a>, which is expected to grow from $4.5 billion in 2023 to nearly $19.8 billion by 2028, represents a significant opportunity for OS Therapeutics as it develops its OST-tADC platform.</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-137316" src="https://xtalks.com/wp-content/uploads/2024/07/Artiva-1024x465.png" alt="Artiva" width="500" height="227" /></p>
<h2><strong>Artiva Biotherapeutics</strong></h2>
<p><strong>IPO Date:</strong> July 18, 2024</p>
<p><strong>Initial IPO Price:</strong> $12.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:ARTV",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Artiva Biotherapeutics, Inc. <a href="https://www.globenewswire.com/news-release/2024/07/18/2915688/0/en/Artiva-Biotherapeutics-Announces-Pricing-of-Upsized-167-0-Million-Initial-Public-Offering.html" target="_blank" rel="noopener">announced</a> the pricing of its upsized initial public offering (IPO), offering 13,920,000 shares of common stock at $12.00 per share. Artiva is a clinical-stage biotechnology company focused on developing cell therapies for autoimmune diseases and cancers.</p>
<p>Trading under the symbol &#8220;<a href="https://www.nasdaq.com/market-activity/stocks/artv" target="_blank" rel="noopener">ARTV</a>&#8221; on the Nasdaq Global Market, Artiva is set to raise approximately $167.0 million in gross proceeds. The offering is expected to close on July 22, 2024.</p>
<p>Founded in 2019 and headquartered in San Diego, Artiva Biotherapeutics specializes in developing natural killer (NK) cell-based therapies. Artivas product candidates are allogeneic, pre-manufactured, cryopreserved and ready-to-ship, offering an off-the-shelf accessible solution. Their lead therapy, AlloNK, is a non-genetically modified NK cell therapy being tested in combination with B-cell targeted monoclonal antibodies in <a href="https://investors.artivabio.com/News-and-Events/news/news-details/2024/Artiva-Biotherapeutics-Announces-First-Patient-Dosed-in-Phase-1-Trial-of-AlloNK-Cell-Therapy-Candidate-in-Lupus-Nephritis/default.aspx" target="_blank" rel="noopener">ongoing Phase I/Ib</a> trials for lupus nephritis (LN)  a type of kidney disease that causes severe damage to the kidneys and affects about <a href="https://www.kidneyfund.org/all-about-kidneys/other-kidney-diseases/lupus-nephritis-symptoms-treatment-and-complications#:~:text=9%20in%2010%20people%20with,people%20aged%2020%2D40%20years." target="_blank" rel="noopener">50 percent</a> of adults with lupus  and other autoimmune indications.</p>
<p>Artiva <a href="https://stockanalysis.com/stocks/artv/revenue/" target="_blank" rel="noopener">reported</a> revenue of $32.75 million for the 12 months ending March 31, 2024, with an impressive annual revenue growth of 579.21 percent. The companys market capitalization stands at $274.78 million.</p>
<p>Artiva&#8217;s AlloNK has shown promising results in <a href="https://clinicaltrials.gov/study/NCT04673617" target="_blank" rel="noopener">ongoing trials</a>, reducing harmful B cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). The company has initiated a Phase I trial for AlloNK in combination with monoclonal antibodies for LN, marking the first use of allogeneic NK cell therapy for an autoimmune disease in a US clinical trial.</p>
<p>Aside from LN, AlloNK is also being <a href="https://www.artivabio.com/nk-cell-therapy-pipeline/" target="_blank" rel="noopener">researched</a> in Phase I trials for B cell malignancies, rheumatoid arthritis and more, as well as Phase II trials <a href="https://www.clinicaltrials.gov/study/NCT05883449" target="_blank" rel="noopener">initiated</a> in collaboration with Affimed for relapsed/refractory Hodgkin lymphoma. Their pipeline also includes two chimeric antigen receptor (CAR)-based therapies that target human epidermal growth factor receptor 2 (HER2)-positive tumors, such as breast and gastric cancers and CD5-positive T-cell lymphomas and leukemias currently in preclinical studies.</p>
<p>With the IPO proceeds, Artiva plans to speed up its clinical trials and expand its treatment offerings. The company expects to share initial results from their ongoing trials in the first half of 2025.</p>
<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-136742" src="https://xtalks.com/wp-content/uploads/2024/07/Alumis-logo-2.png" alt="biotech ipos 2024" width="490" height="126" srcset="https://xtalks.com/wp-content/uploads/2024/07/Alumis-logo-2.png 490w, https://xtalks.com/wp-content/uploads/2024/07/Alumis-logo-2-300x77.png 300w" sizes="auto, (max-width: 490px) 100vw, 490px" /></p>
<h2><strong>Alumis</strong></h2>
<p><strong>IPO Date:</strong> June 27, 2024</p>
<p><strong>IPO Price:</strong> $16.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:ALMS",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Alumis Inc. is a clinical-stage biopharma company dedicated to replacing broad immunosuppression with targeted, effective treatments, aiming to revolutionize the management of immune-mediated diseases.</p>
<p>In conjunction with the IPO, Alumis is conducting a concurrent private placement of 2,500,000 shares at the same offering price to AyurMaya Capital Management Fund, LP, totaling expected gross proceeds of approximately $250 million from both the IPO and private placement. These funds will support ongoing clinical developments and future research initiatives.</p>
<p>Leading Alumis&#8217; product lineup are the oral small molecule ESK-001 and the brain-penetrant A-005, both allosteric tyrosine kinase 2 (TYK2) inhibitors targeting different aspects of immune-mediated diseases. <a href="https://www.alumis.com/pipeline/esk-001/clinical-programs/" target="_blank" rel="noopener">ESK-001</a> is being evaluated in a <a href="https://clinicaltrials.gov/study/NCT05600036" target="_blank" rel="noopener">Phase II trial</a> for its efficacy in treating moderate-to-severe plaque psoriasis and systemic lupus erythematosus. The Phase II STRIDE trial delivered <a href="https://investors.alumis.com/news-releases/news-release-details/alumis-presents-positive-data-phase-2-clinical-trial-esk-001" target="_blank" rel="noopener">positive results</a>, with ESK-001 meeting its primary endpoints of reduction in psoriasis severity. <a href="https://investors.alumis.com/news-releases/news-release-details/alumis-presents-preclinical-data-allosteric-tyk2-inhibitor-005" target="_blank" rel="noopener">A-005</a>, designed to penetrate the central nervous system (CNS), is under study for potential treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis (MS) and Parkinsons disease.</p>
<p>Alumis plans to initiate multiple Phase III trials for ESK-001 in the second half of 2024, reflecting a deep commitment to combatting immune diseases. Additionally, Phase I trials for A-005 <a href="https://www.globenewswire.com/en/news-release/2024/04/30/2872215/0/en/Alumis-Announces-First-Participant-Dosed-in-Phase-1-Clinical-Trial-of-CNS-Penetrant-Allosteric-TYK2-Inhibitor-A-005.html" target="_blank" rel="noopener">began</a> in early 2024, with initial results anticipated by year-end. In March 2024, Alumis secured <a href="https://www.globenewswire.com/en/news-release/2024/03/06/2841374/0/en/Alumis-Announces-Upsized-259M-Series-C-Financing-to-Advance-Clinical-stage-Pipeline-of-Oral-Therapies-Designed-to-Address-Immune-Dysfunction.html" target="_blank" rel="noopener">$259 million</a> in Series C funding led by Foresite Capital, Samsara BioCapital and venBio Partners. This funding is intended to support Phase III trials for ESK-001 in plaque psoriasis, advancing Phase II trials in other conditions and enhancing its precision data analytics for broader autoimmune applications.</p>
<p>Beyond its TYK2 inhibitors, Alumis is advancing a variety of preclinical programs powered by its proprietary precision data analytics platform.</p>
<p>Since its founding in 2021, Alumis has secured over $600 million from notable life science investors, underscoring its potential and commitment to innovation. As the company transitions to the public market, it aims to impact both market and medical practice in immunology.</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-135815" src="https://xtalks.com/wp-content/uploads/2024/05/Rapport-Therapeutics-1024x303.png" alt="biotech ipos 2024" width="600" height="177" srcset="https://xtalks.com/wp-content/uploads/2024/05/Rapport-Therapeutics-1024x303.png 1024w, https://xtalks.com/wp-content/uploads/2024/05/Rapport-Therapeutics-600x177.png 600w, https://xtalks.com/wp-content/uploads/2024/05/Rapport-Therapeutics-300x89.png 300w, https://xtalks.com/wp-content/uploads/2024/05/Rapport-Therapeutics-768x227.png 768w, https://xtalks.com/wp-content/uploads/2024/05/Rapport-Therapeutics-1536x454.png 1536w, https://xtalks.com/wp-content/uploads/2024/05/Rapport-Therapeutics-2048x605.png 2048w" sizes="auto, (max-width: 600px) 100vw, 600px" /></p>
<h2><strong>Rapport Therapeutics</strong></h2>
<p><strong>IPO Date:</strong> June 7, 2024</p>
<p><strong>IPO Price:</strong> $17.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:RAPP",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Rapport Therapeutics is advancing the field of small molecule medicines targeting central nervous system (CNS) disorders through their innovative RAP technology platform, focusing on manipulating receptor-associated proteins (RAPs). These proteins are critical for neuronal receptor function and expression, making them key targets in CNS disorders. Rapport&#8217;s strategic goal is to develop precise, targeted therapies for CNS disorders, which could lead to more effective treatments with fewer side effects.</p>
<p>The company recently issued 8,000,000 shares of common stock at $17.00 per share (totaling $136 million dollars), with an additional 1,200,000 shares available for underwriters to purchase. This IPO supports Rapport&#8217;s ongoing research and development, especially in the CNS disorder space. Rapport has listed its stocks on the Nasdaq Global Market under the ticker &#8220;RAPP.&#8221;</p>
<p>RAP-219, Rapport&#8217;s leading candidate developed using their RAP technology, is an AMPA receptor (AMPAR) negative allosteric modulator (NAM). It targets TARP8, a RAP associated with AMPARs, enhancing specificity. AMPARs regulate brain glutamate activity that has been <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912368/" target="_blank" rel="noopener">implicated</a> in the development of several neurological diseases.</p>
<p>TARP8 is predominantly found in brain regions like the hippocampus, which is directly involved in focal epilepsy. The specificity of RAP-219 might offer a more targeted approach to treating epilepsy, potentially reducing side effects compared to broader-acting drugs.</p>
<p>Rapport Therapeutics also explores other avenues through their RAP technology. They have discovery-stage nicotinic acetylcholine receptor (nAChR) programs aimed at chronic pain (6) and hearing disorders (910), again leveraging their ability to target specific receptor subunits that traditional methods might miss.</p>
<p>Rapport has successfully completed Phase I clinical trials assessing the safety and tolerability of RAP-219 in healthy adults. These trials are foundational in establishing the initial safety profile of RAP-219 before proceeding to more targeted patient populations. The company plans to initiate a <a href="https://classic.clinicaltrials.gov/ct2/show/NCT06377930?term=rap-219+phase2a&amp;draw=2&amp;rank=1" target="_blank" rel="noopener">Phase IIa</a> proof-of-concept trial in mid-2024. This trial will focus on adult patients with drug-resistant focal epilepsy, with expectations to deliver topline results by mid-2025. Additionally, Phase IIa trials for RAP-219 targeting peripheral neuropathic pain and bipolar disorder are scheduled for the second half of 2024 and in 2025.</p>
<p>Another molecule targeting TARP8, RAP-199, is slated to enter Phase I trials in the first half of 2025. This candidate also leverages the RAP technology but with different chemical and pharmacokinetic properties.</p>
<p><img loading="lazy" decoding="async" class="size-full wp-image-133908" src="https://xtalks.com/wp-content/uploads/2024/02/contineum_rgb-1.jpg" alt="biotech IPOs in 2024" width="1024" height="244" srcset="https://xtalks.com/wp-content/uploads/2024/02/contineum_rgb-1.jpg 1024w, https://xtalks.com/wp-content/uploads/2024/02/contineum_rgb-1-600x143.jpg 600w, https://xtalks.com/wp-content/uploads/2024/02/contineum_rgb-1-300x71.jpg 300w, https://xtalks.com/wp-content/uploads/2024/02/contineum_rgb-1-768x183.jpg 768w" sizes="auto, (max-width: 1024px) 100vw, 1024px" /></p>
<h2 class="mceTemp">Contineum Therapeutics</h2>
<p><strong>IPO Date:</strong> April 4, 2024</p>
<p><strong>IPO Price:</strong> $16.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:CTNM",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Contineum Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, recently unveiled the pricing details of its IPO. The offering consisted of 6,875,000 shares of common stock priced at $16.00 per share for public acquisition. Trading of these shares started on the Nasdaq Global Select Market on April 4, 2024, under the ticker symbol CTNM.</p>
<p>The company&#8217;s pipeline features a range of internally developed programs focused on neuroinflammation and immune disorders. A standout within this lineup is PIPE-791, an LPA1 receptor antagonist currently undergoing Phase I trials for idiopathic pulmonary fibrosis and progressive multiple sclerosis. <em>In vitro</em> experiments have highlighted PIPE-791&#8217;s capabilities in encouraging oligodendrocyte differentiation and myelination, as well as its protective effects against cytokine-induced cell death in oligodendrocytes. Furthermore, preclinical <em>in vivo</em> studies have shown its ability to engage central nervous system LPA1 receptors, promoting remyelination and reducing neuroinflammation.</p>
<p>Contineum Therapeutics obtained clearance from the US Food and Drug Administration (FDA) last year to start a Phase I clinical trial for PIPE-791. This randomized, double-blind, placebo-controlled dose-ranging study is anticipated to enroll around 80 healthy volunteer subjects.</p>
<p>Another prominent candidate in Contineum&#8217;s portfolio is PIPE-307, which is being developed as a potential first-in-class selective inhibitor of the M1 receptor. This candidate is currently in Phase II trials for relapsing-remitting multiple sclerosis and is expected to begin Phase II trials for depression by mid-2024. Initial results from Phase I trials have been promising, showing that PIPE-307 has a linear pharmacokinetic (PK) profile that aligns with preclinical modeling. Additionally, it has shown good tolerability across all dosage groups tested. Importantly, the dosages used in the Phase I trials have resulted in brain uptake levels that correlate with the remyelination observed in preclinical studies.</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-133906" src="https://xtalks.com/wp-content/uploads/2024/02/Boundless_Logo-1.jpg" alt="biotech ipos in 2024" width="800" height="128" srcset="https://xtalks.com/wp-content/uploads/2024/02/Boundless_Logo-1.jpg 1024w, https://xtalks.com/wp-content/uploads/2024/02/Boundless_Logo-1-600x96.jpg 600w, https://xtalks.com/wp-content/uploads/2024/02/Boundless_Logo-1-300x48.jpg 300w, https://xtalks.com/wp-content/uploads/2024/02/Boundless_Logo-1-768x123.jpg 768w" sizes="auto, (max-width: 800px) 100vw, 800px" /></p>
<h2>Boundless Bio</h2>
<p><strong>IPO Date:</strong> March 27, 2024</p>
<p><strong>IPO Price:</strong> $16.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:BOLD",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Boundless Bio, a pioneering clinical-stage oncology company dedicated to exploring extrachromosomal DNA (ecDNA) biology to revolutionize therapies for patients with previously refractory oncogene-amplified cancers, recently unveiled the pricing details of its IPO. The offering consisted of 6,250,000 shares of common stock priced at $16.00 per share for public acquisition. Trading of these shares started on the Nasdaq Global Select Market on March 27, 2024, under the ticker symbol BOLD.</p>
<p>The companys primary clinical focus lies in a novel approach to cancer therapeutics, addressing the substantial unmet needs of patients with oncogene-amplified tumors by targeting ecDNA, a fundamental driver of oncogene amplification observed in over 14 percent of cancer patients.</p>
<p>Using its proprietary Spyglass platform, the company identifies key targets crucial for the functionality of ecDNA. It then designs and develops small molecule drugs, known as ecDNA-directed therapies (ecDTx), aimed at inhibiting these targets. This approach blocks the ability of cancer cells to use ecDNA for growth, adaptation and resistance to current treatments.</p>
<p>Boundless Bio is at the forefront of developing the first ecDTx, BBI-355, currently under evaluation in a Phase I/II clinical trial. Additionally, the company announced promising preclinical data last year regarding its second ecDTx, BBI-825, an innovative, orally available, selective inhibitor of ribonucleotide reductase (RNR). BBI-825 has showcased significant RNR inhibition across various tumor cell lines and induced tumor regressions in ecDNA-enabled preclinical cancer models. Presently, it is undergoing assessment in Investigational New Drug (IND)-enabling studies.</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-133900" src="https://xtalks.com/wp-content/uploads/2024/02/Chromocell-logo_as-is-01-1024x198.png" alt="biotech ipos in 2024" width="700" height="135" srcset="https://xtalks.com/wp-content/uploads/2024/02/Chromocell-logo_as-is-01-1024x198.png 1024w, https://xtalks.com/wp-content/uploads/2024/02/Chromocell-logo_as-is-01-600x116.png 600w, https://xtalks.com/wp-content/uploads/2024/02/Chromocell-logo_as-is-01-300x58.png 300w, https://xtalks.com/wp-content/uploads/2024/02/Chromocell-logo_as-is-01-768x149.png 768w, https://xtalks.com/wp-content/uploads/2024/02/Chromocell-logo_as-is-01-1536x297.png 1536w, https://xtalks.com/wp-content/uploads/2024/02/Chromocell-logo_as-is-01.png 2001w" sizes="auto, (max-width: 700px) 100vw, 700px" /></p>
<h2>Channel Therapeutics Corporation &#8211; Chromocell</h2>
<p><strong>IPO Date:</strong> February 15, 2024</p>
<p><strong>IPO Price:</strong> $6.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "AMEX:CHRO",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Chromocell Therapeutics Corporation, a clinical-stage biotech company dedicated to pioneering new non-opioid therapeutics for pain relief, recently disclosed the pricing details of its IPO. The offering comprised 1,100,000 shares of common stock priced at $6.00 per share for public acquisition. Trading of these shares started on the Nasdaq Global Select Market on February 15, 2024, under the ticker symbol CHRO.</p>
<p>The companys primary clinical focus revolves around selectively targeting the sodium ion channel NaV1.7 for treating various forms of chronic neuropathic pain and eye pain. Chromocells leading candidate, CC8464, is designed as a potent and state-dependent inhibitor of human NaV1.7 with target selectivity. This design aims to preferentially impact injured or inflamed tissues while exerting minimal effects on NaV1.7 channels in uninjured or healthy tissues.</p>
<p>CC8464 is currently undergoing Phase I clinical investigation, with encouraging results from animal models of neuropathic pain suggesting its potential efficacy across several neuropathic pain types. Furthermore, it offers promise for addressing erythromelalgia (EM), a rare neuromuscular condition lacking approved treatments.</p>
<p>In February, Chromocell announced a <a href="https://www.benuvia.com/benuvia-chromocell-therapeutics-corp-strategic-partnership-to-advance-healthcare-solutions/" target="_blank" rel="noopener">strategic partnership with Benuvia Operations</a>, a prominent figure in pharmaceutical innovation, aimed at advancing healthcare through pioneering research, development and commercialization efforts. By using the manufacturing and supply services provided by Benuvia, Chromocell anticipates developing clinical programs for one or more licensed products within 18 months, thus accelerating the progress of potentially groundbreaking therapies.</p>
<p><img loading="lazy" decoding="async" class="aligncenter size-large wp-image-131335" src="https://xtalks.com/wp-content/uploads/2024/02/Metagenomi-1-1024x130.png" alt="biotech IPOs in 2024" width="892" height="113" srcset="https://xtalks.com/wp-content/uploads/2024/02/Metagenomi-1-1024x130.png 1024w, https://xtalks.com/wp-content/uploads/2024/02/Metagenomi-1-600x76.png 600w, https://xtalks.com/wp-content/uploads/2024/02/Metagenomi-1-300x38.png 300w, https://xtalks.com/wp-content/uploads/2024/02/Metagenomi-1-768x98.png 768w, https://xtalks.com/wp-content/uploads/2024/02/Metagenomi-1-1536x195.png 1536w, https://xtalks.com/wp-content/uploads/2024/02/Metagenomi-1.png 1920w" sizes="auto, (max-width: 892px) 100vw, 892px" /></p>
<h2>Metagenomi</h2>
<p><strong>IPO Date:</strong> February 8, 2024</p>
<p><strong>IPO Price:</strong> $15.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:MGX",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Metagenomi is a pioneering precision genetic medicines company dedicated to developing curative therapeutics for patients through its proprietary, comprehensive metagenomics-derived toolbox. Recently, it announced the pricing of its IPO of 6,250,000 shares of common stock at a price of $15.00 per share for the public. Trading of these shares commenced on the Nasdaq Global Select Market on February 9, 2024, under the ticker symbol MGX.</p>
<p>Metagenomis groundbreaking discovery platform unlocks novel cellular machinery sourced from natural environments to create next-generation genome editing tools. Its CRISPR-associated transposase (CAST) systems, tailored for large, site-specific gene integrations, consistently achieve programmable transposition into multiple endogenous sites within the human genome.</p>
<p>Preliminary data from non-human primate trials using MG29-1, a novel type V CRISPR system, demonstrate promising outcomes for therapeutic gene knockdown. The study revealed Metagenomis ability to achieve high editing efficiency (up to 55 percent of the entire liver and approximately 75 percent of hepatocytes) with MG29-1 in primary human cells in laboratory settings, as well as in mice and non-human primates.</p>
<p>Furthermore, Metagenomi has been actively constructing libraries of nucleases, deaminases and reverse transcriptases, critical components for advanced engineering systems facilitating larger integrations. Through RNA-Mediated Integration Systems (RIGS), the company achieves both small edits (prime editing) and substantial edits, addressing complex gene modifications such as insertions, deletions and various types of point mutations.</p>
<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-131333" src="https://xtalks.com/wp-content/uploads/2024/02/Telomir-Pharmaceuticals.png" alt="new biotech IPOs in 2024" width="739" height="220" srcset="https://xtalks.com/wp-content/uploads/2024/02/Telomir-Pharmaceuticals.png 739w, https://xtalks.com/wp-content/uploads/2024/02/Telomir-Pharmaceuticals-600x179.png 600w, https://xtalks.com/wp-content/uploads/2024/02/Telomir-Pharmaceuticals-300x89.png 300w" sizes="auto, (max-width: 739px) 100vw, 739px" /></p>
<h2>Telomir Pharmaceuticals</h2>
<p><strong>IPO Date:</strong> February 8, 2024</p>
<p><strong>IPO Price:</strong> $7.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:TELO",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Telomir Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company dedicated to advancing the development and commercialization of TELOMIR-1, an innovative small molecule designed to serve as an oral <em>in situ</em> therapeutic treatment for human stem cells. Recently, the company announced the pricing of its IPO of 1,000,000 shares of common stock at a public offering price of $7.00 per share. Trading of these shares commenced on the Nasdaq Capital Market on February 9, 2024, under the ticker symbol &#8220;TELO.&#8221;</p>
<p>TELOMIR-1 represents a pioneering approach as the first small molecule intended to elongate DNA&#8217;s protective telomere caps, potentially facilitating age reversal. By leveraging its metal-binding properties to target specific classes of enzymes, TELOMIR-1 is poised to selectively influence the key processes responsible for the concentration and accumulation of iron and copper in serum, with implications for diseases such as hemochromatosis and cancer.</p>
<p>Telomir Pharmaceuticals initially focuses on treatments aimed at inhibiting the production of pro-inflammatory cytokines, notably IL-17, through the oral administration of TELOMIR-1 as a therapeutic intervention for stem cells <em>in situ</em>. Investigations into TELOMIR-1s potential as a therapeutic agent extend to addressing age-related inflammatory conditions like hemochromatosis and aiding in post-chemotherapy recovery. This is achieved by disrupting and preventing the IL-17-induced inflammatory pathways that contribute to the systemic imbalance of cellular metals.</p>
<p><img loading="lazy" decoding="async" class="size-large wp-image-131332" src="https://xtalks.com/wp-content/uploads/2024/02/Kyverna-Therapeutics-1-1024x260.jpg" alt="Kyverna Therapeutics is a new biotech IPO in 2024" width="892" height="226" srcset="https://xtalks.com/wp-content/uploads/2024/02/Kyverna-Therapeutics-1-1024x260.jpg 1024w, https://xtalks.com/wp-content/uploads/2024/02/Kyverna-Therapeutics-1-600x153.jpg 600w, https://xtalks.com/wp-content/uploads/2024/02/Kyverna-Therapeutics-1-300x76.jpg 300w, https://xtalks.com/wp-content/uploads/2024/02/Kyverna-Therapeutics-1-768x195.jpg 768w, https://xtalks.com/wp-content/uploads/2024/02/Kyverna-Therapeutics-1-1536x391.jpg 1536w, https://xtalks.com/wp-content/uploads/2024/02/Kyverna-Therapeutics-1.jpg 1998w" sizes="auto, (max-width: 892px) 100vw, 892px" /></p>
<h2>Kyverna Therapeutics</h2>
<p><strong>IPO Date:</strong> February 7, 2024</p>
<p><strong>IPO Price:</strong> $22.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:KYTX",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>Kyverna Therapeutics, Inc., a leading clinical-stage biopharmaceutical company dedicated to pioneering cell therapies for individuals afflicted by autoimmune diseases, has officially concluded its expanded IPO of 16,675,000 shares of common stock. Trading of Kyvernas common stock commenced on the Nasdaq Global Select Market on February 8, 2024, under the ticker symbol KYTX.</p>
<p>The focal point of Kyverna&#8217;s efforts lies in its lead product candidate, KYV-101, which is progressing through clinical development across rheumatology and neurology. Notably, Phase II trials for multiple sclerosis and myasthenia gravis, a Phase I/II trial for systemic sclerosis, and two ongoing multi-center, open-label Phase I trials in the US and Germany for patients with lupus nephritis underscore the breadth of its potential impact. KYV-101, a fully human CD19 CAR T-cell therapy tailored for individuals with B cell-driven autoimmune diseases, recently obtained fast track designation from the FDA for the treatment of multiple sclerosis.</p>
<p>Kyverna harnesses cutting-edge CAR T engineering and insights gleaned from conventional CAR T-cell therapies for cancer to amass a formidable collection of cell therapy assets and tools targeting various facets of autoimmune disease pathogenesis. Specifically, KYV-101 zeroes in on CD19, a surface protein expressed by B cells that plays a pivotal role in numerous autoimmune disorders. The company remains committed to exploring additional indications for KYV-101 and cultivating a robust pipeline of innovative immunotherapy candidates aimed at addressing unmet medical needs in the realm of autoimmune diseases.</p>
<hr />
<p>Related: <a href="https://xtalks.com/how-kyverna-therapeutics-is-pioneering-cell-therapy-for-autoimmune-diseases-3685/">How Kyverna Therapeutics Is Pioneering Cell Therapy for Autoimmune Diseases</a></p>
<hr />
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-130804" src="https://xtalks.com/wp-content/uploads/2024/02/Fractyl-Health.png" alt="Fractyl health is one of the biotech IPOs in 2024" width="700" height="210" srcset="https://xtalks.com/wp-content/uploads/2024/02/Fractyl-Health.png 975w, https://xtalks.com/wp-content/uploads/2024/02/Fractyl-Health-600x180.png 600w, https://xtalks.com/wp-content/uploads/2024/02/Fractyl-Health-300x90.png 300w, https://xtalks.com/wp-content/uploads/2024/02/Fractyl-Health-768x231.png 768w" sizes="auto, (max-width: 700px) 100vw, 700px" /></p>
<h2>Fractyl Health</h2>
<p><strong>IPO Date:</strong> February 1, 2024</p>
<p><strong>IPO Price:</strong> $15.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:GUTS",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p><a href="https://www.fractyl.com/" target="_blank" rel="noopener">Fractyl Health</a>, a leading metabolic therapeutics company dedicated to advancing innovative solutions for type 2 diabetes (T2D) and obesity treatment, has recently disclosed the pricing details of its IPO. The company will offer 7,333,333 shares of common stock at a public offering price of $15.00 per share, resulting in total gross proceeds of approximately $110.0 million. Fractyl Healths common stock commenced trading on the Nasdaq Global Market under the ticker symbol GUTS on February 2, 2024.</p>
<p>Fractyl Health is actively developing two promising therapies for T2D treatment. Revita, an outpatient endoscopic procedural therapy, which aims to eliminate insulin needs and enhance glycemic control by ablating dysfunctional duodenal mucosa. Rejuva, a local adeno-associated virus (AAV)-delivered pancreatic gene therapy, seeks to enhance islet health through advanced delivery systems and proprietary screening methods, targeting the pancreas with metabolically active gene therapy candidates.</p>
<p>In a recent development, Fractyl Health announced the selection of RJVA-001 as its inaugural clinical T2D candidate in the Rejuva gene therapy platform. RJVA-001 represents the first GLP-1 pancreatic gene therapy (GLP1 PGTx) candidate nominated by the company, designed to address issues such as treatment discontinuation and metabolic rebound commonly observed with existing GLP-1-based therapies. Fractyl Health has initiated discussions with European regulators to establish an investigational new drug (IND)-enabling pathway for RJVA-001 in the treatment of T2D. The company anticipates completing IND-enabling studies, or equivalent milestones, for RJVA-001 by the second half of 2024.</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-130806" src="https://xtalks.com/wp-content/uploads/2024/02/Alto-Neuroscience.jpg" alt="Alto Neuroscience is one of the biotech IPOs in 2024" width="700" height="248" srcset="https://xtalks.com/wp-content/uploads/2024/02/Alto-Neuroscience.jpg 924w, https://xtalks.com/wp-content/uploads/2024/02/Alto-Neuroscience-600x213.jpg 600w, https://xtalks.com/wp-content/uploads/2024/02/Alto-Neuroscience-300x106.jpg 300w, https://xtalks.com/wp-content/uploads/2024/02/Alto-Neuroscience-768x273.jpg 768w" sizes="auto, (max-width: 700px) 100vw, 700px" /></p>
<h2>Alto Neuroscience</h2>
<p><strong>IPO Date:</strong> February 1, 2024</p>
<p><strong>IPO Price:</strong> $16.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NYSE:ANRO",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p><a href="https://www.altoneuroscience.com/" target="_blank" rel="noopener">Alto Neuroscience</a> is a clinical-stage biopharmaceutical company committed to reshaping psychiatry through the application of neurobiology to craft personalized and highly effective treatment options. Recently, it disclosed the pricing of its expanded IPO of 8,040,000 shares of common stock at a public offering price of $16.00 per share. Trading of the shares started on the New York Stock Exchange on February 2, 2024, under the ticker symbol ANRO.</p>
<p>Alto Neuroscience uses an AI-enabled platform to enhance the identification of patients likely to respond to novel product candidates and propel drug development through biomarkers. Currently, several noteworthy candidates are undergoing Phase II evaluation. For instance, in 2023, Alto Neuroscience disclosed encouraging results from its Phase 2a investigation of ALTO-300, a groundbreaking treatment for depression. Post-administration of ALTO-300, patients characterized by an electroencephalogram (EEG) biomarker exhibited substantial clinical amelioration in depression symptoms and higher response rates. These findings underscore the potential of ALTO-300 as an innovative treatment for major depressive disorder (MDD).</p>
<p>Another noteworthy candidate, ALTO-100, also demonstrates efficacy and favorable safety in patients with post-traumatic stress disorder (PTSD) in its Phase II trial. The PTSD patient group defined by biomarkers (n=44) displayed a mean reduction of 17.5 points in CAPS-5 scores at Week 4, compared to 12.9 points in the non-biomarker patient group (n=40), alongside a favorable safety and tolerability profile.</p>
<p>By harnessing its AI-enabled Precision Psychiatry Platform, Alto Neuroscience can predict clinical response and match each patient to the appropriate product candidate by identifying and prospectively replicating brain biomarkers through analysis of EEG activity, neurocognitive task performance, wearable devices and other metrics.</p>
<p><img loading="lazy" decoding="async" class="aligncenter size-full wp-image-136517" src="https://xtalks.com/wp-content/uploads/2024/07/FibroBiologics-scaled.jpg" alt="" width="2560" height="739" srcset="https://xtalks.com/wp-content/uploads/2024/07/FibroBiologics-scaled.jpg 2560w, https://xtalks.com/wp-content/uploads/2024/07/FibroBiologics-scaled-600x173.jpg 600w, https://xtalks.com/wp-content/uploads/2024/07/FibroBiologics-300x87.jpg 300w, https://xtalks.com/wp-content/uploads/2024/07/FibroBiologics-1024x296.jpg 1024w, https://xtalks.com/wp-content/uploads/2024/07/FibroBiologics-768x222.jpg 768w, https://xtalks.com/wp-content/uploads/2024/07/FibroBiologics-1536x443.jpg 1536w, https://xtalks.com/wp-content/uploads/2024/07/FibroBiologics-2048x591.jpg 2048w" sizes="auto, (max-width: 2560px) 100vw, 2560px" /></p>
<h2>FibroBiologics</h2>
<p><strong>IPO Date:</strong> January 31, 2024</p>
<p><strong>IPO Price:</strong> $30.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:FBLG",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p>&nbsp;</p>
<p>FibroBiologics, a clinical-stage biotech company, <a href="https://ir.fibrobiologics.com/news-events/press-releases/detail/21/fibrobiologics-announces-direct-listing-on-nasdaq-under-the-stock-ticker-fblg" target="_blank" rel="noopener">commenced</a> trading on the Nasdaq under the stock ticker FBLG following its direct listing on January 31, 2024. The offering included 4,806,226 shares of common stock at a reference price of $30.00 per share, allowing existing shareholders to sell their shares without underwriters. On June 4, 2024, FibroBiologics offered up to <a href="https://ir.fibrobiologics.com/sec-filings/all-sec-filings/content/0001493152-24-022517/forms-1a.htm" target="_blank" rel="noopener">1,742,160 units</a>, each consisting of one share of common stock and one warrant to purchase an additional share, priced at $11.48 per unit, leveraging its current market standing.</p>
<p>Founded in Houston, Texas, FibroBiologics emerged from its predecessor, FibroGenesis, in 2021. The company focuses on treating chronic diseases such as degenerative disc disease, multiple sclerosis (MS), wound healing, certain cancers and life extension applications like thymic and splenic involution reversal. Using fibroblasts, which can regenerate tissue and organs similarly to stem cells but with quicker culture doubling time, FibroBiologics offers a non-invasive harvesting method from skin donors.</p>
<p>Their pipeline includes CybroCell for degenerative disc disease, which uses allogeneic fibroblast cells to repair intervertebral disc cartilage, showing positive results in animal studies and receiving the US Food and Drug Administration (FDA) conditional <a href="https://www.businesswire.com/news/home/20181128005255/en/FDA-Clears-SpinalCyte-IND-Application-for-Universal-Donor-Cell-Therapy-to-Treat-Lower-Back-Pain" target="_blank" rel="noopener">Investigational New Drug (IND) clearance</a> for a Phase I/II clinical trial. The global degenerative disc disease market is valued to reach <a href="https://www.gminsights.com/industry-analysis/degenerative-disc-disease-treatment-market" target="_blank" rel="noopener">$49.7 billion in 2032</a>.</p>
<p>FibroBiologics investigational cell therapy, CYMS101, for MS leverages fibroblasts&#8217; immunomodulatory properties and demonstrated safety and preliminary efficacy in a Phase I trial in Mexico, and FibroBiologics plans to file an IND for a Phase II trial in the US. Statista estimated that the market for MS drugs will hit an annual revenue of <a href="https://www.statista.com/outlook/hmo/pharmaceuticals/multiple-sclerosis-drugs/worldwide" target="_blank" rel="noopener">$21.52 billion in 2024</a>.</p>
<p>CYWC628 for wound healing has shown significant improvements in preclinical studies, with an IND submission expected in 2024. The wound care market, valued at approximately $17 billion globally in 2021, is projected to grow to <a href="https://www.marketsandmarkets.com/Market-Reports/wound-care-market-371.html" target="_blank" rel="noopener">$28.6 billion by 2028</a>.</p>
<p>CYTER915 focuses on regenerating the thymus and spleen to enhance immune function and extend human life. It taps into the anti-aging therapeutics market, which is projected to reach <a href="https://www.insightaceanalytic.com/report/global-anti-aging-therapeutics-market-2022-/1249" target="_blank" rel="noopener">$2.53 billion by 2031</a>.</p>
<p>FibroBiologics recently expanded its patent portfolio (<a href="https://www.sec.gov/Archives/edgar/data/1958777/000119312523130251/d494812dex99.pdf" target="_blank" rel="noopener">over 150 patents issued/pending</a>), reinforcing its position in regenerative medicine. The company was granted an <a href="https://ir.fibrobiologics.com/news-events/press-releases/detail/32/fibrobiologics-granted-patent-for-regeneration-of-cartilage-type-cells-by-the-australian-patent-office" target="_blank" rel="noopener">Australian patent</a> for cartilage regeneration, three <a href="https://ir.fibrobiologics.com/news-events/press-releases/detail/23/fibrobiologics-announces-three-united-states-patents-for-fibroblast-technology" target="_blank" rel="noopener">US patents</a> for cartilage repair, disc degenerative disease treatment and gene therapy and three <a href="https://ir.fibrobiologics.com/news-events/press-releases/detail/22/fibrobiologics-announces-three-japanese-patents-on-fibroblast-technology" target="_blank" rel="noopener">Japanese patents</a> focusing on enhancing fibroblast therapeutic activity. They also filed a US patent application for using fibroblast technology to potentially treat <a href="https://ir.fibrobiologics.com/news-events/press-releases/detail/30/fibrobiologics-files-patent-application-covering-fibroblast-based-technology-for-the-potential-treatment-of-lupus" target="_blank" rel="noopener">lupus</a>, showcasing fibroblasts&#8217; versatility in modulating immune responses.</p>
<p>FibroBiologics faces competition from companies like Aesculap Implant Systems (<a href="https://www.ijssurgery.com/content/15/4/612" target="_blank" rel="noopener">activL Artificial Disc</a>) in degenerative disc disease, TG Therapeutics <a href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-announces-fda-approval-briumvitm-ublituximab" target="_blank" rel="noopener">Briumvi (ublituximab)</a> in MS and numerous entities in wound healing, including Smith &amp; Nephews <a href="https://www.smith-nephew.com/en-ca/news/2022/01/24/20220124-pico-7-and-pico-14-negative-pressure-wound-therapy-systems#:~:text=The%20U.S.%20Food%20and%20Drug,Post%2Doperative%20Seroma" target="_blank" rel="noopener">PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy (sNPWT) system</a> for Class I and II wounds. Despite intense competition, FibroBiologics aims to differentiate itself with unique fibroblast-based therapies, focusing on high unmet needs and partnering with contract research organizations (CROs) for efficient clinical trials. The company is well-positioned to advance its innovative platform and deliver groundbreaking treatments.</p>
<p><img loading="lazy" decoding="async" class="aligncenter size-large wp-image-130811" src="https://xtalks.com/wp-content/uploads/2024/02/ArriVent-1024x249.png" alt="ArriVent Biopharma is one of the biotech IPOs in 2024." width="892" height="217" srcset="https://xtalks.com/wp-content/uploads/2024/02/ArriVent-1024x249.png 1024w, https://xtalks.com/wp-content/uploads/2024/02/ArriVent-600x146.png 600w, https://xtalks.com/wp-content/uploads/2024/02/ArriVent-300x73.png 300w, https://xtalks.com/wp-content/uploads/2024/02/ArriVent-768x187.png 768w, https://xtalks.com/wp-content/uploads/2024/02/ArriVent-1536x374.png 1536w, https://xtalks.com/wp-content/uploads/2024/02/ArriVent.png 1770w" sizes="auto, (max-width: 892px) 100vw, 892px" /></p>
<h2>ArriVent BioPharma</h2>
<p><strong>IPO Date:</strong> January 25, 2024</p>
<p><strong>IPO Price:</strong> $18.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:AVBP",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p><!-- TradingView Widget END --></p>
<p>&nbsp;</p>
<p><a href="https://arrivent.com/" target="_blank" rel="noopener">ArriVent BioPharma</a> is a clinical-stage biopharmaceutical company committed to identifying, developing and commercializing differentiated medicines to meet the unmet medical needs of cancer patients. Recently, it announced the pricing of its increased IPO of 9,722,222 shares of its common stock at a public offering price of $18.00 per share. ArriVents common stock started trading on the Nasdaq Global Market on January 26, 2024, under the ticker symbol AVBP.</p>
<p>As a clinical-stage entity, ArriVent is actively assessing its leading drug candidate, furmonertinib, an oral, brain penetrant, epidermal growth factor receptor (EGFR) mutant-selective inhibitor in its Phase III clinical trial.In 2023, the US Food and Drug Administration (FDA) granted Breakthrough Therapy designation for furmonertinib for the treatment of patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Interim results from the trial demonstrated that furmonertinib has promising anti-tumor activity as a single agent with a well-tolerated safety profile in first-line and previously treated patients. The pivotal Phase III FURVENT trial of furmonertinib for the treatment of first-line NSCLC with EGFR exon 20 insertion mutations is currently enrolling patients globally.</p>
<p>ArriVent is constructing its pipeline with a profound grasp of cancer biology and unmet medical needs and is extending these competencies to other medications and research collaborations.</p>
<p><img loading="lazy" decoding="async" class="aligncenter wp-image-130809" src="https://xtalks.com/wp-content/uploads/2024/02/CG-Oncology-1024x457.jpg" alt="CG Oncology is one of the biotech IPOs in 2024." width="700" height="313" srcset="https://xtalks.com/wp-content/uploads/2024/02/CG-Oncology-1024x457.jpg 1024w, https://xtalks.com/wp-content/uploads/2024/02/CG-Oncology-scaled-600x268.jpg 600w, https://xtalks.com/wp-content/uploads/2024/02/CG-Oncology-300x134.jpg 300w, https://xtalks.com/wp-content/uploads/2024/02/CG-Oncology-768x343.jpg 768w, https://xtalks.com/wp-content/uploads/2024/02/CG-Oncology-1536x686.jpg 1536w, https://xtalks.com/wp-content/uploads/2024/02/CG-Oncology-2048x915.jpg 2048w" sizes="auto, (max-width: 700px) 100vw, 700px" /></p>
<h2>CG Oncology</h2>
<p><strong>IPO Date:</strong>January 24, 2024</p>
<p><strong>IPO Price:</strong> $19.00</p>
<p><b>Current Share Price:</b></p>
<div class="tradingview-widget-container">
<p><script type="text/javascript" src="https://s3.tradingview.com/external-embedding/embed-widget-single-quote.js" async>
  {
  "symbol": "NASDAQ:CGON",
  "width": 350,
  "isTransparent": false,
  "colorTheme": "light",
  "locale": "en"
}
  </script></p>
</div>
<p><!-- TradingView Widget END --></p>
<p>&nbsp;</p>
<p><a href="https://xtalks.com/gsks-arexvy-leads-over-pfizers-abrysvo-in-year-one-of-rsv-vaccine-market-battle-3707/" target="_blank" rel="noopener">CG Oncology</a> is a late-stage clinical biopharma company dedicated to the development and commercialization of a potential backbone bladder-sparing therapeutic for patients suffering from bladder cancer. Recently, it disclosed the completion of its increased IPO of 23,000,000 shares of its common stock. CG Oncologys common stock is now listed on the Nasdaq Global Select Market under the ticker symbol CGON.</p>
<p>CG Oncologys product candidate, cretostimogene grenadenorepvec, represents an investigational engineered oncolytic immunotherapy. In Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC), cretostimogene has demonstrated clinical benefit and has generally been well-tolerated in clinical trials, both as a monotherapy and in combination with other therapies. Additionally, it is undergoing Phase II evaluation in combination with pembrolizumab for the same indication. Furthermore, cretostimogene is being assessed in combination with nivolumab for other types of bladder cancer. They are currently planning further studies in bladder cancer.</p>
<p>Last month, the FDA granted fast track and breakthrough therapy designations to cretostimogene grenadenorepvec for potential therapeutic use in patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ, with or without Ta or T1 tumors. This decision is supported by ongoing clinical trials, including the Phase III BOND-003 trial, which demonstrated that intravesically delivered oncolytic immunotherapy provided clinical benefit in the form of complete responses with acceptable tolerability.</p>
<hr />
<p>To have your company featured on Xtalks, please email Vera Kovacevic, PhD, at: <a href="/cdn-cgi/l/email-protection#57213225363c172f23363b3c247934383a"><span class="__cf_email__" data-cfemail="85f3e0f7e4eec5fdf1e4e9eef6abe6eae8">[email&#160;protected]</span></a><br />
<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script src="https://platform.linkedin.com/in.js" type="text/javascript"> lang: en_US</script><br />
<script type="IN/FollowCompany" data-id="1845094" data-counter="bottom"></script></p>
<div class="_form_92"></div>
<p><script src="https://xtalks.activehosted.com/f/embed.php?id=92" charset="utf-8"><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span></script></p>
</div>
					</div><!-- .entry-content -->
					<footer class="entry-footer">
						<div class="row">
							<div class="small-12 columns">
											<div class="keywords">
				<strong>Keywords: </strong>
				<ul>
																																																																						<li><a href="https://xtalks.com/tag/biotech/" title="Biotech">Biotech</a></li>, <li><a href="https://xtalks.com/tag/featured/" title="Featured">Featured</a></li>, <li><a href="https://xtalks.com/tag/highlight/" title="Highlight">Highlight</a></li>, <li><a href="https://xtalks.com/tag/initial-public-offering/" title="Initial Public Offering">Initial Public Offering</a></li>, <li><a href="https://xtalks.com/tag/ipo/" title="IPO">IPO</a></li>				</ul>
			</div>
									</div>
						</div>
					</footer><!-- .entry-footer -->

						<script type="application/ld+json">
		{
			"@context": "https://schema.org",
      "@type": "VideoObject",
      "name": "Biotech IPOs in 2024: Navigating the New Wave of Innovation",
      "description": "An initial public offering (IPO) is the process by which a privately held company offers its shares to the public for the first time, allowing it to become a publicly traded company. In the biotech industry, a biotech IPO refers to a specific case where a biotechnology company goes public and lists its shares on a stock exchange. This enables the company to raise funds from public investors. Successful biotech IPOs in 2024 have the potential to generate substantial returns for early investors and provide the crucial capital required for biotech firms to sustain and advance their research and development endeavors.\r\n\r\n\r\n\r\nRelated: Biotech IPOs in 2023: Shaping the Future of Innovation\r\n\r\n\r\n\r\n[embed]https:\/\/youtu.be\/JUjMomWFSpI[\/embed]\r\n\r\nHere are the 29 biotech IPOs in 2024 that have made it to Wall Street so far:\r\n\r\n\r\nJupiter Neurosciences\r\nIPO Date: December 3, 2024\r\n\r\nInitial IPO Price: $4.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nJupiter Neurosciences, a clinical-stage pharmaceutical company focused on neuroinflammation, recently launched its IPO on the Nasdaq Capital Market under the ticker symbol \"JUNS.\" The IPO offered 2,750,000 shares of common stock priced at $4.00 per share, aiming to raise $11 million in gross proceeds. Trading began on December 3, 2024, and the offering closed the following day.\r\n\r\nAt the core of Jupiter's platform is Jotrol, a novel formulation of resveratrol, a plant-based compound recognized for its anti-inflammatory and neuroprotective effects. Unlike traditional resveratrol products, which often suffer from poor absorption and gastrointestinal side effects, Jotrol leverages patented micellar technology to improve bioavailability, enabling effective therapeutic dosing.\r\n\r\nJotrol is being developed as a treatment for central nervous system (CNS) disorders, including Parkinson\u2019s disease, Alzheimer\u2019s disease and rare conditions such as Friedreich\u2019s ataxia and mucopolysaccharidosis type 1. The company has received Orphan Drug designation for Friedreich\u2019s ataxia, granting it advantages like market exclusivity and eligibility for Priority Review vouchers.\r\n\r\nPreclinical research conducted at the University of Miami demonstrated Jotrol's potential in a Parkinson\u2019s disease mouse model, addressing key symptoms such as dopamine deficits and the loss of nigral cells.\r\n\r\nFunds raised from the IPO will support the advancement of Jotrol\u2019s development, including a Phase II clinical trial for Parkinson\u2019s disease and a proof-of-concept study targeting biomarkers for mild cognitive impairment and Alzheimer\u2019s disease.\r\n\r\nJupiter has also established strategic partnerships in the Asia-Pacific region with Sichuan Kelun and Tianjin Pharmaceuticals, integrating Jotrol into traditional Chinese medicine practices. With international patents secured until 2036, the company is well-positioned to accelerate commercialization and out-licensing opportunities in this high-growth market.\r\n\r\nDespite financial challenges and the complexities of scaling operations in a competitive landscape, Jupiter is committed to pursuing grant funding to support proof-of-concept trials. The company\u2019s innovative approach to addressing neuroinflammation and mitochondrial dysfunction positions it to tackle unmet needs in neurodegenerative and rare diseases.\r\n\r\nBy combining resveratrol\u2019s scientific and traditional medicinal roots, Jupiter aims to carve a distinctive niche in the pharmaceutical industry, focusing on innovative solutions for critical therapeutic areas.\r\n\r\n\r\nInvizyne Technologies\r\nIPO Date: November 13, 2024\r\n\r\nInitial IPO Price: $8.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nInvizyne Technologies has entered the biomanufacturing sector with the successful completion of its IPO on November 14, 2024. The IPO raised $15 million in gross proceeds through the sale of 1,875,000 shares priced at $8.00 each. Trading under the ticker symbol \u201cIZTC,\u201d the company\u2019s shares debuted on the Nasdaq Capital Market on November 13, 2024.\r\n\r\nInvizyne\u2019s innovative cell-free enzymatic system operates by leveraging enzymes to precisely assemble complex molecules, bypassing the limitations of traditional cellular processes. This approach allows the company to produce a wide range of commercially valuable chemicals \u2014 including active pharmaceutical ingredients, biofuels, food flavors and cosmetics \u2014 in a more efficient and sustainable manner than conventional synthetic biology methods.\r\n\r\nAt the heart of Invizyne\u2019s innovation is its proprietary platform, SimplePath, which transforms renewable resources into complex molecules. The platform addresses inefficiencies and high costs associated with traditional methods such as chemical synthesis and natural extraction. SimplePath uses cascades of enzymatic reactions to efficiently convert raw materials into target compounds, offering a scalable and environmentally friendly alternative to legacy production methods.\r\n\r\nSince its inception in 2019, Invizyne has concentrated on using SimplePath to produce key chemicals. Current projects include cannabigerolic acid, a precursor to cannabinoids with therapeutic potential, and isobutanol, an essential biofuel component.\r\n\r\nSimplePath\u2019s near-theoretical yields enable the majority of input materials to be converted into the desired products with minimal waste.\r\n\r\nA study published in Nature Communications highlighted that Invizyne achieved exceptional metrics in isobutanol production, reaching titers of up to 275 g\/L with a 95 percent yield in multi-day runs using glucose as the input.\r\n\r\nThe company\u2019s efforts have been bolstered by a $2 million project under the Department of Defense\u2019s (DoD) BioMADE initiative, which supports enzyme production for cell-free biomanufacturing of sustainable aviation fuel (SAF). This initiative is a critical milestone for scaling production at a 100L pilot facility and aligns with the growing SAF market, projected to reach $27.4 billion by 2032. The partnership also reinforces SimplePath\u2019s potential in renewable fuel production.\r\n\r\nBioMADE is a US initiative aimed at advancing industrial biomanufacturing innovations and workforce development to maintain global leadership in biotechnology. Invizyne\u2019s SAF project, conducted in collaboration with the University of Georgia, builds on previous funding from the US Department of Energy\u2019s Bioenergy Technologies Office (BETO), which awarded $5.85 million for isobutanol production development.\r\n\r\nThrough these projects, Invizyne continues to demonstrate the flexibility of its SimplePath platform, which can be applied across industries to create pharmaceuticals, biofuels, food additives and sustainable industrial chemicals. With its groundbreaking enzyme-based systems, Invizyne is paving the way for a greener and more efficient future in biomanufacturing.\r\n\r\n\r\nGelteq\r\nIPO Date: October 29, 2024\r\n\r\nInitial IPO Price: $4.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nGelteq Limited, a biotech company specializing in ingestible gel delivery technologies, recently launched its IPO, generating $5.2 million in gross proceeds. The IPO was priced at $4.00 per share, comprising 1,300,000 shares, which began trading on the Nasdaq Global Market under the ticker \"GELS\" on October 29, 2024.\r\n\r\nGelteq\u2019s core technology is a proprietary gel platform that offers tailored drug delivery solutions for applications across pharmaceuticals, nutraceuticals, pet care, and sports supplements. The platform\u2019s stable gel matrix can encapsulate various ingredients, supporting controlled release, improved bioavailability, and an enhanced user experience.\r\n\r\nThe company's formulations enable delivery of active compounds like branched-chain amino acids, protein, caffeine, and essential minerals, which makes them suitable for uses in sports performance, nutrition, and therapeutic settings.\r\n\r\nGelteq's gels address common challenges in medication adherence, improving taste, lowering choking hazards, and making swallowing easier \u2014 particularly beneficial for individuals with dysphagia, children, and older adults with specific dietary or swallowing requirements.\r\n\r\nFurther, Gelteq\u2019s technology customizes ingredient release profiles along the gastrointestinal tract, optimizing absorption and targeting specific areas based on each ingredient's properties.\r\n\r\nTo meet increasing demand, Gelteq is enhancing its production capabilities with a Good Manufacturing Practice (GMP)-certified facility, anticipated to be fully operational by 2025.\r\n\r\nIn the pharmaceutical sector, Gelteq is progressing its lead product \u2014 a gel-based pain management solution \u2014 through the US Food and Drug Administration's (FDA) 505(b)(2) pathway, utilizing bioequivalence studies for quicker approval and positioning the gel as an alternative to conventional oral dosage forms. The platform\u2019s flexibility allows for multi-ingredient and high-dosage formulations, accommodating both lipid and non-lipid components in a user-friendly format.\r\n\r\nBacked by a growing patent portfolio and collaborations in human and animal health, Gelteq is advancing its goal of improving therapeutic outcomes and patient compliance across various health markets.\r\n\r\n\r\nPolyrizon\r\nIPO Date: October 29, 2024\r\n\r\nInitial IPO Price: $4.38\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nBiotech company Polyrizon Ltd., known for its expertise in medical device hydrogels, recently completed its IPO, securing $4.2 million in gross proceeds. The IPO was priced at $4.38 per unit, comprising 958,903 units, each containing one ordinary share and three warrants for additional share purchases at a per-share exercise price of $4.38. Trading began on October 29, 2024, on the Nasdaq Capital Market, under the ticker symbol \"PLRZ.\"\r\n\r\nThe funds raised from the IPO will support the preclinical and clinical advancement of Polyrizon\u2019s novel hydrogel product candidates, facilitating research and development (R&amp;D) activities. Additional allocations include working capital, possible future acquisitions, and repayment of specific outstanding debts.\r\n\r\nPolyrizon Ltd. is pioneering innovative nasal spray-based hydrogel technologies through two unique platforms: Capture and Contain (C&amp;C) and Trap and Target (T&amp;T).\r\n\r\nThe C&amp;C platform functions as a \"biological mask,\" forming a protective hydrogel barrier in the nasal passage to block viruses and allergens. Its primary candidate, PL-14, which addresses nasal allergies, is slated for FDA submission via the 510(k) pathway. Preclinical trials are projected to start in the second quarter of 2025, followed by pivotal trials toward the end of the year.\r\n\r\nTwo additional C&amp;C candidates, PL-15 and PL-16, are focused on COVID-19 and influenza prevention and are expected to proceed toward De Novo classification, with clinical trials projected beyond 2025.\r\n\r\nPolyrizon\u2019s T&amp;T platform offers a different solution, aiming at the intranasal delivery of active pharmaceutical ingredients (APIs) with extended release, targeting potential uses in central nervous system (CNS) treatments, opioid overdose response, and allergic rhinitis. Early testing for this platform is planned from late 2024 to early 2026, with further preclinical and Phase I trials contingent on additional funding.\r\n\r\nPolyrizon\u2019s R&amp;D initiatives are bolstered by strategic partnerships. Its agreement with SciSparc grants Polyrizon exclusive rights to the SCI-160 platform, enabling non-opioid pain treatment development with milestone-linked royalties. Additionally, a collaboration with NurExone supports the development of an intranasal delivery system for exosome-based therapies aimed at treating spinal cord injuries, with potential expansion to other neurological applications.\r\n\r\nSepterna\r\nIPO Date: October 25, 2024\r\n\r\nInitial IPO Price: $18.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nSepterna, Inc., a clinical-stage biotech company focused on developing therapies based on G protein-coupled receptors (GPCRs), has reached a major milestone by completing its IPO. The South San Francisco company is known for its cutting-edge approach to GPCR drug discovery, utilizing its proprietary Native Complex Platform to build a strong portfolio targeting key areas like endocrinology, immunology, inflammation and metabolic diseases.\r\n\r\nSepterna\u2019s IPO led to the issuance of 18.4 million shares at $18.00 each, including an additional 2.4 million shares acquired by underwriters exercising their option in full. The IPO raised $331.2 million in gross proceeds before deducting underwriting discounts, commissions and other related expenses. Shares of Septerna began trading on the Nasdaq Global Market (under the ticker SEPN) on October 25, 2024, with the IPO officially closing on October 30, 2024.\r\n\r\nThis funding boost will help drive Septerna\u2019s pipeline forward and support clinical studies in its primary therapeutic areas. With GPCR-targeted therapies addressing critical medical challenges, Septerna is strategically positioned for impact in the industry.\r\n\r\nThe company\u2019s leading program, SEP-786, addresses hypoparathyroidism, a rare disorder affecting roughly 70,000 people in the US that can lead to severe issues such as seizures and heart complications. SEP-786 is an oral parathyroid hormone 1 receptor (PTH1R) agonist aiming to restore mineral balance, with Phase I trial results expected by mid-2025.\r\n\r\nSepterna's SEP-631 is being developed for chronic spontaneous urticaria, a painful inflammatory skin condition impacting 1.5 million people in the U.S. This selective mas-related G-protein coupled receptor member X2 (MRGPRX2) inhibitor works by modulating mast cell activity, with regulatory submissions for trial initiation expected soon.\r\n\r\nSepterna\u2019s thyroid-stimulating hormone receptor (TSHR) modulators target Graves\u2019 disease and thyroid eye disease, both of which require significant treatment. The company\u2019s TSHR modulators could offer a disease-modifying oral therapy, with lead compounds advancing toward clinical candidate selection.\r\n\r\nSepterna\u2019s pipeline also includes incretin programs aimed at addressing obesity and type 2 diabetes, which affect over 800 million people globally. Through oral agonists for glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP) and glucagon receptors, Septerna\u2019s approach may overcome some limitations of current injectable treatments, with key compounds nearing the development candidate stage.\r\n\r\nSepterna\u2019s IPO success underscores investor confidence in its scientific vision and potential to innovate small molecule therapeutics, advancing treatments for complex medical conditions.\r\n\r\n\r\nUpstream Bio\r\nIPO Date: October 11, 2024\r\n\r\nInitial IPO Price: $17.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nUpstream Bio recently closed its upsized IPO, raising approximately $293 million after the underwriters exercised their option to purchase an additional 2,250,000 shares. The offering comprised 17,250,000 shares of common stock at $17 per share, and the stock began trading on the Nasdaq Global Select Market on October 11, 2024, under the ticker \u201cUPB.\u201d Proceeds from the IPO will support Upstream Bio\u2019s development of innovative therapies for inflammatory diseases, particularly severe respiratory disorders.\r\n\r\nUpstream Bio is advancing verekitug, its lead monoclonal antibody targeting the receptor for thymic stromal lymphopoietin (TSLP), into clinical trials for severe respiratory disorders. Verekitug is the only known TSLP receptor antagonist in clinical development, designed to inhibit TSLP's upstream inflammatory effects. The company has already completed three Phase I trials, showing promising pharmacokinetics and safety data. Verekitug's Phase Ib results demonstrated rapid, sustained receptor occupancy and significant reductions in key biomarkers like fractional exhaled nitric oxide and eosinophil levels in asthma patients.\r\n\r\nCurrently, two Phase II trials are underway \u2014 one for severe asthma and the other for chronic rhinosinusitis with nasal polyps (CRSwNP). Both trials aim to evaluate 12- and 24-week dosing intervals, potentially allowing for less frequent dosing compared to current biologics. Results from the CRSwNP trial are expected in late 2025, with asthma trial data anticipated in the second half of 2026. Additionally, Upstream plans to initiate a Phase II clinical trial for chronic obstructive pulmonary disease (COPD) in late 2025.\r\n\r\nBeyond these, Upstream plans to leverage verekitug\u2019s attributes for other TSLP-driven diseases, exploring its potential across multiple inflammatory conditions. Strategic collaborations and potential acquisitions are expected to position the company to address unmet needs in respiratory care.\r\n\r\n\r\nCAMP4 Therapeutics Corporation\r\nIPO Date: October 10, 2024\r\n\r\nInitial IPO Price: $11.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nCAMP4 Therapeutics, a clinical-stage biopharmaceutical company, recently priced its IPO at $11.00 per share, generating approximately $75 million in gross proceeds. CAMP4 is focused on developing regulatory RNA-based therapeutics that upregulate gene expression to restore healthy protein levels. Their RNA Actuating Platform (RAP) identifies regulatory RNA sequences that control protein-coding genes, allowing CAMP4 to create antisense oligonucleotide therapeutics to modulate gene expression.\r\n\r\nOn October 1, 2024, CAMP4 entered into a strategic research collaboration with BioMarin Pharmaceutical Inc. to advance novel therapeutics for rare genetic conditions. This collaboration combines CAMP4\u2019s target discovery capabilities with BioMarin\u2019s expertise in genetic medicines, with BioMarin having the right to select two targets from CAMP4\u2019s RAP platform to move into clinical development.\r\n\r\nThe company\u2019s lead product candidate, CMP-CPS-001, is designed to treat urea cycle disorders by increasing the expression of CPS1, a key enzyme in the urea cycle. It is currently undergoing Phase I clinical trials, with data from the single ascending dose (SAD) portion expected in the first quarter of 2025, and multiple ascending dose (MAD) data anticipated in the second half of 2025. CMP-CPS-001 has also received Rare Pediatric Disease and Orphan Drug designations from the US Food and Drug Administration (FDA), signaling potential market exclusivity and regulatory support.\r\n\r\nIn addition to CMP-CPS-001, CAMP4 is advancing its CMP-SYNGAP program targeting SYNGAP1-related neurodevelopmental disorders, which cause cognitive impairment and epilepsy. Preclinical results were promising, and the company plans to initiate Good Laboratory Practice (GLP) toxicology studies in 2025.\r\n\r\nLooking ahead, CAMP4 intends to form more strategic partnerships to maximize the value of its RAP platform and expand its pipeline to address metabolic and central nervous system (CNS) diseases. The funds from the IPO will be used to advance clinical trials, expand the RAP platform and support future product development initiatives.\r\n\r\n\r\nBioAge Labs, Inc. \r\nIPO Date: September 26, 2024\r\n\r\nInitial IPO Price: $18.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nBioAge Labs, Inc., a clinical-stage biopharmaceutical company, recently priced its upsized IPO of 11,000,000 shares at $18.00 each, raising $198.0 million before deducting expenses. Underwriters were granted a 30-day option to buy an additional 1,650,000 shares. The stock began trading on the Nasdaq Global Select Market under the ticker \u201cBIOA\u201d on September 26, 2024.\r\n\r\nOn October 1, 2024, BioAge confirmed the closing of the upsized IPO, including the full exercise of the underwriters' option, totaling 12,650,000 shares. Additionally, BioAge closed a concurrent private placement on September 27, selling 588,888 shares to an existing stockholder. The combined gross proceeds from the IPO, underwriters' option and private placement amounted to approximately $238.3 million.\r\n\r\nBioAge\u2019s investigational oral drug, azelaprag, is a small molecule agonist of the apelin receptor (APJ), designed to replicate exercise benefits. In preclinical obesity models, azelaprag more than doubled weight loss when combined with glucagon-like peptide-1 (GLP-1) receptor agonists. Phase Ib clinical trials demonstrated reduced muscle atrophy and improved metabolism in older adults.\r\n\r\nCurrently, BioAge is running two Phase II trials: the ongoing Study to Evaluate the Reduction of Insulin-Related Disorders and Enhance Satiety (STRIDES) trial with tirzepatide, with results expected in the third quarter of 2025, and a trial with semaglutide, set to start in the first half of 2025, with topline results anticipated in the second half of 2026. An insulin sensitivity proof-of-concept trial with azelaprag monotherapy is also planned for the first half of 2025.\r\n\r\nThe company pipeline also includes brain-penetrating nucleotide-binding domain and leucine-rich repeat protein 3 (NLRP3) inhibitors targeting neuroinflammatory diseases. An Investigational New Drug (IND) application for one such NLRP3 inhibitor has been planned for the second half of 2025 and likely, a Phase I trial in the first half of 2026.\r\n\r\n\r\nKairos Pharma\u00a0\r\nIPO Date: September 16, 2024\r\n\r\nInitial IPO Price: $4.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nKairos Pharma successfully closed its IPO on September 17, 2024, raising $6.2 million through the sale of 1,550,000 shares at $4.00 per share. Trading began on the NYSE American under the symbol \"KAPA\" on September 16, 2024. Underwriters were granted a 45-day option to purchase an additional 232,500 shares. With net proceeds estimated at $5.76 million, the company plans to advance its robust oncology pipeline, which targets immune suppression and drug resistance in cancers.\r\n\r\nAt the forefront of Kairos\u2019 development efforts is ENV 105, a therapeutic antibody currently in Phase I trials for lung cancer and Phase II trials for prostate cancer. ENV 105 specifically targets CD105, a molecule that becomes upregulated in tumors resistant to standard therapies, including androgen receptor inhibitors and EGFR-targeted drugs. Early trials demonstrated a promising clinical benefit rate of 62 percent in heavily pre-treated prostate cancer patients.\r\n\r\nPreclinical candidates include the KROS portfolio, with KROS 101 and 102 targeting glucocorticoid-induced tumor necrosis factor receptor (GITR) ligands to modulate T cell activity and function, and KROS 201, an autologous T cell therapy designed to eliminate glioblastoma cancer stem cells.\r\n\r\nKairos received a $3.2 million grant from the National Cancer Institute to support the development of ENV 105. This funding will be used for companion biomarker research in prostate cancer, helping identify patients most likely to benefit from the therapy.\r\n\r\nOther products in development include ENV 205, which targets mitochondrial DNA to reverse chemotherapy resistance, and KROS 301, a small molecule aimed at inhibiting the nuclear factor-kappa B (NF-\u0138\u03b2) pathway, which has been found to promote tumor growth and resistance to therapies, in triple-negative breast cancer.\r\n\r\nThe IPO proceeds will support these ongoing trials, pipeline expansions and preclinical studies, solidifying Kairos' commitment to addressing critical unmet needs in oncology\u200b.\r\n\r\n\r\nImpact BioMedical\u00a0\r\nIPO Date: September 16, 2024\r\n\r\nInitial IPO Price: $3.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nImpact BioMedical Inc. completed its IPO on September 17, 2024, after debuting on the NYSE American the previous day. The company offered 1.5 million shares priced at $3.00 per share, with Revere Securities, LLC as the lead underwriter. The IPO included a 45-day option for underwriters to acquire an additional 225,000 shares. In connection with the offering, Impact issued warrants for the purchase of up to 75,000 shares at an exercise price of $3.75 per share, with the potential to extend to 86,250 shares if the overallotment option is exercised.\r\n\r\nImpact BioMedical is advancing an array of cutting-edge technologies through its subsidiaries. At the forefront is its Linebacker platform, a series of polyphenol-based compounds designed to target oncology, inflammation and neurological disorders. These compounds, derived from natural sources like berries and nuts, have demonstrated the potential to inhibit PIM kinase, a driver of several cancers. Linebacker-1 and Linebacker-2 have been licensed to ProPhase Laboratories for global development, creating opportunities for future milestone and royalty payments.\r\n\r\nAnother notable product is Laetose, a sugar substitute that lowers caloric intake and glycemic response while also inhibiting tumor necrosis factor alpha. Impact BioMedical is exploring partnerships to advance Laetose\u2019s applications in consumer markets and biopharmaceuticals.\r\n\r\nThe company also collaborates with Chemia Corporation to develop 3F, a fragrance technology with antimicrobial properties that could be used in insect repellents, detergents and more. Equivir, a blend of polyphenols with antiviral effects, is licensed to ProPhase Laboratories, with potential applications in upper respiratory wellness and beyond.\r\n\r\nThese innovative offerings, paired with strategic partnerships and licensing agreements, could propel Impact BioMedical's efforts to develop next-generation wellness and biopharmaceutical solutions.\r\n\r\n\r\nZenas BioPharma\u00a0\r\nIPO Date: September 13, 2024\r\n\r\nInitial IPO Price: $17.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nZenas BioPharma launched its IPO, pricing 13,235,294 shares at $17 per share, aiming to raise approximately $225 million in gross proceeds. The company is listed on the Nasdaq Global Select Market under the ticker symbol \"ZBIO,\" with the IPO closing on September 16, 2024. On September 19, 2024, the underwriters fully exercised their option to purchase an additional 1,985,294 shares at the initial offering price, bringing the total to 15,220,588 shares sold and raising gross proceeds of $258.7 million.\r\n\r\nNotably, Zenas' current market cap stands at $715 million which could indicate strong investor confidence in its immunology therapies.\r\n\r\nAs an emerging growth company, the funds will be directed toward advancing its pipeline of transformative immunology therapies. Their lead product, obexelimab, a bifunctional monoclonal antibody, is designed to inhibit B cells without depleting them, holding promise in autoimmune disease treatment.\r\n\r\nZenas is advancing multiple clinical trials, including a Phase III trial for immunoglobulin G4-related disease (IgG4-RD), which is currently enrolling patients globally. Obexelimab is also being tested in a Phase II\/III trial for warm autoimmune hemolytic anemia (wAIHA), and Phase II trials are underway for multiple sclerosis (MS) and systemic lupus erythematosus (SLE). Additionally, Zenas is developing two global programs \u2014 ZB002 (an anti-TNF\u03b1 monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion) \u2014 along with regional programs ZB001 and ZB005, targeting various inflammatory and autoimmune conditions. The IPO will accelerate trial progress and expand Zenas' pipeline toward commercialization.\r\n\r\n\r\nBicara Therapeutics\u00a0\r\nIPO Date: September 12, 2024\r\n\r\nInitial IPO Price: $18.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nBicara Therapeutics Inc., a clinical-stage biopharmaceutical company advancing bifunctional therapies for solid tumors, announced the pricing of its IPO on September 12, 2024. Offering 17,500,000 shares at $18.00 per share, the company raised approximately $315 million. Following the full exercise of underwriters\u2019 options, the IPO closed on September 16, 2024, with a total of 20,125,000 shares sold, pushing gross proceeds to $362 million.\r\n\r\nBicara\u2019s lead asset, ficerafusp alfa, is a bifunctional antibody designed to target both epidermal growth factor receptor (EGFR) and transforming growth factor beta (TGF-\u03b2). This dual mechanism holds promise in treating various solid tumors by inhibiting tumor growth while reducing the immunosuppressive environment in the tumor microenvironment.\r\n\r\nEarly clinical results have been compelling, particularly in head and neck squamous cell carcinoma (HNSCC), where ficerafusp alfa combined with pembrolizumab achieved a 54 percent overall response rate (ORR), and an even higher 64 percent ORR in human papillomavirus (HPV)-negative patients.\r\n\r\nWith these promising data, Bicara plans to launch a pivotal Phase II\/III trial by late 2024 or early 2025, testing ficerafusp alfa combined with pembrolizumab as a first-line treatment for recurrent\/metastatic HNSCC. The company is also exploring the drug\u2019s potential in other EGFR-expressing solid tumors like colorectal cancer and cutaneous squamous cell carcinoma.\r\n\r\nBicara\u2019s bifunctional approach aims to provide longer-lasting responses and improved survival outcomes for patients with few treatment options. Funds from the IPO will support ongoing clinical trials and future pipeline expansion, helping Bicara potentially bring new treatment options to cancer patients who currently have limited alternatives.\r\n\r\n\r\nMBX Biosciences\u00a0\r\nIPO Date: September 12, 2024\r\n\r\nInitial IPO Price: $16.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nMBX Biosciences announced the pricing of its IPO, selling 10.2 million shares of common stock at $16.00 per share, expecting to raise $163.2 million. The underwriters also have a 30-day option to buy an additional 1.53 million shares. The shares started trading on Nasdaq under the ticker symbol \"MBX.\" On September 16, MBX announced the closing of its upsized IPO, which included the full exercise of the underwriters' option to purchase additional shares, bringing the total to 11.73 million shares sold. This upsized offering raised approximately $187.7 million in gross proceeds, surpassing the initial estimate of $163.2 million.\r\n\r\nThe IPO supports the development of MBX\u2019s innovative pipeline of precision peptide therapies, driven by its proprietary Precision Endocrine Peptide (PEP) platform. MBX is progressing through critical clinical trials, including Phase II testing for MBX 2109 and Phase I for MBX 1416, with other treatments, like MBX 4291, in the preclinical stage.\r\n\r\nMBX 2109, the lead candidate, is a long-acting parathyroid hormone peptide prodrug designed for chronic hypoparathyroidism (HP). Now in Phase II trials, MBX 2109 offers once-weekly dosing with continuous PTH exposure, aiming to improve outcomes by reducing the need for daily supplements. Phase I results indicated that the treatment was well-tolerated and worked for a longer period between doses.\r\n\r\nMBX 1416, in Phase I development for post-bariatric hypoglycemia (PBH), is a GLP-1 receptor antagonist intended to reduce hypoglycemic events through once-weekly dosing. MBX 4291, still in preclinical testing, is being developed for obesity, potentially offering once-monthly dosing based on preclinical data.\r\n\r\nThe IPO positions MBX Biosciences to accelerate its pipeline, addressing unmet needs in endocrine and metabolic disorders with long-acting, novel therapies designed to enhance patient management and improve efficacy.\r\n\r\n\r\nActuate Therapeutics\r\nIPO Date: August 12, 2024\r\n\r\nInitial IPO Price: $8.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nActuate Therapeutics, a clinical-stage biopharmaceutical company targeting tough-to-treat cancers made an IPO on August 13, 2024. The company priced its IPO at $8.00 per share, raising a decent $30 million through the sale of 3.75 million shares. This influx of capital is set to fuel the advancement of their lead compound, elraglusib (formerly 9-ING-41), a small molecule designed to inhibit glycogen synthase kinase-3 beta (GSK-3\u03b2) in refractory cancers.\r\n\r\nElraglusib is an innovative drug that infiltrates cancer cells and disrupts GSK-3\u03b2, a key enzyme that orchestrates the survival, growth and spread of tumor cells. By blocking this enzyme, elraglusib not only aims to kill cancer cells but also boosts the body\u2019s immune response against tumors. Actuate is currently putting elraglusib through its paces in a randomized Phase II trial for metastatic pancreatic cancer, where early data has shown promising survival benefits \u2014 12.2 months in the treatment arm versus 7.3 months in the control group.\r\n\r\nThe IPO officially closed on August 14, 2024, with Actuate\u2019s stock debuting on the Nasdaq under the ticker \"ACTU\". Beyond pancreatic cancer, Actuate is exploring elraglusib\u2019s potential in other tough-to-treat cancers within its pipeline like glioblastoma, lung and colorectal cancers, as well as pediatric cancers, such as Ewing sarcoma, through ongoing Phase I\/II studies.\r\n\r\nElraglusib\u2019s significance is underscored by its Fast Track and Orphan Drug Designations from the US Food and Drug Administration (FDA) for pancreatic cancer, signaling its potential to meet critical unmet medical needs. Actuate is also expanding the drug\u2019s versatility by developing oral forms, potentially widening its application across multiple cancer types, including melanoma and colorectal cancer.\r\n\r\nIn a symbolic gesture, Actuate rang the Nasdaq opening bell on August 23, 2024, marking their official entry as a publicly traded entity.\r\n\r\n\r\nOS Therapies\r\nIPO Date: July 31, 2024\r\n\r\nInitial IPO Price: $4.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nAmid the 2024 biotech IPO surge, OS Therapeutics Incorporated (OSTX) raised $6.4 million through its IPO, pricing 1.6 million shares at $4.00 each. Net proceeds, around $6.0 million, will fuel the company\u2019s clinical development programs and support corporate operations.\r\n\r\nOS Therapeutics' second quarter (Q2) 2024 financial results showcased a solid financial foundation, with $11.5 million in cash and cash equivalents as of June 30, 2024. This, combined with IPO proceeds, will fund ongoing and future clinical trials, including the pivotal Phase IIb trial of OST-HER2 in recurrent osteosarcoma, a bone cancer that keeps returning. Operating expenses were primarily driven by R&amp;D activities, with a clear focus on high-impact areas such as immunotherapy and antibody-drug conjugates (ADCs).\r\n\r\nIn a strategic leap, OS Therapeutics joined Johnson &amp; Johnson Innovation \u2013 JLABS, gaining access to cutting-edge research facilities and strategic mentorship. This collaboration is expected to accelerate the development of its key pipeline candidates, OST-HER2 and OST-tADC.\r\n\r\nOST-HER2, OS Therapeutics' flagship product, uses bioengineered Listeria monocytogenes to provoke a potent immune response against HER2 (human epidermal growth factor receptor 2)-expressing cancer cells. With a Phase IIb trial nearing completion and key FDA designations \u00ad\u2014 including Fast Track, Orphan Drug and Rare Pediatric Disease, and actively seeking Breakthrough Therapy \u2014 the company is poised for a potential Biologics License Application (BLA) soon.\r\n\r\nOS Therapeutics is also pioneering the OST-tADC platform, using SiLinkers technology to precisely target cancer cells with minimal damage to healthy tissues. The ADC market, which is expected to grow from $4.5 billion in 2023 to nearly $19.8 billion by 2028, represents a significant opportunity for OS Therapeutics as it develops its OST-tADC platform.\r\n\r\n\r\nArtiva Biotherapeutics\r\nIPO Date: July 18, 2024\r\n\r\nInitial IPO Price: $12.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nArtiva Biotherapeutics, Inc. announced the pricing of its upsized initial public offering (IPO), offering 13,920,000 shares of common stock at $12.00 per share. Artiva is a clinical-stage biotechnology company focused on developing cell therapies for autoimmune diseases and cancers.\r\n\r\nTrading under the symbol \"ARTV\" on the Nasdaq Global Market, Artiva is set to raise approximately $167.0 million in gross proceeds. The offering is expected to close on July 22, 2024.\r\n\r\nFounded in 2019 and headquartered in San Diego, Artiva Biotherapeutics specializes in developing natural killer (NK) cell-based therapies. Artiva\u2019s product candidates are allogeneic, pre-manufactured, cryopreserved and ready-to-ship, offering an \u201coff-the-shelf\u201d accessible solution. Their lead therapy, AlloNK, is a non-genetically modified NK cell therapy being tested in combination with B-cell targeted monoclonal antibodies in ongoing Phase I\/Ib trials for lupus nephritis (LN) \u2014 a type of kidney disease that causes severe damage to the kidneys and affects about 50 percent of adults with lupus \u2014 and other autoimmune indications.\r\n\r\nArtiva reported revenue of $32.75 million for the 12 months ending March 31, 2024, with an impressive annual revenue growth of 579.21 percent. The company\u2019s market capitalization stands at $274.78 million.\r\n\r\nArtiva's AlloNK has shown promising results in ongoing trials, reducing harmful B cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). The company has initiated a Phase I trial for AlloNK in combination with monoclonal antibodies for LN, marking the first use of allogeneic NK cell therapy for an autoimmune disease in a US clinical trial.\r\n\r\nAside from LN, AlloNK is also being researched in Phase I trials for B cell malignancies, rheumatoid arthritis and more, as well as Phase II trials initiated in collaboration with Affimed for relapsed\/refractory Hodgkin lymphoma. Their pipeline also includes two chimeric antigen receptor (CAR)-based therapies that target human epidermal growth factor receptor 2 (HER2)-positive tumors, such as breast and gastric cancers and CD5-positive T-cell lymphomas and leukemias currently in preclinical studies.\r\n\r\nWith the IPO proceeds, Artiva plans to speed up its clinical trials and expand its treatment offerings. The company expects to share initial results from their ongoing trials in the first half of 2025.\r\n\r\n\r\nAlumis\r\nIPO Date: June 27, 2024\r\n\r\nIPO Price: $16.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nAlumis Inc. is a clinical-stage biopharma company dedicated to replacing broad immunosuppression with targeted, effective treatments, aiming to revolutionize the management of immune-mediated diseases.\r\n\r\nIn conjunction with the IPO, Alumis is conducting a concurrent private placement of 2,500,000 shares at the same offering price to AyurMaya Capital Management Fund, LP, totaling expected gross proceeds of approximately $250 million from both the IPO and private placement. These funds will support ongoing clinical developments and future research initiatives.\r\n\r\nLeading Alumis' product lineup are the oral small molecule ESK-001 and the brain-penetrant A-005, both allosteric tyrosine kinase 2 (TYK2) inhibitors targeting different aspects of immune-mediated diseases. ESK-001 is being evaluated in a Phase II trial for its efficacy in treating moderate-to-severe plaque psoriasis and systemic lupus erythematosus. The Phase II STRIDE trial delivered positive results, with ESK-001 meeting its primary endpoints of reduction in psoriasis severity. A-005, designed to penetrate the central nervous system (CNS), is under study for potential treatment of neuroinflammatory and neurodegenerative diseases such as multiple sclerosis (MS) and Parkinson\u2019s disease.\r\n\r\nAlumis plans to initiate multiple Phase III trials for ESK-001 in the second half of 2024, reflecting a deep commitment to combatting immune diseases. Additionally, Phase I trials for A-005 began in early 2024, with initial results anticipated by year-end. In March 2024, Alumis secured $259 million in Series C funding led by Foresite Capital, Samsara BioCapital and venBio Partners. This funding is intended to support Phase III trials for ESK-001 in plaque psoriasis, advancing Phase II trials in other conditions and enhancing its precision data analytics for broader autoimmune applications.\r\n\r\nBeyond its TYK2 inhibitors, Alumis is advancing a variety of preclinical programs powered by its proprietary precision data analytics platform.\r\n\r\nSince its founding in 2021, Alumis has secured over $600 million from notable life science investors, underscoring its potential and commitment to innovation. As the company transitions to the public market, it aims to impact both market and medical practice in immunology.\r\n\r\n\r\nRapport Therapeutics\r\nIPO Date: June 7, 2024\r\n\r\nIPO Price: $17.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nRapport Therapeutics is advancing the field of small molecule medicines targeting central nervous system (CNS) disorders through their innovative RAP technology platform, focusing on manipulating receptor-associated proteins (RAPs). These proteins are critical for neuronal receptor function and expression, making them key targets in CNS disorders. Rapport's strategic goal is to develop precise, targeted therapies for CNS disorders, which could lead to more effective treatments with fewer side effects.\r\n\r\nThe company recently issued 8,000,000 shares of common stock at $17.00 per share (totaling $136 million dollars), with an additional 1,200,000 shares available for underwriters to purchase. This IPO supports Rapport's ongoing research and development, especially in the CNS disorder space. Rapport has listed its stocks on the Nasdaq Global Market under the ticker \"RAPP.\"\r\n\r\nRAP-219, Rapport's leading candidate developed using their RAP technology, is an AMPA receptor (AMPAR) negative allosteric modulator (NAM). It targets TARP\u03b38, a RAP associated with AMPARs, enhancing specificity. AMPARs regulate brain glutamate activity that has been implicated in the development of several neurological diseases.\r\n\r\nTARP\u03b38 is predominantly found in brain regions like the hippocampus, which is directly involved in focal epilepsy. The specificity of RAP-219 might offer a more targeted approach to treating epilepsy, potentially reducing side effects compared to broader-acting drugs.\r\n\r\nRapport Therapeutics also explores other avenues through their RAP technology. They have discovery-stage nicotinic acetylcholine receptor (nAChR) programs aimed at chronic pain (\u03b16) and hearing disorders (\u03b19\u03b110), again leveraging their ability to target specific receptor subunits that traditional methods might miss.\r\n\r\nRapport has successfully completed Phase I clinical trials assessing the safety and tolerability of RAP-219 in healthy adults. These trials are foundational in establishing the initial safety profile of RAP-219 before proceeding to more targeted patient populations. The company plans to initiate a Phase IIa proof-of-concept trial in mid-2024. This trial will focus on adult patients with drug-resistant focal epilepsy, with expectations to deliver topline results by mid-2025. Additionally, Phase IIa trials for RAP-219 targeting peripheral neuropathic pain and bipolar disorder are scheduled for the second half of 2024 and in 2025.\r\n\r\nAnother molecule targeting TARP\u03b38, RAP-199, is slated to enter Phase I trials in the first half of 2025. This candidate also leverages the RAP technology but with different chemical and pharmacokinetic properties.\r\n\r\n\r\nContineum Therapeutics\r\nIPO Date: April 4, 2024\r\n\r\nIPO Price: $16.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nContineum Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&amp;I) indications, recently unveiled the pricing details of its IPO. The offering consisted of 6,875,000 shares of common stock priced at $16.00 per share for public acquisition. Trading of these shares started on the Nasdaq Global Select Market on April 4, 2024, under the ticker symbol \u201cCTNM.\u201d\r\n\r\nThe company's pipeline features a range of internally developed programs focused on neuroinflammation and immune disorders. A standout within this lineup is PIPE-791, an LPA1 receptor antagonist currently undergoing Phase I trials for idiopathic pulmonary fibrosis and progressive multiple sclerosis. In vitro experiments have highlighted PIPE-791's capabilities in encouraging oligodendrocyte differentiation and myelination, as well as its protective effects against cytokine-induced cell death in oligodendrocytes. Furthermore, preclinical in vivo studies have shown its ability to engage central nervous system LPA1 receptors, promoting remyelination and reducing neuroinflammation.\r\n\r\nContineum Therapeutics obtained clearance from the US Food and Drug Administration (FDA) last year to start a Phase I clinical trial for PIPE-791. This randomized, double-blind, placebo-controlled dose-ranging study is anticipated to enroll around 80 healthy volunteer subjects.\r\n\r\nAnother prominent candidate in Contineum's portfolio is PIPE-307, which is being developed as a potential first-in-class selective inhibitor of the M1 receptor. This candidate is currently in Phase II trials for relapsing-remitting multiple sclerosis and is expected to begin Phase II trials for depression by mid-2024. Initial results from Phase I trials have been promising, showing that PIPE-307 has a linear pharmacokinetic (PK) profile that aligns with preclinical modeling. Additionally, it has shown good tolerability across all dosage groups tested. Importantly, the dosages used in the Phase I trials have resulted in brain uptake levels that correlate with the remyelination observed in preclinical studies.\r\n\r\n\r\nBoundless Bio\r\nIPO Date: March 27, 2024\r\n\r\nIPO Price: $16.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nBoundless Bio, a pioneering clinical-stage oncology company dedicated to exploring extrachromosomal DNA (ecDNA) biology to revolutionize therapies for patients with previously refractory oncogene-amplified cancers, recently unveiled the pricing details of its IPO. The offering consisted of 6,250,000 shares of common stock priced at $16.00 per share for public acquisition. Trading of these shares started on the Nasdaq Global Select Market on March 27, 2024, under the ticker symbol \u201cBOLD.\u201d\r\n\r\nThe company\u2019s primary clinical focus lies in a novel approach to cancer therapeutics, addressing the substantial unmet needs of patients with oncogene-amplified tumors by targeting ecDNA, a fundamental driver of oncogene amplification observed in over 14 percent of cancer patients.\r\n\r\nUsing its proprietary Spyglass platform, the company identifies key targets crucial for the functionality of ecDNA. It then designs and develops small molecule drugs, known as ecDNA-directed therapies (ecDTx), aimed at inhibiting these targets. This approach blocks the ability of cancer cells to use ecDNA for growth, adaptation and resistance to current treatments.\r\n\r\nBoundless Bio is at the forefront of developing the first ecDTx, BBI-355, currently under evaluation in a Phase I\/II clinical trial. Additionally, the company announced promising preclinical data last year regarding its second ecDTx, BBI-825, an innovative, orally available, selective inhibitor of ribonucleotide reductase (RNR). BBI-825 has showcased significant RNR inhibition across various tumor cell lines and induced tumor regressions in ecDNA-enabled preclinical cancer models. Presently, it is undergoing assessment in Investigational New Drug (IND)-enabling studies.\r\n\r\n\r\nChannel Therapeutics Corporation - Chromocell\r\nIPO Date: February 15, 2024\r\n\r\nIPO Price: $6.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nChromocell Therapeutics Corporation, a clinical-stage biotech company dedicated to pioneering new non-opioid therapeutics for pain relief, recently disclosed the pricing details of its IPO. The offering comprised 1,100,000 shares of common stock priced at $6.00 per share for public acquisition. Trading of these shares started on the Nasdaq Global Select Market on February 15, 2024, under the ticker symbol \u201cCHRO.\u201d\r\n\r\nThe company\u2019s primary clinical focus revolves around selectively targeting the sodium ion channel NaV1.7 for treating various forms of chronic neuropathic pain and eye pain. Chromocell\u2019s leading candidate, CC8464, is designed as a potent and state-dependent inhibitor of human NaV1.7 with target selectivity. This design aims to preferentially impact injured or inflamed tissues while exerting minimal effects on NaV1.7 channels in uninjured or healthy tissues.\r\n\r\nCC8464 is currently undergoing Phase I clinical investigation, with encouraging results from animal models of neuropathic pain suggesting its potential efficacy across several neuropathic pain types. Furthermore, it offers promise for addressing erythromelalgia (EM), a rare neuromuscular condition lacking approved treatments.\r\n\r\nIn February, Chromocell announced a strategic partnership with Benuvia Operations, a prominent figure in pharmaceutical innovation, aimed at advancing healthcare through pioneering research, development and commercialization efforts. By using the manufacturing and supply services provided by Benuvia, Chromocell anticipates developing clinical programs for one or more licensed products within 18 months, thus accelerating the progress of potentially groundbreaking therapies.\r\n\r\n\r\nMetagenomi\r\nIPO Date: February 8, 2024\r\n\r\nIPO Price: $15.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nMetagenomi is a pioneering precision genetic medicines company dedicated to developing curative therapeutics for patients through its proprietary, comprehensive metagenomics-derived toolbox. Recently, it announced the pricing of its IPO of 6,250,000 shares of common stock at a price of $15.00 per share for the public. Trading of these shares commenced on the Nasdaq Global Select Market on February 9, 2024, under the ticker symbol \u201cMGX.\u201d\r\n\r\nMetagenomi\u2019s groundbreaking discovery platform unlocks novel cellular machinery sourced from natural environments to create next-generation genome editing tools. Its CRISPR-associated transposase (CAST) systems, tailored for large, site-specific gene integrations, consistently achieve programmable transposition into multiple endogenous sites within the human genome.\r\n\r\nPreliminary data from non-human primate trials using MG29-1, a novel type V CRISPR system, demonstrate promising outcomes for therapeutic gene knockdown. The study revealed Metagenomi\u2019s ability to achieve high editing efficiency (up to 55 percent of the entire liver and approximately 75 percent of hepatocytes) with MG29-1 in primary human cells in laboratory settings, as well as in mice and non-human primates.\r\n\r\nFurthermore, Metagenomi has been actively constructing libraries of nucleases, deaminases and reverse transcriptases, critical components for advanced engineering systems facilitating larger integrations. Through RNA-Mediated Integration Systems (RIGS), the company achieves both small edits (prime editing) and substantial edits, addressing complex gene modifications such as insertions, deletions and various types of point mutations.\r\n\r\n\r\nTelomir Pharmaceuticals\r\nIPO Date: February 8, 2024\r\n\r\nIPO Price: $7.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nTelomir Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company dedicated to advancing the development and commercialization of TELOMIR-1, an innovative small molecule designed to serve as an oral in situ therapeutic treatment for human stem cells. Recently, the company announced the pricing of its IPO of 1,000,000 shares of common stock at a public offering price of $7.00 per share. Trading of these shares commenced on the Nasdaq Capital Market on February 9, 2024, under the ticker symbol \"TELO.\"\r\n\r\nTELOMIR-1 represents a pioneering approach as the first small molecule intended to elongate DNA's protective telomere caps, potentially facilitating age reversal. By leveraging its metal-binding properties to target specific classes of enzymes, TELOMIR-1 is poised to selectively influence the key processes responsible for the concentration and accumulation of iron and copper in serum, with implications for diseases such as hemochromatosis and cancer.\r\n\r\nTelomir Pharmaceuticals initially focuses on treatments aimed at inhibiting the production of pro-inflammatory cytokines, notably IL-17, through the oral administration of TELOMIR-1 as a therapeutic intervention for stem cells in situ. Investigations into TELOMIR-1\u2019s potential as a therapeutic agent extend to addressing age-related inflammatory conditions like hemochromatosis and aiding in post-chemotherapy recovery. This is achieved by disrupting and preventing the IL-17-induced inflammatory pathways that contribute to the systemic imbalance of cellular metals.\r\n\r\n\r\nKyverna Therapeutics\r\nIPO Date: February 7, 2024\r\n\r\nIPO Price: $22.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nKyverna Therapeutics, Inc., a leading clinical-stage biopharmaceutical company dedicated to pioneering cell therapies for individuals afflicted by autoimmune diseases, has officially concluded its expanded IPO of 16,675,000 shares of common stock. Trading of Kyverna\u2019s common stock commenced on the Nasdaq Global Select Market on February 8, 2024, under the ticker symbol \u201cKYTX.\u201d\r\n\r\nThe focal point of Kyverna's efforts lies in its lead product candidate, KYV-101, which is progressing through clinical development across rheumatology and neurology. Notably, Phase II trials for multiple sclerosis and myasthenia gravis, a Phase I\/II trial for systemic sclerosis, and two ongoing multi-center, open-label Phase I trials in the US and Germany for patients with lupus nephritis underscore the breadth of its potential impact. KYV-101, a fully human CD19 CAR T-cell therapy tailored for individuals with B cell-driven autoimmune diseases, recently obtained fast track designation from the FDA for the treatment of multiple sclerosis.\r\n\r\nKyverna harnesses cutting-edge CAR T engineering and insights gleaned from conventional CAR T-cell therapies for cancer to amass a formidable collection of cell therapy assets and tools targeting various facets of autoimmune disease pathogenesis. Specifically, KYV-101 zeroes in on CD19, a surface protein expressed by B cells that plays a pivotal role in numerous autoimmune disorders. The company remains committed to exploring additional indications for KYV-101 and cultivating a robust pipeline of innovative immunotherapy candidates aimed at addressing unmet medical needs in the realm of autoimmune diseases.\r\n\r\n\r\n\r\nRelated: How Kyverna Therapeutics Is Pioneering Cell Therapy for Autoimmune Diseases\r\n\r\n\r\n\r\n\r\nFractyl Health\r\nIPO Date: February 1, 2024\r\n\r\nIPO Price: $15.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nFractyl Health, a leading metabolic therapeutics company dedicated to advancing innovative solutions for type 2 diabetes (T2D) and obesity treatment, has recently disclosed the pricing details of its IPO. The company will offer 7,333,333 shares of common stock at a public offering price of $15.00 per share, resulting in total gross proceeds of approximately $110.0 million. Fractyl Health\u2019s common stock commenced trading on the Nasdaq Global Market under the ticker symbol \u201cGUTS\u201d on February 2, 2024.\r\n\r\nFractyl Health is actively developing two promising therapies for T2D treatment. Revita, an outpatient endoscopic procedural therapy, which aims to eliminate insulin needs and enhance glycemic control by ablating dysfunctional duodenal mucosa. Rejuva, a local adeno-associated virus (AAV)-delivered pancreatic gene therapy, seeks to enhance islet health through advanced delivery systems and proprietary screening methods, targeting the pancreas with metabolically active gene therapy candidates.\r\n\r\nIn a recent development, Fractyl Health announced the selection of RJVA-001 as its inaugural clinical T2D candidate in the Rejuva gene therapy platform. RJVA-001 represents the first GLP-1 pancreatic gene therapy (GLP1 PGTx) candidate nominated by the company, designed to address issues such as treatment discontinuation and metabolic rebound commonly observed with existing GLP-1-based therapies. Fractyl Health has initiated discussions with European regulators to establish an investigational new drug (IND)-enabling pathway for RJVA-001 in the treatment of T2D. The company anticipates completing IND-enabling studies, or equivalent milestones, for RJVA-001 by the second half of 2024.\r\n\r\n\r\nAlto Neuroscience\r\nIPO Date: February 1, 2024\r\n\r\nIPO Price: $16.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nAlto Neuroscience is a clinical-stage biopharmaceutical company committed to reshaping psychiatry through the application of neurobiology to craft personalized and highly effective treatment options. Recently, it disclosed the pricing of its expanded IPO of 8,040,000 shares of common stock at a public offering price of $16.00 per share. Trading of the shares started on the New York Stock Exchange on February 2, 2024, under the ticker symbol \u201cANRO.\u201d\r\n\r\nAlto Neuroscience uses an AI-enabled platform to enhance the identification of patients likely to respond to novel product candidates and propel drug development through biomarkers. Currently, several noteworthy candidates are undergoing Phase II evaluation. For instance, in 2023, Alto Neuroscience disclosed encouraging results from its Phase 2a investigation of ALTO-300, a groundbreaking treatment for depression. Post-administration of ALTO-300, patients characterized by an electroencephalogram (EEG) biomarker exhibited substantial clinical amelioration in depression symptoms and higher response rates. These findings underscore the potential of ALTO-300 as an innovative treatment for major depressive disorder (MDD).\r\n\r\nAnother noteworthy candidate, ALTO-100, also demonstrates efficacy and favorable safety in patients with post-traumatic stress disorder (PTSD) in its Phase II trial. The PTSD patient group defined by biomarkers (n=44) displayed a mean reduction of 17.5 points in CAPS-5 scores at Week 4, compared to 12.9 points in the non-biomarker patient group (n=40), alongside a favorable safety and tolerability profile.\r\n\r\nBy harnessing its AI-enabled Precision Psychiatry Platform, Alto Neuroscience can predict clinical response and match each patient to the appropriate product candidate by identifying and prospectively replicating brain biomarkers through analysis of EEG activity, neurocognitive task performance, wearable devices and other metrics.\r\n\r\n\r\nFibroBiologics\r\nIPO Date: January 31, 2024\r\n\r\nIPO Price: $30.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nFibroBiologics, a clinical-stage biotech company, commenced trading on the Nasdaq under the stock ticker \u201cFBLG\u201d following its direct listing on January 31, 2024. The offering included 4,806,226 shares of common stock at a reference price of $30.00 per share, allowing existing shareholders to sell their shares without underwriters. On June 4, 2024, FibroBiologics offered up to 1,742,160 units, each consisting of one share of common stock and one warrant to purchase an additional share, priced at $11.48 per unit, leveraging its current market standing.\r\n\r\nFounded in Houston, Texas, FibroBiologics emerged from its predecessor, FibroGenesis, in 2021. The company focuses on treating chronic diseases such as degenerative disc disease, multiple sclerosis (MS), wound healing, certain cancers and life extension applications like thymic and splenic involution reversal. Using fibroblasts, which can regenerate tissue and organs similarly to stem cells but with quicker culture doubling time, FibroBiologics offers a non-invasive harvesting method from skin donors.\r\n\r\nTheir pipeline includes CybroCell for degenerative disc disease, which uses allogeneic fibroblast cells to repair intervertebral disc cartilage, showing positive results in animal studies and receiving the US Food and Drug Administration (FDA) conditional Investigational New Drug (IND) clearance for a Phase I\/II clinical trial. The global degenerative disc disease market is valued to reach $49.7 billion in 2032.\r\n\r\nFibroBiologics\u2019 investigational cell therapy, CYMS101, for MS leverages fibroblasts' immunomodulatory properties and demonstrated safety and preliminary efficacy in a Phase I trial in Mexico, and FibroBiologics plans to file an IND for a Phase II trial in the US. Statista estimated that the market for MS drugs will hit an annual revenue of $21.52 billion in 2024.\r\n\r\nCYWC628 for wound healing has shown significant improvements in preclinical studies, with an IND submission expected in 2024. The wound care market, valued at approximately $17 billion globally in 2021, is projected to grow to $28.6 billion by 2028.\r\n\r\nCYTER915 focuses on regenerating the thymus and spleen to enhance immune function and extend human life. It taps into the anti-aging therapeutics market, which is projected to reach $2.53 billion by 2031.\r\n\r\nFibroBiologics recently expanded its patent portfolio (over 150 patents issued\/pending), reinforcing its position in regenerative medicine. The company was granted an Australian patent for cartilage regeneration, three US patents for cartilage repair, disc degenerative disease treatment and gene therapy and three Japanese patents focusing on enhancing fibroblast therapeutic activity. They also filed a US patent application for using fibroblast technology to potentially treat lupus, showcasing fibroblasts' versatility in modulating immune responses.\r\n\r\nFibroBiologics faces competition from companies like Aesculap Implant Systems (activL Artificial Disc) in degenerative disc disease, TG Therapeutics\u2019 Briumvi (ublituximab) in MS and numerous entities in wound healing, including Smith &amp; Nephew\u2019s PICO 7 and PICO 14 Single Use Negative Pressure Wound Therapy (sNPWT) system for Class I and II wounds. Despite intense competition, FibroBiologics aims to differentiate itself with unique fibroblast-based therapies, focusing on high unmet needs and partnering with contract research organizations (CROs) for efficient clinical trials. The company is well-positioned to advance its innovative platform and deliver groundbreaking treatments.\r\n\r\n\r\nArriVent BioPharma\r\nIPO Date: January 25, 2024\r\n\r\nIPO Price: $18.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nArriVent BioPharma is a clinical-stage biopharmaceutical company committed to identifying, developing and commercializing differentiated medicines to meet the unmet medical needs of cancer patients. Recently, it announced the pricing of its increased IPO of 9,722,222 shares of its common stock at a public offering price of $18.00 per share. ArriVent\u2019s common stock started trading on the Nasdaq Global Market on January 26, 2024, under the ticker symbol \u201cAVBP.\u201d\r\n\r\nAs a clinical-stage entity, ArriVent is actively assessing its leading drug candidate, furmonertinib, an oral, brain penetrant, epidermal growth factor receptor (EGFR) mutant-selective inhibitor in its Phase III clinical trial.\u00a0In 2023, the US Food and Drug Administration (FDA) granted Breakthrough Therapy designation for furmonertinib for the treatment of patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. Interim results from the trial demonstrated that furmonertinib has promising anti-tumor activity as a single agent with a well-tolerated safety profile in first-line and previously treated patients. The pivotal Phase III FURVENT trial of furmonertinib for the treatment of first-line NSCLC with EGFR exon 20 insertion mutations is currently enrolling patients globally.\r\n\r\nArriVent is constructing its pipeline with a profound grasp of cancer biology and unmet medical needs and is extending these competencies to other medications and research collaborations.\r\n\r\n\r\nCG Oncology\r\nIPO Date:\u00a0January 24, 2024\r\n\r\nIPO Price: $19.00\r\n\r\nCurrent Share Price:\r\n\r\n\r\n\r\n\r\n\r\n\r\n\r\n&nbsp;\r\n\r\nCG Oncology is a late-stage clinical biopharma company dedicated to the development and commercialization of a potential backbone bladder-sparing therapeutic for patients suffering from bladder cancer. Recently, it disclosed the completion of its increased IPO of 23,000,000 shares of its common stock. CG Oncology\u2019s common stock is now listed on the Nasdaq Global Select Market under the ticker symbol \u201cCGON.\u201d\r\n\r\nCG Oncology\u2019s product candidate, cretostimogene grenadenorepvec, represents an investigational engineered oncolytic immunotherapy. In Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC), cretostimogene has demonstrated clinical benefit and has generally been well-tolerated in clinical trials, both as a monotherapy and in combination with other therapies. Additionally, it is undergoing Phase II evaluation in combination with pembrolizumab for the same indication. Furthermore, cretostimogene is being assessed in combination with nivolumab for other types of bladder cancer. They are currently planning further studies in bladder cancer.\r\n\r\nLast month, the FDA granted fast track and breakthrough therapy designations to cretostimogene grenadenorepvec for potential therapeutic use in patients with high-risk BCG-unresponsive NMIBC with carcinoma in situ, with or without Ta or T1 tumors. This decision is supported by ongoing clinical trials, including the Phase III BOND-003 trial, which demonstrated that intravesically delivered oncolytic immunotherapy provided clinical benefit in the form of complete responses with acceptable tolerability.\r\n\r\n\r\n\r\nTo have your company featured on Xtalks, please email Vera Kovacevic, PhD, at: verak@xtalks.com",
      "thumbnailUrl": "https:\/\/xtalks.com\/wp-content\/uploads\/2024\/02\/Biotech-IPOs-in-2024-scaled-e1707165831193.jpg",
      "uploadDate": "Dec 05, 2024 @ 7:02 PM EST",
      "contentUrl": "https:\/\/xtalks.com\/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709\/",
      "embedUrl": ""    }
	</script>
	
					<hr>

							<!-- pagination here -->
		<div class="highlight-posts">
			<div class="flex">
				<h3 class="section-header query-header">Related Vitals</h3>
			</div>
			<div class="highlight-slider">
				<!-- the loop -->
									<div class="columns">
						
<div class="alt-card">
	<header >
				<a href="https://xtalks.com/super-bowl-2026-pharma-tv-ads-pharma-takes-the-field-with-health-awareness-weight-loss-and-more-4621/"><h3>Super Bowl 2026 Pharma TV Ads: Pharma Takes the Field with Health Awareness, Weight Loss and More</h3></a>
	</header>
	<div class="alt-card__content">
					<div class="alt-card__media" style="">
				<a href="https://xtalks.com/super-bowl-2026-pharma-tv-ads-pharma-takes-the-field-with-health-awareness-weight-loss-and-more-4621/">
					<img width="1000" height="562" src="https://xtalks.com/wp-content/uploads/2026/02/novartis-super-bowl-2026-pre-release-relax-your-tight-end-ft-rob-gronkowski-song-by-enya-large-1.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="Super Bowl Pharma Ads 2026" decoding="async" loading="lazy" srcset="https://xtalks.com/wp-content/uploads/2026/02/novartis-super-bowl-2026-pre-release-relax-your-tight-end-ft-rob-gronkowski-song-by-enya-large-1.jpg 1000w, https://xtalks.com/wp-content/uploads/2026/02/novartis-super-bowl-2026-pre-release-relax-your-tight-end-ft-rob-gronkowski-song-by-enya-large-1-300x169.jpg 300w, https://xtalks.com/wp-content/uploads/2026/02/novartis-super-bowl-2026-pre-release-relax-your-tight-end-ft-rob-gronkowski-song-by-enya-large-1-768x432.jpg 768w, https://xtalks.com/wp-content/uploads/2026/02/novartis-super-bowl-2026-pre-release-relax-your-tight-end-ft-rob-gronkowski-song-by-enya-large-1-600x337.jpg 600w" sizes="auto, (max-width: 1000px) 100vw, 1000px" />									</a>
			</div>
					<div class="alt-card__meta">
			<a href="https://xtalks.com/category/news/"><small>News</small></a>			<span class="entry-meta"><small><time class="entry-date published" datetime="2026-02-06T17:47:55-05:00">February 6, 2026</time></small></span>		</div>
	</div>
</div>
					</div>
									<div class="columns">
						
<div class="alt-card">
	<header>
				<a href="https://xtalks.com/fda-transitions-to-qmsr-updating-how-medical-device-inspections-are-conducted-4620/"><h3>FDA Transitions to QMSR, Updating How Medical Device Inspections Are Conducted</h3></a>
	</header>
	<div class="alt-card__content">
					<div class="alt-card__media" style="">
				<a href="https://xtalks.com/fda-transitions-to-qmsr-updating-how-medical-device-inspections-are-conducted-4620/">
					<img width="1280" height="720" src="https://xtalks.com/wp-content/uploads/2026/02/FDA-QMSR.png" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="FDA QMSR, QMSR Final Rule" decoding="async" loading="lazy" srcset="https://xtalks.com/wp-content/uploads/2026/02/FDA-QMSR.png 1280w, https://xtalks.com/wp-content/uploads/2026/02/FDA-QMSR-300x169.png 300w, https://xtalks.com/wp-content/uploads/2026/02/FDA-QMSR-1024x576.png 1024w, https://xtalks.com/wp-content/uploads/2026/02/FDA-QMSR-768x432.png 768w, https://xtalks.com/wp-content/uploads/2026/02/FDA-QMSR-600x338.png 600w" sizes="auto, (max-width: 1280px) 100vw, 1280px" />									</a>
			</div>
					<div class="alt-card__meta">
			<a href="https://xtalks.com/category/news/"><small>News</small></a>			<span class="entry-meta"><small><time class="entry-date published updated" datetime="2026-02-06T17:00:18-05:00">February 6, 2026</time></small></span>		</div>
	</div>
</div>
					</div>
									<div class="columns">
						
<div class="alt-card">
	<header>
				<a href="https://xtalks.com/fda-seeks-additional-information-on-subcutaneous-anifrolumab-bla-4619/"><h3>FDA Seeks Additional Information on Subcutaneous Anifrolumab BLA</h3></a>
	</header>
	<div class="alt-card__content">
					<div class="alt-card__media" style="">
				<a href="https://xtalks.com/fda-seeks-additional-information-on-subcutaneous-anifrolumab-bla-4619/">
					<img width="1280" height="720" src="https://xtalks.com/wp-content/uploads/2026/02/FDA-complete-response-letter-anifrolumab.png" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="FDA complete response letter anifrolumab, subcutaneous anifrolumab, anifrolumab astrazeneca" decoding="async" loading="lazy" srcset="https://xtalks.com/wp-content/uploads/2026/02/FDA-complete-response-letter-anifrolumab.png 1280w, https://xtalks.com/wp-content/uploads/2026/02/FDA-complete-response-letter-anifrolumab-300x169.png 300w, https://xtalks.com/wp-content/uploads/2026/02/FDA-complete-response-letter-anifrolumab-1024x576.png 1024w, https://xtalks.com/wp-content/uploads/2026/02/FDA-complete-response-letter-anifrolumab-768x432.png 768w, https://xtalks.com/wp-content/uploads/2026/02/FDA-complete-response-letter-anifrolumab-600x338.png 600w" sizes="auto, (max-width: 1280px) 100vw, 1280px" />									</a>
			</div>
					<div class="alt-card__meta">
			<a href="https://xtalks.com/category/news/"><small>News</small></a>			<span class="entry-meta"><small><time class="entry-date published" datetime="2026-02-05T11:53:47-05:00">February 5, 2026</time></small></span>		</div>
	</div>
</div>
					</div>
									<div class="columns">
						
<div class="alt-card">
	<header>
				<a href="https://xtalks.com/world-cancer-day-2026-a-focus-on-prevention-and-raising-treatment-bars-4617/"><h3>World Cancer Day 2026: A Focus on Prevention and Raising Treatment Bars</h3></a>
	</header>
	<div class="alt-card__content">
					<div class="alt-card__media" style="">
				<a href="https://xtalks.com/world-cancer-day-2026-a-focus-on-prevention-and-raising-treatment-bars-4617/">
					<img width="1200" height="591" src="https://xtalks.com/wp-content/uploads/2026/02/shutterstock_2418865645-scaled-e1770224725931.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="World Cancer Day 2026" decoding="async" loading="lazy" />									</a>
			</div>
					<div class="alt-card__meta">
			<a href="https://xtalks.com/category/blogs/"><small>Blogs</small></a>			<span class="entry-meta"><small><time class="entry-date published" datetime="2026-02-04T12:06:15-05:00">February 4, 2026</time></small></span>		</div>
	</div>
</div>
					</div>
									<div class="columns">
						
<div class="alt-card">
	<header>
				<a href="https://xtalks.com/medtech-ma-in-2026-tracking-deal-activity-4616/"><h3>MedTech M&#038;A in 2026: Tracking Deal Activity</h3></a>
	</header>
	<div class="alt-card__content">
					<div class="alt-card__media" style="">
				<a href="https://xtalks.com/medtech-ma-in-2026-tracking-deal-activity-4616/">
					<img width="1280" height="720" src="https://xtalks.com/wp-content/uploads/2026/02/Medtech-MA-2026.png" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="MedTech M&amp;A 2026, medtech m&amp;a news 2026, medical device m&amp;a news 2026" decoding="async" loading="lazy" srcset="https://xtalks.com/wp-content/uploads/2026/02/Medtech-MA-2026.png 1280w, https://xtalks.com/wp-content/uploads/2026/02/Medtech-MA-2026-300x169.png 300w, https://xtalks.com/wp-content/uploads/2026/02/Medtech-MA-2026-1024x576.png 1024w, https://xtalks.com/wp-content/uploads/2026/02/Medtech-MA-2026-768x432.png 768w, https://xtalks.com/wp-content/uploads/2026/02/Medtech-MA-2026-600x338.png 600w" sizes="auto, (max-width: 1280px) 100vw, 1280px" />									</a>
			</div>
					<div class="alt-card__meta">
			<a href="https://xtalks.com/category/blogs/life-science-blogs/medical-device-blogs/"><small>Medical Device Blogs</small></a>			<span class="entry-meta"><small><time class="entry-date published" datetime="2026-02-03T16:52:26-05:00">February 3, 2026</time></small></span>		</div>
	</div>
</div>
					</div>
							</div>
		</div>
		
					<hr>

							<!-- pagination here -->
		<div class="highlight-posts">
			<div class="flex">
				<h3 class="section-header query-header">Related Webinars</h3>
			</div>
			<div class="highlight-slider">
				<!-- the loop -->
									<div class="columns">
						
<div class="alt-card">
	<header>
					<small class="webinar-date">March 25, 2026</small>
					<a href="https://xtalks.com/webinars/dpyd-from-guidelines-to-go-live-implementing-testing-in-the-lab/"><h3>DPYD, From Guidelines to Go-Live: Implementing Testing in the Lab</h3></a>
	</header>
	<div class="alt-card__content">
					<div class="alt-card__media" style="">
				<a href="https://xtalks.com/webinars/dpyd-from-guidelines-to-go-live-implementing-testing-in-the-lab/">
					<img width="1600" height="400" src="https://xtalks.com/wp-content/uploads/2026/02/AgenaBiosciences_Mar25_Hero_1600x400.jpg" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://xtalks.com/wp-content/uploads/2026/02/AgenaBiosciences_Mar25_Hero_1600x400.jpg 1600w, https://xtalks.com/wp-content/uploads/2026/02/AgenaBiosciences_Mar25_Hero_1600x400-300x75.jpg 300w, https://xtalks.com/wp-content/uploads/2026/02/AgenaBiosciences_Mar25_Hero_1600x400-1024x256.jpg 1024w, https://xtalks.com/wp-content/uploads/2026/02/AgenaBiosciences_Mar25_Hero_1600x400-768x192.jpg 768w, https://xtalks.com/wp-content/uploads/2026/02/AgenaBiosciences_Mar25_Hero_1600x400-1536x384.jpg 1536w, https://xtalks.com/wp-content/uploads/2026/02/AgenaBiosciences_Mar25_Hero_1600x400-600x150.jpg 600w" sizes="auto, (max-width: 1600px) 100vw, 1600px" />									</a>
			</div>
					<div class="alt-card__meta">
						<img src="https://xtalks.com/wp-content/uploads/2026/02/Agena-Bioscience-Webpage.png" width="114" height="38" alt="" />		</div>
	</div>
</div>
					</div>
										<div class="columns">
						
<div class="alt-card">
	<header>
					<small class="webinar-date">March 12, 2026</small>
					<a href="https://xtalks.com/webinars/how-to-build-a-measurable-evidence-engine-for-cell-gene-and-rna-therapies/"><h3>How to Build a Measurable Evidence Engine for Cell, Gene and RNA Therapies</h3></a>
	</header>
	<div class="alt-card__content">
					<div class="alt-card__media" style="">
				<a href="https://xtalks.com/webinars/how-to-build-a-measurable-evidence-engine-for-cell-gene-and-rna-therapies/">
					<img width="1600" height="400" src="https://xtalks.com/wp-content/uploads/2026/02/Hero-Desktop-1.png" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://xtalks.com/wp-content/uploads/2026/02/Hero-Desktop-1.png 1600w, https://xtalks.com/wp-content/uploads/2026/02/Hero-Desktop-1-300x75.png 300w, https://xtalks.com/wp-content/uploads/2026/02/Hero-Desktop-1-1024x256.png 1024w, https://xtalks.com/wp-content/uploads/2026/02/Hero-Desktop-1-768x192.png 768w, https://xtalks.com/wp-content/uploads/2026/02/Hero-Desktop-1-1536x384.png 1536w, https://xtalks.com/wp-content/uploads/2026/02/Hero-Desktop-1-600x150.png 600w" sizes="auto, (max-width: 1600px) 100vw, 1600px" />									</a>
			</div>
					<div class="alt-card__meta">
						<img src="https://xtalks.com/wp-content/uploads/2026/02/DNAnexus-Webpage.png" width="114" height="38" alt="" />		</div>
	</div>
</div>
					</div>
										<div class="columns">
						
<div class="alt-card">
	<header>
					<small class="webinar-date">March 17, 2026</small>
					<a href="https://xtalks.com/webinars/dna-isolation-in-non-invasive-sampling-material-design-for-devices/"><h3>DNA Isolation in Non-Invasive Sampling Material Design for Devices</h3></a>
	</header>
	<div class="alt-card__content">
					<div class="alt-card__media" style="">
				<a href="https://xtalks.com/webinars/dna-isolation-in-non-invasive-sampling-material-design-for-devices/">
					<img width="1600" height="400" src="https://xtalks.com/wp-content/uploads/2026/02/Porex-Filtration-Hero-Webpage.png" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://xtalks.com/wp-content/uploads/2026/02/Porex-Filtration-Hero-Webpage.png 1600w, https://xtalks.com/wp-content/uploads/2026/02/Porex-Filtration-Hero-Webpage-300x75.png 300w, https://xtalks.com/wp-content/uploads/2026/02/Porex-Filtration-Hero-Webpage-1024x256.png 1024w, https://xtalks.com/wp-content/uploads/2026/02/Porex-Filtration-Hero-Webpage-768x192.png 768w, https://xtalks.com/wp-content/uploads/2026/02/Porex-Filtration-Hero-Webpage-1536x384.png 1536w, https://xtalks.com/wp-content/uploads/2026/02/Porex-Filtration-Hero-Webpage-600x150.png 600w" sizes="auto, (max-width: 1600px) 100vw, 1600px" />									</a>
			</div>
					<div class="alt-card__meta">
						<img src="https://xtalks.com/wp-content/uploads/2026/02/Porex-Filtration-Webpage.png" width="114" height="38" alt="" />		</div>
	</div>
</div>
					</div>
										<div class="columns">
						
<div class="alt-card">
	<header>
					<small class="webinar-date">March 11, 2026</small>
					<a href="https://xtalks.com/webinars/quality-management-accelerating-qa-qc-and-time-to-market-with-intelligent-solutions-ai/"><h3>Quality Management: Accelerating QA/QC and Time-to-Market with Intelligent Solutions &#038; AI</h3></a>
	</header>
	<div class="alt-card__content">
					<div class="alt-card__media" style="">
				<a href="https://xtalks.com/webinars/quality-management-accelerating-qa-qc-and-time-to-market-with-intelligent-solutions-ai/">
					<img width="1600" height="400" src="https://xtalks.com/wp-content/uploads/2026/02/Tenthpin_Mar11_Hero_1600x400.png" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://xtalks.com/wp-content/uploads/2026/02/Tenthpin_Mar11_Hero_1600x400.png 1600w, https://xtalks.com/wp-content/uploads/2026/02/Tenthpin_Mar11_Hero_1600x400-300x75.png 300w, https://xtalks.com/wp-content/uploads/2026/02/Tenthpin_Mar11_Hero_1600x400-1024x256.png 1024w, https://xtalks.com/wp-content/uploads/2026/02/Tenthpin_Mar11_Hero_1600x400-768x192.png 768w, https://xtalks.com/wp-content/uploads/2026/02/Tenthpin_Mar11_Hero_1600x400-1536x384.png 1536w, https://xtalks.com/wp-content/uploads/2026/02/Tenthpin_Mar11_Hero_1600x400-600x150.png 600w" sizes="auto, (max-width: 1600px) 100vw, 1600px" />									</a>
			</div>
					<div class="alt-card__meta">
						<img src="https://xtalks.com/wp-content/uploads/2026/02/Tenthpin-Webpage.png" width="114" height="38" alt="" />		</div>
	</div>
</div>
					</div>
										<div class="columns">
						
<div class="alt-card">
	<header>
					<small class="webinar-date">March 31, 2026</small>
					<a href="https://xtalks.com/webinars/drug-development-insights-what-new-industry-data-reveals-for-2026/"><h3>Drug Development Insights: What New Industry Data Reveals for 2026</h3></a>
	</header>
	<div class="alt-card__content">
					<div class="alt-card__media" style="">
				<a href="https://xtalks.com/webinars/drug-development-insights-what-new-industry-data-reveals-for-2026/">
					<img width="1600" height="400" src="https://xtalks.com/wp-content/uploads/2026/01/PPD_Mar12_Hero_1600x400.png" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://xtalks.com/wp-content/uploads/2026/01/PPD_Mar12_Hero_1600x400.png 1600w, https://xtalks.com/wp-content/uploads/2026/01/PPD_Mar12_Hero_1600x400-300x75.png 300w, https://xtalks.com/wp-content/uploads/2026/01/PPD_Mar12_Hero_1600x400-1024x256.png 1024w, https://xtalks.com/wp-content/uploads/2026/01/PPD_Mar12_Hero_1600x400-768x192.png 768w, https://xtalks.com/wp-content/uploads/2026/01/PPD_Mar12_Hero_1600x400-1536x384.png 1536w, https://xtalks.com/wp-content/uploads/2026/01/PPD_Mar12_Hero_1600x400-600x150.png 600w" sizes="auto, (max-width: 1600px) 100vw, 1600px" />									</a>
			</div>
					<div class="alt-card__meta">
						<img src="https://xtalks.com/wp-content/uploads/2026/01/PPD-Webpage-1.png" width="114" height="38" alt="" />		</div>
	</div>
</div>
					</div>
								</div>
		</div>
		
					<hr>

					
				</div>
			</div>

			<div class="row">
				<div class="columns small-12 small-centered medium-9">
											<div class="comments-card__margin-bottom">
							<div class="comment-signup-wrapper">
								<h3 id="reply-title" class="comment-reply-title">Join or login to leave a comment</h3>
								<a class="xtk_btn orange" href="https://xtalks.com/register">JOIN</a>
								<a class="xtk_btn orange" href="https://xtalks.com/login?redirect_to=https%3A%2F%2Fxtalks.com%2Fbiotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709%2F">LOGIN</a>
							</div>
						</div>
									</div>
			</div>

			<div id="subscribe" class="row">
				<div class="columns small-12 small-centered medium-9">
						<div class="newsletter">
		<div class="newsletter__header">
			<h2>Subscribe to our newsletters</h2>
			<p>Not a member yet? Sign up for our newsletters and receive webinars, vitals, and updates for your topic of choice</p>
		</div>
		
                <div class='gf_browser_gecko gform_wrapper gform_legacy_markup_wrapper gform-theme--no-framework' data-form-theme='legacy' data-form-index='0' id='gform_wrapper_15' ><div id='gf_15' class='gform_anchor' tabindex='-1'></div><form method='post' enctype='multipart/form-data' target='gform_ajax_frame_15' id='gform_15'  action='/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/#gf_15' data-formid='15' novalidate>
                        <div class='gform-body gform_body'><ul id='gform_fields_15' class='gform_fields top_label form_sublabel_below description_below validation_below'><li id="field_15_4" class="gfield gfield--type-checkbox gfield--type-choice preferences field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><label class='gfield_label gform-field-label gfield_label_before_complex' >Preferences</label><div class='ginput_container ginput_container_checkbox'><ul class='gfield_checkbox' id='input_15_4'><li class='gchoice gchoice_15_4_1'>
								<input class='gfield-choice-input' name='input_4.1' type='checkbox'  value='Xtalks Vitals'  id='choice_15_4_1'   />
								<label for='choice_15_4_1' id='label_15_4_1' class='gform-field-label gform-field-label--type-inline'>Xtalks Vitals</label>
							</li><li class='gchoice gchoice_15_4_2'>
								<input class='gfield-choice-input' name='input_4.2' type='checkbox'  value='Vitals Life Science'  id='choice_15_4_2'   />
								<label for='choice_15_4_2' id='label_15_4_2' class='gform-field-label gform-field-label--type-inline'>Vitals Life Science</label>
							</li><li class='gchoice gchoice_15_4_3'>
								<input class='gfield-choice-input' name='input_4.3' type='checkbox'  value='Vitals Food Industry'  id='choice_15_4_3'   />
								<label for='choice_15_4_3' id='label_15_4_3' class='gform-field-label gform-field-label--type-inline'>Vitals Food Industry</label>
							</li><li class='gchoice gchoice_15_4_4'>
								<input class='gfield-choice-input' name='input_4.4' type='checkbox'  value='Vitals Medical Devices'  id='choice_15_4_4'   />
								<label for='choice_15_4_4' id='label_15_4_4' class='gform-field-label gform-field-label--type-inline'>Vitals Medical Devices</label>
							</li><li class='gchoice gchoice_15_4_5'>
								<input class='gfield-choice-input' name='input_4.5' type='checkbox'  value='Marketing Insights Blog'  id='choice_15_4_5'   />
								<label for='choice_15_4_5' id='label_15_4_5' class='gform-field-label gform-field-label--type-inline'>Marketing Insights Blog</label>
							</li></ul></div></li><li id="field_15_1" class="gfield gfield--type-text input gfield_contains_required field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><label class='gfield_label gform-field-label' for='input_15_1'>First Name<span class="gfield_required"><span class="gfield_required gfield_required_asterisk">*</span></span></label><div class='ginput_container ginput_container_text'><input name='input_1' id='input_15_1' type='text' value='' class='medium'    placeholder='First Name*' aria-required="true" aria-invalid="false"   /></div></li><li id="field_15_2" class="gfield gfield--type-text input gfield_contains_required field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><label class='gfield_label gform-field-label' for='input_15_2'>Last Name<span class="gfield_required"><span class="gfield_required gfield_required_asterisk">*</span></span></label><div class='ginput_container ginput_container_text'><input name='input_2' id='input_15_2' type='text' value='' class='medium'    placeholder='Last Name*' aria-required="true" aria-invalid="false"   /></div></li><li id="field_15_6" class="gfield gfield--type-text input gfield_contains_required field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><label class='gfield_label gform-field-label' for='input_15_6'>Country<span class="gfield_required"><span class="gfield_required gfield_required_asterisk">*</span></span></label><div class='ginput_container ginput_container_text'><input name='input_6' id='input_15_6' type='text' value='' class='medium'    placeholder='Country' aria-required="true" aria-invalid="false"   /></div></li><li id="field_15_3" class="gfield gfield--type-email input gfield_contains_required field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><label class='gfield_label gform-field-label' for='input_15_3'>Email<span class="gfield_required"><span class="gfield_required gfield_required_asterisk">*</span></span></label><div class='ginput_container ginput_container_email'>
                            <input name='input_3' id='input_15_3' type='email' value='' class='medium'   placeholder='Email*' aria-required="true" aria-invalid="false"  />
                        </div></li><li id="field_15_7" class="gfield gfield--type-captcha field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><label class='gfield_label gform-field-label' for='input_15_7'>CAPTCHA</label><div id='input_15_7' class='ginput_container ginput_recaptcha' data-sitekey='6Lcq-IkUAAAAABcKBuP4EKMBw_jqicJGvASAr-yq'  data-theme='light' data-tabindex='0'  data-badge=''></div></li></ul></div>
        <div class='gform-footer gform_footer top_label'> <input type='submit' id='gform_submit_button_15' class='gform_button button' onclick='gform.submission.handleButtonClick(this);' data-submission-type='submit' value='Subscribe'  /> <input type='hidden' name='gform_ajax' value='form_id=15&amp;title=&amp;description=&amp;tabindex=0&amp;theme=legacy&amp;styles=[]&amp;hash=fe784b084358a07b9b7ebe30e8d8e281' />
            <input type='hidden' class='gform_hidden' name='gform_submission_method' data-js='gform_submission_method_15' value='iframe' />
            <input type='hidden' class='gform_hidden' name='gform_theme' data-js='gform_theme_15' id='gform_theme_15' value='legacy' />
            <input type='hidden' class='gform_hidden' name='gform_style_settings' data-js='gform_style_settings_15' id='gform_style_settings_15' value='[]' />
            <input type='hidden' class='gform_hidden' name='is_submit_15' value='1' />
            <input type='hidden' class='gform_hidden' name='gform_submit' value='15' />
            
            <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' />
            <input type='hidden' class='gform_hidden' name='state_15' value='WyJbXSIsIjI0NjQ1OTAwMjE0ZjBmZjE5OWZjOGJjMTk3ZDI2MGFlIl0=' />
            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_target_page_number_15' id='gform_target_page_number_15' value='0' />
            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_source_page_number_15' id='gform_source_page_number_15' value='1' />
            <input type='hidden' name='gform_field_values' value='' />
            
        </div>
                        </form>
                        </div>
		                <iframe style='display:none;width:0px;height:0px;' src='about:blank' name='gform_ajax_frame_15' id='gform_ajax_frame_15' title='This iframe contains the logic required to handle Ajax powered Gravity Forms.'></iframe>
		                <script type="text/javascript">
/* <![CDATA[ */
 gform.initializeOnLoaded( function() {gformInitSpinner( 15, 'https://xtalks.com/wp-content/plugins/gravityforms/images/spinner.svg', true );jQuery('#gform_ajax_frame_15').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_15');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_15').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_15').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_15').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_15').removeClass('gform_validation_error');}setTimeout( function() { /* delay the scroll by 50 milliseconds to fix a bug in chrome */ jQuery(document).scrollTop(jQuery('#gform_wrapper_15').offset().top - mt); }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_15').val();gformInitSpinner( 15, 'https://xtalks.com/wp-content/plugins/gravityforms/images/spinner.svg', true );jQuery(document).trigger('gform_page_loaded', [15, current_page]);window['gf_submitting_15'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_15').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_15').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [15]);window['gf_submitting_15'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_15').text());}else{jQuery('#gform_15').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger("gform_pre_post_render", [{ formId: "15", currentPage: "current_page", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( "gform_wrapper_15" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( "span" );            visibilitySpan.id = "gform_visibility_test_15";            gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( "gform_visibility_test_15" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 15, current_page );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } );} ); 
/* ]]> */
</script>
		<div class="newsletter__footer">
			<small>Please review our privacy policy and understand that we may occasionally inform you of related Xtalks content if you click subscribe. You may unsubscribe at anytime.</small>
		</div>
	</div>
					</div>
			</div>

		</article><!-- #post-## -->


		
		</main><!-- #main -->
	</div><!-- #primary -->


	</div><!-- #content -->

	
	
	<footer id="colophon" class="site-footer" role="contentinfo">
		<div class="footer-links">
			<div class="row">
				<div class="small-12 columns">
											<section id="nav_menu-2" class="widget widget_nav_menu"><h2 class="widget-title">Webinars</h2><div class="menu-webinars-container"><ul id="menu-webinars" class="menu"><li id="menu-item-446" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-446"><a href="https://xtalks.com/webinars/">All Life Sciences</a></li>
<li id="menu-item-188842" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188842"><a href="https://xtalks.com/pharma/">Pharma</a></li>
<li id="menu-item-188843" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188843"><a href="https://xtalks.com/biotech/">Biotech</a></li>
<li id="menu-item-188844" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188844"><a href="https://xtalks.com/medtech/">Medtech</a></li>
<li id="menu-item-188845" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188845"><a href="https://xtalks.com/healthcare/">Healthcare</a></li>
<li id="menu-item-188846" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188846"><a href="https://xtalks.com/research/">Research</a></li>
<li id="menu-item-188847" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188847"><a href="https://xtalks.com/food-industry/">Food</a></li>
</ul></div></section><section id="nav_menu-6" class="widget widget_nav_menu"><h2 class="widget-title">Features</h2><div class="menu-news-features-jobs-container"><ul id="menu-news-features-jobs" class="menu"><li id="menu-item-188814" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188814"><a href="https://xtalks.com/vitals/">All Xtalks Editorial</a></li>
<li id="menu-item-8937" class="menu-item menu-item-type-taxonomy menu-item-object-category current-post-ancestor current-menu-parent current-post-parent menu-item-8937"><a href="https://xtalks.com/category/news/">News</a></li>
<li id="menu-item-8938" class="menu-item menu-item-type-taxonomy menu-item-object-category current-post-ancestor current-menu-parent current-post-parent menu-item-8938"><a href="https://xtalks.com/category/blogs/">Blogs</a></li>
<li id="menu-item-188815" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188815"><a href="https://xtalks.com/category/spotlight/">Xtalks Spotlight</a></li>
<li id="menu-item-188816" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188816"><a href="https://clinicaledge.xtalks.com/magazine/resource-hub/?_gl=1*63gm5c*_gcl_au*MTM2MjIzODQ5MS4xNzYxNjYwNzQ5*_ga*NDczMDA4MjE0LjE3NjE2NjA3NDk.*_ga_5XXFSWKDKQ*czE3NjQ1NjE0MDgkbzckZzEkdDE3NjQ1NjI3MTkkajU5JGwwJGgw">Xtalks Clinical Edge</a></li>
<li id="menu-item-188817" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188817"><a href="https://xtalks.com/job/">Search Industry Jobs</a></li>
<li id="menu-item-188818" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188818"><a href="https://xtalks.com/post-your-job/?credits=none">Post Jobs</a></li>
</ul></div></section><section id="nav_menu-7" class="widget widget_nav_menu"><h2 class="widget-title">Partner</h2><div class="menu-partner-with-us-container"><ul id="menu-partner-with-us" class="menu"><li id="menu-item-188819" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188819"><a href="https://xtalks.com/partner-with-us/">All Services</a></li>
<li id="menu-item-188820" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188820"><a href="https://xtalks.com/product/xtalks-webinars/">Host a Webinar</a></li>
<li id="menu-item-188821" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188821"><a href="https://xtalks.com/product/xtalks-spotlight/">Spotlight Videos</a></li>
<li id="menu-item-188822" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188822"><a href="https://xtalks.com/product/xtalks-editorial-feature/">Editorial Features</a></li>
<li id="menu-item-188823" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188823"><a href="https://xtalks.com/product/xtalks-clinical-edge-digital-magazine/">Digital Magazine</a></li>
<li id="menu-item-188825" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188825"><a href="https://xtalks.com/product/xtalks-life-science-podcast/">Life Science Podcast</a></li>
<li id="menu-item-188824" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188824"><a href="https://xtalks.com/product/xtalks-life-science-podcast/">Email Marketing</a></li>
</ul></div></section><section id="nav_menu-4" class="widget widget_nav_menu"><h2 class="widget-title">About</h2><div class="menu-about-container"><ul id="menu-about" class="menu"><li id="menu-item-453" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-453"><a href="https://xtalks.com/about/">About Us</a></li>
<li id="menu-item-456" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-456"><a href="https://xtalks.com/contact/">Contact Us</a></li>
<li id="menu-item-454" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-454"><a href="https://xtalks.com/frequently-asked-questions/">FAQ</a></li>
<li id="menu-item-455" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-455"><a href="https://xtalks.com/team/">Meet the Team</a></li>
<li id="menu-item-20629" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-20629"><a href="https://xtalks.com/privacy-policy/">Privacy Policy</a></li>
<li id="menu-item-20630" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-20630"><a href="https://xtalks.com/terms-of-use/">Terms of Use</a></li>
<li id="menu-item-188509" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-188509"><a href="#" id="privacy-preferences">Privacy Preferences</a></li>
</ul></div></section><section id="nav_menu-5" class="widget widget_nav_menu"><h2 class="widget-title">My Xtalks</h2><div class="menu-my-xtalks-container"><ul id="menu-my-xtalks" class="menu"><li id="menu-item-458" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-458"><a href="https://xtalks.com/login/">Login</a></li>
<li id="menu-item-14779" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-14779"><a href="https://xtalks.com/my-profile/">My Profile</a></li>
<li id="menu-item-14780" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-14780"><a href="https://xtalks.com/my-profile/edit-profile/">Edit Profile</a></li>
<li id="menu-item-457" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-457"><a href="https://xtalks.com/register/">Join Xtalks</a></li>
<li id="menu-item-123052" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-123052"><a href="https://xtalks.com/peer-circles/">Xtalks Peer Circles</a></li>
<li id="menu-item-10043" class="back-to-top menu-item menu-item-type-custom menu-item-object-custom menu-item-10043"><a href="#">Back To Top</a></li>
</ul></div></section>									</div>
			</div>
		</div>
		<div class="popup-modal ">
			<div class="popup-login">
				<div class="close-popup">
					<i class="fa fa-times close"></i>
				</div>
				<div class="row scrollable">
					<div class="columns small-12 medium-8 medium-centered">
							<div class="login-text">
							<h3>Login</h3>
							<p><strong>Already have an account at Xtalks? Login with:</strong></p>
							
<!--
	wsl_render_auth_widget
	WordPress Social Login 3.0.3.
	http://wordpress.org/plugins/wordpress-social-login/
-->

<style type="text/css">
.wp-social-login-connect-with{}.wp-social-login-provider-list{}.wp-social-login-provider-list a{}.wp-social-login-provider-list img{}.wsl_connect_with_provider{}</style>

<div class="wp-social-login-widget">

	<div class="wp-social-login-connect-with"></div>

	<div class="wp-social-login-provider-list">
	<a rel="nofollow" href="https://xtalks.com/wp-login.php?wpe-login=true&#038;action=wordpress_social_authenticate&#038;mode=login&#038;provider=Facebook&#038;redirect_to=https%3A%2F%2Fxtalks.com%2Fbiotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709%2F" data-provider="Facebook" class="wp-social-login-provider wp-social-login-provider-facebook" title="First agree with terms &amp; policy">
		<span> Facebook</span>
	</a>
	<a rel="nofollow" href="https://xtalks.com/wp-login.php?wpe-login=true&#038;action=wordpress_social_authenticate&#038;mode=login&#038;provider=LinkedIn&#038;redirect_to=https%3A%2F%2Fxtalks.com%2Fbiotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709%2F" data-provider="LinkedIn" class="wp-social-login-provider wp-social-login-provider-linkedin" title="First agree with terms &amp; policy">
		<span> LinkedIn</span>
	</a>

	</div>

	<div class="wp-social-login-widget-clearing"></div>

</div>

<!-- wsl_render_auth_widget -->

							<p class="break-line-login">Or</p>
						</div>
						
													<form name="loginform" id="loginform" action="https://xtalks.com/wp-login.php?wpe-login=true" method="post"><div class="wp-success"></div><p class="login-username">
				<label for="user_login">Username or Email Address</label>
				<input type="text" name="log" id="user_login" autocomplete="username" class="input" value="" size="20" />
			</p><p class="login-password">
				<label for="user_pass">Password</label>
				<input type="password" name="pwd" id="user_pass" autocomplete="current-password" spellcheck="false" class="input" value="" size="20" />
			</p><a href="https://xtalks.com/wp-login.php?action=lostpassword">Lost Password?</a><p class="login-remember"><label><input name="rememberme" type="checkbox" id="rememberme" value="forever" checked="checked" /> Remember Me</label></p><p class="login-submit">
				<input type="submit" name="wp-submit" id="wp-submit" class="button button-primary" value="Log In" />
				<input type="hidden" name="redirect_to" value="https://xtalks.com/my-profile/" />
			</p></form>												<p class="login-message">Don&#039;t have an account?<span class="join-option"><a href="#">Join</a></span></p>
					</div>
				</div>
			</div>
							<div class="popup-join">
					<div class="close-popup">
						<i class="fa fa-times close"></i>
					</div>
					<div class="row scrollable">
						<div class="columns small-12 medium-8 medium-centered text-center">
							<h3>Join</h3>
							<p>Create an account for access to webinars, jobs, news, blogs, discussions and more. Join thousands of other professionals from life science, medical device and food industries.</p>
							<p><strong>Create an account using</strong></p>
							
<!--
	wsl_render_auth_widget
	WordPress Social Login 3.0.3.
	http://wordpress.org/plugins/wordpress-social-login/
-->

<style type="text/css">
.wp-social-login-connect-with{}.wp-social-login-provider-list{}.wp-social-login-provider-list a{}.wp-social-login-provider-list img{}.wsl_connect_with_provider{}</style>

<div class="wp-social-login-widget">

	<div class="wp-social-login-connect-with"></div>

	<div class="wp-social-login-provider-list">
	<a rel="nofollow" href="https://xtalks.com/wp-login.php?wpe-login=true&#038;action=wordpress_social_authenticate&#038;mode=login&#038;provider=Facebook&#038;redirect_to=https%3A%2F%2Fxtalks.com%2Fbiotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709%2F" data-provider="Facebook" class="wp-social-login-provider wp-social-login-provider-facebook" title="First agree with terms &amp; policy">
		<span> Facebook</span>
	</a>
	<a rel="nofollow" href="https://xtalks.com/wp-login.php?wpe-login=true&#038;action=wordpress_social_authenticate&#038;mode=login&#038;provider=LinkedIn&#038;redirect_to=https%3A%2F%2Fxtalks.com%2Fbiotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709%2F" data-provider="LinkedIn" class="wp-social-login-provider wp-social-login-provider-linkedin" title="First agree with terms &amp; policy">
		<span> LinkedIn</span>
	</a>

	</div>

	<div class="wp-social-login-widget-clearing"></div>

</div>

<!-- wsl_render_auth_widget -->

							<p class="break-line-join">Or</p>
							<p class="create-text">Create an Account Using Your Email</p>
														
                <div class='gf_browser_gecko gform_wrapper gravity-theme gform-theme--no-framework gform-registration_wrapper need-confirmation_wrapper' data-form-theme='gravity-theme' data-form-index='0' id='gform_wrapper_11' ><div id='gf_11' class='gform_anchor' tabindex='-1'></div>
                        <div class='gform_heading'>
							<p class='gform_required_legend'>&quot;<span class="gfield_required gfield_required_asterisk">*</span>&quot; indicates required fields</p>
                        </div><form method='post' enctype='multipart/form-data' target='gform_ajax_frame_11' id='gform_11' class='gform-registration need-confirmation' action='/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/#gf_11' data-formid='11' novalidate>
                        <div class='gform-body gform_body'><div id='gform_fields_11' class='gform_fields top_label form_sublabel_below description_below validation_below'><div id="field_11_7" class="gfield gfield--type-hidden gfield--input-type-hidden gform_hidden field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><div class='ginput_container ginput_container_text'><input name='input_7' id='input_11_7' type='hidden' class='gform_hidden'  aria-invalid="false" value='' /></div></div><div id="field_11_1" class="gfield gfield--type-text gfield--input-type-text gf_left_half gfield--width-half gfield_contains_required field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><label class='gfield_label gform-field-label' for='input_11_1'>First Name<span class="gfield_required"><span class="gfield_required gfield_required_asterisk">*</span></span></label><div class='ginput_container ginput_container_text'><input name='input_1' id='input_11_1' type='text' value='' class='large'    placeholder='First Name' aria-required="true" aria-invalid="false"   /></div></div><div id="field_11_2" class="gfield gfield--type-text gfield--input-type-text gf_right_half gfield--width-half gfield_contains_required field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><label class='gfield_label gform-field-label' for='input_11_2'>Last Name<span class="gfield_required"><span class="gfield_required gfield_required_asterisk">*</span></span></label><div class='ginput_container ginput_container_text'><input name='input_2' id='input_11_2' type='text' value='' class='large'    placeholder='Last Name' aria-required="true" aria-invalid="false"   /></div></div><div id="field_11_3" class="gfield gfield--type-email gfield--input-type-email gfield_contains_required field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><label class='gfield_label gform-field-label' for='input_11_3'>Business Email<span class="gfield_required"><span class="gfield_required gfield_required_asterisk">*</span></span></label><div class='ginput_container ginput_container_email'>
                            <input name='input_3' id='input_11_3' type='email' value='' class='large'   placeholder='Enter your business email address' aria-required="true" aria-invalid="false"  />
                        </div></div><fieldset id="field_11_8" class="gfield gfield--type-checkbox gfield--type-choice gfield--input-type-checkbox gfield_contains_required field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><legend class='gfield_label gform-field-label screen-reader-text gfield_label_before_complex' ><span class="gfield_required"><span class="gfield_required gfield_required_asterisk">*</span></span></legend><div class='ginput_container ginput_container_checkbox'><div class='gfield_checkbox ' id='input_11_8'><div class='gchoice gchoice_11_8_1'>
								<input class='gfield-choice-input' name='input_8.1' type='checkbox'  value='true'  id='choice_11_8_1'   />
								<label for='choice_11_8_1' id='label_11_8_1' class='gform-field-label gform-field-label--type-inline'>You read and agreed to our <a href="https://stagingxtalks.wpengine.com/privacy-policy/" target="blank">privacy policy</a></label>
							</div></div></div></fieldset><div id="field_11_9" class="gfield gfield--type-captcha gfield--input-type-captcha field_sublabel_below gfield--no-description field_description_below field_validation_below gfield_visibility_visible"  ><label class='gfield_label gform-field-label' for='input_11_9'>CAPTCHA</label><div id='input_11_9' class='ginput_container ginput_recaptcha' data-sitekey='6Lcq-IkUAAAAABcKBuP4EKMBw_jqicJGvASAr-yq'  data-theme='light' data-tabindex='0'  data-badge=''></div></div><div id="field_11_10" class="gfield gfield--type-honeypot gform_validation_container field_sublabel_below gfield--has-description field_description_below field_validation_below gfield_visibility_visible"  ><label class='gfield_label gform-field-label' for='input_11_10'>Email</label><div class='ginput_container'><input name='input_10' id='input_11_10' type='text' value='' autocomplete='new-password'/></div><div class='gfield_description' id='gfield_description_11_10'>This field is for validation purposes and should be left unchanged.</div></div></div></div>
        <div class='gform-footer gform_footer top_label'> <input type='submit' id='gform_submit_button_11' class='gform_button button' onclick='gform.submission.handleButtonClick(this);' data-submission-type='submit' value='Join'  /> <input type='hidden' name='gform_ajax' value='form_id=11&amp;title=&amp;description=&amp;tabindex=0&amp;theme=gravity-theme&amp;hash=11dd19d60f296618e574ca66fee1a6c5' />
            <input type='hidden' class='gform_hidden' name='gform_submission_method' data-js='gform_submission_method_11' value='iframe' />
            <input type='hidden' class='gform_hidden' name='gform_theme' data-js='gform_theme_11' id='gform_theme_11' value='gravity-theme' />
            <input type='hidden' class='gform_hidden' name='gform_style_settings' data-js='gform_style_settings_11' id='gform_style_settings_11' value='' />
            <input type='hidden' class='gform_hidden' name='is_submit_11' value='1' />
            <input type='hidden' class='gform_hidden' name='gform_submit' value='11' />
            
            <input type='hidden' class='gform_hidden' name='gform_unique_id' value='' />
            <input type='hidden' class='gform_hidden' name='state_11' value='WyJbXSIsIjI0NjQ1OTAwMjE0ZjBmZjE5OWZjOGJjMTk3ZDI2MGFlIl0=' />
            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_target_page_number_11' id='gform_target_page_number_11' value='0' />
            <input type='hidden' autocomplete='off' class='gform_hidden' name='gform_source_page_number_11' id='gform_source_page_number_11' value='1' />
            <input type='hidden' name='gform_field_values' value='' />
            
        </div>
                        </form>
                        </div>
		                <iframe style='display:none;width:0px;height:0px;' src='about:blank' name='gform_ajax_frame_11' id='gform_ajax_frame_11' title='This iframe contains the logic required to handle Ajax powered Gravity Forms.'></iframe>
		                <script type="text/javascript">
/* <![CDATA[ */
 gform.initializeOnLoaded( function() {gformInitSpinner( 11, 'https://xtalks.com/wp-content/plugins/gravityforms/images/spinner.svg', true );jQuery('#gform_ajax_frame_11').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_11');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_11').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_11').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_11').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_11').removeClass('gform_validation_error');}setTimeout( function() { /* delay the scroll by 50 milliseconds to fix a bug in chrome */ jQuery(document).scrollTop(jQuery('#gform_wrapper_11').offset().top - mt); }, 50 );if(window['gformInitDatepicker']) {gformInitDatepicker();}if(window['gformInitPriceFields']) {gformInitPriceFields();}var current_page = jQuery('#gform_source_page_number_11').val();gformInitSpinner( 11, 'https://xtalks.com/wp-content/plugins/gravityforms/images/spinner.svg', true );jQuery(document).trigger('gform_page_loaded', [11, current_page]);window['gf_submitting_11'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_11').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_11').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [11]);window['gf_submitting_11'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_11').text());}else{jQuery('#gform_11').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger("gform_pre_post_render", [{ formId: "11", currentPage: "current_page", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( "gform_wrapper_11" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( "span" );            visibilitySpan.id = "gform_visibility_test_11";            gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( "gform_visibility_test_11" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 11, current_page );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } );} ); 
/* ]]> */
</script>
														<p class="join-message">Have an account? <span class="login-option"><a href="#">Login Here</a></span></p>
							<div class="privacy-policy-overlay">
								<div class="privacy-policy-wrapper">
									<div class="row">
										<div class="small-12 columns">
											<h4>To create an account, you will need to agree to the privacy policy and terms of use by clicking the agree button at the bottom of this form.</h4>
											<button type="button" class="jump_to_bottom xtk_btn orange">Jump to bottom</button>
											<div class="privacy-policy-viewer">
												<h3>Privacy Policy</h3>
												<p>This privacy policy describes the privacy practices for <u>www.Xtalks.com</u> (hereafter referred to as the Site). Citizens of the UK and EU should refer to <a href="#EUUK">EU and UK &#8211; PRIVACY POLICY  HONEYCOMB WORLDWIDE INC.</a> All users of the Site should read this privacy policy in conjunction with the Sites <a href="#TERMS"><strong><u>TERMS OF USE</u></strong></a>. The Site is owned and operated by Honeycomb Worldwide Inc. (hereafter referred to as Honeycomb, we, us or our).</p>
<p>By using the Site, you agree to be bound by the Sites Terms of Use and accept our Privacy Policy. Please note that our Privacy Policy and Terms of Use may be updated or modified at any time without notice and your continued use of the Site will indicate your acceptance of the revised terms.</p>
<p>This privacy notice applies solely to information collected by the Site. It will notify you of the following:</p>
<ul>
<li>What personally identifiable information is collected from you through the Site, how it is used and with whom it may be shared</li>
<li>What choices are available to you regarding the use of your data</li>
<li>The security procedures in place to protect the misuse of your information</li>
<li>How you can correct any inaccuracies in the information</li>
</ul>
<p><strong>Information Collection and Use</strong></p>
<p>Our Site uses cookies and/or other technologies. We may use cookies to help identify user preferences and estimate audience size. If you do not wish to receive cookies, you may change the settings on your Internet browser to alert you when a cookie is sent to your computer. You may then decide whether to accept it. Not accepting cookies may result in the reduced functionality of certain areas of the Site.</p>
<p>Our Site may also record clickstream data. Clickstream is a virtual breadcrumb trail that a user leaves behind while browsing. We may record paths you have taken (e.g. sections or stories clicked and the order in which it is done) and use this information to provide customized content. Clickstream data is not retained after your visit to our Site and does not identify you specifically.</p>
<p>When browsing the Site, we will collect your IP address along with information from networks collected before and after you visit the Site. Aggregated user data may be used to analyze audience demographics and user information. Aggregated user data may be shared with third parties.</p>
<p>We may collect personally identifiable information, which may include your name, job title, organization, email address, mailing address and telephone number. This information is primarily required to deliver our services to you. You may be required to provide personally identifiable information to:</p>
<ul>
<li>Access content on the Site</li>
<li>Participate in, or contribute to, discussion forums, polls, quizzes and blogs</li>
<li>Register for newsletters, webinars and other virtual events</li>
<li>Setup your My Profile page that will provide you with one-click access when registering for virtual events and enable you to better customize your user experience</li>
</ul>
<p>By entering your contact information on the Site and clicking Join, you agree to receive emails from us.</p>
<p><strong>Third Party Use of Information</strong></p>
<p>By entering your contact information to register for a webinar and clicking Register, you agree to permit us to share your contact information with third parties.</p>
<p>When you register for live or archived webinars, virtual events or other content (e.g. white papers) developed in conjunction with or by our partners, sponsors or other third party affiliates, we may share your contact information with these third parties. We may also share any additional information you supply during the event registration process or during your participation in an event (e.g. as polling data, messaging, score cards, surveys and other feedback) with the partners, sponsors or co-hosts of the event.</p>
<p>By entering your contact information in a poll or quiz, you agree that the associated information you supply may be shared with third parties by us.</p>
<p>By registering for webinars, other events or other content developed by or sponsored by our partners, you agree that your contact information may be shared with our partners as outlined above. Our partners have signed agreements binding them to abide by the applicable laws in their use of the information provided to them by us. Our partners are prohibited from sharing contact information provided by us with any third parties or agents outside their organization. For further clarification on their use of this information, you should also refer to the privacy policies of the partners associated with the content you wish to access.</p>
<p>Our partners may contact you after you have registered for access to the content or events on our Site that they have helped develop or have sponsored. By registering for access to this content, you agree to be contacted by our partners about relevant offers, services, initiatives and/or developments.</p>
<p>By participating in discussion forums on the Site, you understand that the information may be viewed and collected by others.</p>
<p>If you provide a testimonial or commentary about Honeycomb, its services or the services of its partners, you agree that we may use these testimonials or comments in our marketing literature both on and off the Site.</p>
<p><strong>Opting Out</strong></p>
<p>You may do any of the following at any time by contacting us via the email address or phone number provided on our Site:</p>
<ul>
<li>Opt out of future contacts from us</li>
<li>See what data we have about you, if any</li>
<li>Change or correct any data we have about you</li>
<li>Amend or update your information via your My Profile page</li>
<li>Ask us to delete any data we have about you</li>
<li>Express any concern you have about our use of your data</li>
</ul>
<p><strong>Security</strong></p>
<p>We take precautions to protect your information. When you submit sensitive information on our Site, your information is protected both online and offline. We use encryption to protect sensitive information transmitted online and we protect your information offline. Only our employees who need your information to perform a specific task (for example, customer service or marketing) are granted access to personally identifiable information. The computers and servers in which we store personally identifiable information are kept in a secure environment.<a name="EUUK"></a></p>
<p>If you feel that we are not abiding by this privacy policy, please contact us immediately at 416- 977-6555 or <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="09616c65796d6c7a6249717d6865627a276a6664">[email&#160;protected]</a></p>
<h3><strong><u>EU and UK &#8211; PRIVACY POLICY  HONEYCOMB WORLDWIDE INC.</u></strong></h3>
<ol>
<li><a href="#wel">Welcome</a></li>
<li><a href="#who">Who we are</a></li>
<li><a href="#oureu">Our EU and UK Representatives</a></li>
<li><a href="#howto1">How to Contact Us</a></li>
<li><a href="#whatpersonal">What personal data we collect</a></li>
<li><a href="#dataacc">Data Accuracy</a></li>
<li><a href="#howwe">How We Collect Your Personal Data</a></li>
<li><a href="#whywe">Why We Use Your Personal Data</a></li>
<li><a href="#yourright">Your Rights</a></li>
<li><a href="#howtoexer">How to exercise your rights</a></li>
<li><a href="#howlong">How long we hold your personal data</a></li>
<li><a href="#whydowe">Who do we share your personal data with?</a></li>
<li><a href="#dowetran">Do we transfer personal data Overseas?</a></li>
<li><a href="#thirdparty">Third-party links</a></li>
<li><a href="#link1">Marketing</a></li>
<li><a href="#howtowith">How to withdraw consent</a></li>
<li><a href="#doweuse">Do we use automated decision-making or profiling?</a></li>
<li><a href="#howwekeep">How We Keep Your Personal Data Secure</a></li>
<li><a href="#howtocom">How to complain</a></li>
</ol>
<p>This document is provided in a layered format, using the headings set out above. If you are reading this online, please click on the numbers to be referred to the relevant section.<a id="wel"></a></p>
<h3>Welcome</h3>
<p><a id="who"></a><a id="oureu"></a><br />
Welcome to Honeycomb Worldwide Inc.s privacy notice,<u>applicable to EEA and UK residents</u>.</p>
<p>We appreciate the trust you place in us when sharing your personal data. We understand this is a big responsibility and the security of that data is very important to us. In this document, we will explain what information we collect, why and how we collect it, how we use it and how we protect your personal data.</p>
<p>We will also explain what rights you have regarding your personal data and how you can exercise those rights.</p>
<p>Please note that our website is not intended for children and we do not knowingly collect data relating to children.</p>
<h3>Who we are</h3>
<p><a id="howto1"></a><br />
We are Honeycomb Worldwide Inc. (hereafter referred to as Honeycomb, we, us or our) and are the parent company for Xtalks.</p>
<p>We are the data controller for ourselves and Xtalks, which means that we determine what personal data is collected by each organisation, how this personal data is going to be used and how this personal data is protected.</p>
<h3>Our EU and UK Representatives</h3>
<p>We have appointedGRCILaw to act as our EU Representative. If you wish to exercise your rights under the EU General Data Protection Regulation (GDPR) or have any queries in relation to your rights or privacy matters generally please email<a href="about:blank"><span class="__cf_email__" data-cfemail="ed88989f889dad8a9f8e84818c9ac38e8280">[email&#160;protected]</span></a>or post your request or query to Head of Data Privacy Manager Service,GRCILaw Limited, IT Governance Europe, Third Floor, The Boyne Tower, Bull Ring, Lagavooren, Drogheda, Co. Louth, A92 F682.</p>
<p>We have appointed GRCI Law Limited to act as our UK Representative. If you wish to exercise your rights under the UK General Data Protection Regulation (GDPR), or have any queries in relation to your rights or privacy matters generally please email our Representative at <a href="/cdn-cgi/l/email-protection#d4a1bfa6b1a494b3a6b7bdb8b5a3fab7bbb9"><span class="__cf_email__" data-cfemail="81f4eaf3e4f1c1e6f3e2e8ede0f6afe2eeec">[email&#160;protected]</span></a> or post your request or query to UK Representative, Unit 3, Clive Court, Bartholomew&#8217;s Walk, Cambridgeshire Business Park, Ely, Cambridgeshire, CB7 4EA, UK</p>
<p>When contacting our Representatives please ensure you include our company name in any correspondence.</p>
<h3>How to Contact Us</h3>
<p>In addition to contacting our EU Representative, you can contact us at:</p>
<p>Honeycomb Worldwide Inc.</p>
<p>Name or title of data privacy manager: Andrew Juurinen</p>
<p>Email address:<a href="about:blank"><strong><em><span class="__cf_email__" data-cfemail="bcd4d9d0ccd8d9cfd7fcc4c8ddd0d7cf92dfd3d1">[email&#160;protected]</span></em></strong></a></p>
<p>Postal address: ATTN: Andrew Juurinen, 1235 Bay Street, Suite 802, Toronto, Ontario, M5R 3K4, Canada</p>
<p>or send us a message through our website at<a href="about:blank"><strong><em>https://xtalks.com/contact/</em></strong></a> <a id="whatpersonal"></a><a id="dataacc"></a></p>
<h3>What personal data we collect</h3>
<p>We may collect, use, store and/or transfer different kinds of personal data about you. Personal data we collect includes:</p>
<ul>
<li><strong>Identity Data</strong>includes first name, last name, username or similar identifier, marital status, title, date of birth, gender, employer, and job title.</li>
<li><strong>Contact Data</strong>includes billing address, address, email address and telephone numbers.</li>
<li><strong>Resume Data </strong>includes application materials and answers to screener questions given to employers through the Xtalks Job Platform and answers to any questionnaires. This information may be associated with a profile.</li>
<li><strong>Transaction Data</strong>includes details about payments and other details of products and services bought from us.</li>
<li><strong>Technical Data</strong>includes internet protocol (IP) address, login data, browser type and version, time zone setting and location, browser plug-in types and versions, operating system and platform and other technology on the devices used to access our website.</li>
<li><strong>Profile Data</strong>includes username and password, purchases or orders made, interests, preferences, feedback, and survey responses.</li>
<li><strong>Images and personal appearance</strong> include copies of passports or drivers licences.</li>
</ul>
<ul>
<li><strong>Usage Data</strong>includes information about how individuals use our website and services and online activity based on their interaction with us, our websites and applications for example searches, site visits browsing actions and patterns.</li>
<li><strong>Marketing and Communications Data</strong>includes preferences in receiving marketing from us and our third parties and communication preferences.</li>
<li><strong>Publicly Available Data</strong> includes identity and contact data from publicly available data sources such as Companies House and LinkedIn.</li>
</ul>
<p>We do not collect any details about race or ethnicity, religious or philosophical beliefs, sex life, sexual orientation, political opinions, trade union membership, information about health or genetic and biometric data.<a id="howwe"></a></p>
<h3>Data Accuracy</h3>
<p>It is important that the personal data we hold about you is accurate and current. Please keep us informed if your personal data changes during your relationship with us.</p>
<h3>How We Collect Your Personal Data</h3>
<p>The data we collect depends on the context of your interactions with us and the choices that you make, including your privacy settings and the features that you use.</p>
<p>Most of the personal data that we collect about you will be information that you provide to us directly:</p>
<ul>
<li>when you register for an account with us and use our services</li>
<li>when you register for a webinar, virtual event, or other content, host a webinar or take part in a webinar</li>
<li>when you attend training with us</li>
<li>when you fill in forms or correspond with us by post, phone, email or otherwise.</li>
<li>When you subscribe to our service or publications</li>
<li>when you take part in an event (e.g. as polling data, messaging, score cards, and other feedback)</li>
<li>where you provide necessary information, e.g., for verification and billing purposes.</li>
<li>when you take part in discussion boards or other forms of social media</li>
<li>when you request marketing material to be sent to you</li>
<li>when you enter a competition, promotion, or survey</li>
</ul>
<p>We collect information through your behaviour and interactions with us:</p>
<ul>
<li>when you interact with our website, we may automatically collect technical data about your equipment, browsing actions and patterns. We collect this personal data by using cookies, server logs and other similar technologies</li>
<li>from information from your device and actions taken on xtalks.com e.g., searches you run or webinars and jobs you click on</li>
<li>when you apply to jobs or for webinars, use screener or assessment questions or log in from third party sites</li>
<li>information we learn about you through our relationship and the way you interact with us</li>
</ul>
<p>In some circumstances we may also receive information from:</p>
<ul>
<li>regulatory bodies</li>
<li>other companies supplying services to us</li>
<li>data analytics to improve our website, products/services, marketing, customer relationships and experiences</li>
<li>publicly accessible social media networks such as Facebook, Instagram, LinkedIn, Google, and Twitter</li>
<li>providers of technical, payment and delivery services</li>
<li>publicly availably sources such as Companies House and LinkedIn</li>
</ul>
<p>Click<a href="about:blank">here</a>for moreinformation about our use of cookies and how to disable them.<a id="whywe"></a></p>
<h3>Why We Use Your Personal Data</h3>
<p>When we collect or otherwise process any personal information within the scope of European data protection laws, we do so where:</p>
<ul>
<li>necessary to provide our services, fulfil a transaction or otherwise perform a contract with you or at your request prior to entering into a contract</li>
<li>it is in our legitimate interest to use personal information in such a way to ensure that we provide the our services in the best way that we can, protect the security of our systems, customers and website users and detect or prevent fraud, wherever we process your personal data for these purposes, we ensure that your interests, rights and freedoms are carefully considered</li>
<li>it is our legal obligation to use your personal information to comply with any legal obligations imposed upon us</li>
</ul>
<p>Please contact us if you have any questions about how why we use your personal data.<a id="yourright"></a></p>
<h3>Your Rights</h3>
<p>You have several rights under data protection laws, the rights available to you depend on our reason for processing your information and are set out below:</p>
<p><strong>Access</strong> the right to request a copy of the personal data we hold on you. In most cases, this will be free of charge, however in some limited circumstances, for example, repeated requests for further copies, we may apply an administration fee.</p>
<p><strong>Rectification of personal data</strong>  this right enables you to have any incomplete or inaccurate data we hold about you corrected, though we may need to verify the accuracy of the new data you provide to us.</p>
<p><strong>Erasure of personal data</strong> &#8211; You can ask us to delete or remove your personal information in some circumstances such as where there is no good reason for us continuing to process it. We may not always be able to comply with your request of erasure for specific legal reasons which will be notified to you, job applicants who submit their personal info through the job application portal may also need to contact the potential Employer to have this data deleted or requested.</p>
<p><strong>Restriction of processing personal data</strong> &#8211; this enables you to ask us to suspend the processing of your personal data in the following scenarios: (a) if you want us to establish the datas accuracy; (b) where our use of the data is unlawful but you do not want us to erase it; (c) where you need us to hold the data even if we no longer require it as you need it to establish, exercise or defend legal claims; or (d) you have objected to our use of your data but we need to verify whether we have overriding legitimate grounds to use it.</p>
<p><strong>Objection to processing of personal data</strong> &#8211; you can ask us to stop processing your personal information, and we will do so, if we are relying on legitimate interests to process your personal information, except if we can show compelling legal grounds for the processing; or if we are processing your personal information for direct marketing purposes.</p>
<p><strong>Automated decision making</strong>  you have the right to ask for a decision to be made manually, where a decision is made using automated means and this harmfully affects you.</p>
<p><strong>Portability</strong>  you have the right to have personal data we hold about you transferred securely to another service provider in electronic form.<a id="howtoexer"></a></p>
<h3>How to exercise your rights</h3>
<p>if you wish to exercise your rights or want further information about your rights please contact us.</p>
<p>In most circumstances you do not need to pay any charge for exercising your rights. We have 30 days to respond to you.</p>
<p>If you would like to unsubscribe from any email from us, you can also click on the unsubscribe button at the bottom of the email or edit your subscription preferences <a href="about:blank">here</a>. It may take up to 7 days for this to take place.<a id="howlong"></a></p>
<h3>How long we hold your personal data</h3>
<p>We will keep your personal data for no longer than is necessary to fulfil the purposes we collected it for, including for the purposes of satisfying any legal, accounting, or reporting requirements.</p>
<p>Job Applicants data when making job application is uploaded to Xtalks.com servers, then emailed directly to the potential Employers email address to which the job applicant applied. After transmission of the data is complete, the personal data is deleted from our servers.</p>
<p>We keep basic information about our customers and website users (including Contact, Identity, and Transaction Data) for no more than two years after they cease being customers or website users. We keep Financial Data of our customers for no more than six years after they cease being customers.<br />
<a id="dowetran"></a><a id="whydowe"></a></p>
<h3>Who do we share your personal data with?</h3>
<p>We may from time to time share your personal data with the following organisations who also must keep your information confidential, safe, and secure:</p>
<ol>
<li>potential Employers as part of a job application</li>
<li>service providers providing IT and system administration support and software services</li>
<li>payment Service providers such as PayPal Inc</li>
<li>third parties engaged in the course of the services we supply including webinar hosts</li>
<li>third party service providers to assist us with insight analytics, such as Google Analytics</li>
<li>third parties, employees, partners, agents, professionals, and subcontractors who supply products, services, and administrative support to us</li>
<li>law and law enforcement agencies, judicial bodies, credit reference agencies, fraud prevention agencies, governmental entities, tax authorities or government and regulatory bodies</li>
<li>where required as part of any proposed sale, reorganisation, transfer, financial arrangement, asset disposal or other transaction relating to our business and/or business assets</li>
<li>anyone else with your permission</li>
</ol>
<p>(Please note this list is non-exhaustive and there may be other examples where we need to share with other parties to provide our services as effectively as we can).</p>
<h3>Do we transfer personal data Overseas?</h3>
<p><a id="thirdparty"></a><br />
Where necessary to deliver our services, we will transfer personal information to countries outside the EEA. In circumstances where personal data is transferred outside the EEA, we will only do so:</p>
<ul>
<li>where the transfer is to a country which has been assessed by the European Commission (or an equivalent UK body) as ensuring an adequate level of protection for personal data;</li>
<li>with your consent; or</li>
<li>where the transfer is compliant with the GDPR and other applicable laws.</li>
</ul>
<h3>Third-party links</h3>
<p><a id="link1"></a><br />
Our website may include links to third-party websites, plug-ins, and applications. Clicking on those links or enabling those connections may allow third parties to collect or share data about you. We do not control these third-party websites and are not responsible for their privacy statements. When you leave our website, we encourage you to read the privacy notice of every website you visit.</p>
<h3>Marketing</h3>
<p><a id="howtowith"></a><a id="doweuse"></a><a id="howwekeep"></a><br />
Our Company would like to send you information about products and services of ours that we think you might like.</p>
<p>You have the right at any time to stop us from contacting you for these purposes</p>
<p>please contact us If you no longer wish to be contacted for these purposes.</p>
<p>If you have opted out from our marketing communications, it is possible that your details may be recaptured through public sources in an unconnected marketing campaign. We will try to make sure this does not happen, but if it does, we are sorry, and we would ask that in those circumstances you opt out again. Where processing of data is based on your consent, you have the right to withdraw your consent to processing without affecting the lawfulness of processing based on consent before its withdrawal.</p>
<h3>How to withdraw consent</h3>
<p>You can withdraw consent at any timewhere we are relying on consent to process your personal data. However, this will not affect the lawfulness of any processing carried out before you withdraw your consent. If you withdraw your consent, we may not be able to supply certain products or services to you. We will tell you if this is the case at the time you withdraw your consent.</p>
<h3>Do we use automated decision-making or profiling?</h3>
<p>We do not use automated decision-making or profiling.</p>
<h3>How We Keep Your Personal Data Secure</h3>
<p>We have put in place appropriate security measures to prevent your personal data from being accidentally lost, used or accessed in an unauthorised way, altered, or disclosed. In addition, we limit access to your personal data to those employees, agents, contractors and other third parties who have a business need to know. They will only process your personal data on our instructions, and they are subject to a duty of confidentiality.</p>
<h3><a id="howtocom"></a>How to complain</h3>
<p>You have the right to make a complaint at any time to the Information Commissioners Office (ICO), the UK supervisory authority for data protection issues (<a href="about:blank">www.ico.org.uk</a>) or if you wish to make a complaint to a different National Data Protection Authority please use this link to find the appropriate contact details https:// edpb.europa.eu/about-edpb/board/members_en</p>
<p>We would, however, appreciate the chance to deal with your concerns before you approach the ICO or another National Data Protection Authority so please <a href="about:blank">contact us</a>.<a id="changesto"></a></p>
<h2><strong>TERMS OF USE</strong></h2>
<p>This notice details the Terms of Use for use of the website at<u>www.Xtalks.com</u>(hereafter referred to as the Site). Users of the Site should read the Terms of Use in conjunction with the sites<strong><u>Privacy Policy</u></strong>. The Site is owned and operated by Honeycomb Worldwide Inc. (hereafter referred to as Honeycomb, we, us or our).</p>
<p>By using the Site, you agree to be bound by the Sites Terms of Use and accept our Privacy Policy. Please note that our Privacy Policy and Terms of Use may be updated or modified at any time without notice and your continued use of the Site will indicate your acceptance of the revised terms.</p>
<p>All rights to the content on the Site are reserved by Honeycomb. No part of the Site may be reproduced, stored in any retrieval system, or transmitted in any form  electronic, mechanical, photocopying, recording or otherwise  without prior consent from us. Such requests for consent should be forwarded to <a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="4a222f263a2e2f39210a323e2b26213964292527">[email&#160;protected]</a>.</p>
<p><strong>Limitation of Liability</strong></p>
<p>While every care has been taken to ensure the data and information on the Site is accurate, we cannot accept, and hereby disclaim any liability to any party for loss or damage caused by errors or omissions resulting from negligence, accident or any other cause.</p>
<p>Further, neither the information on the Site nor the information provided during webinars or other events is business, legal or tax advice and should not be relied on as such.</p>
<p><strong>Third Party Materials</strong></p>
<p>Opinions and views expressed or implied on the Site are not necessarily those of Honeycomb and the company does not endorse any sponsors or advertisers, or their products or services, and accepts no responsibility for content provided by such parties.</p>
<p>The Site may include links to third party sites. We take no responsibility for the functionality of those links or the content posted on the third party sites to which you are redirected.</p>
<p><strong>Intellectual Property</strong></p>
<p><strong>2004-2021 Honeycomb Worldwide Inc.</strong></p>
<p>All registered and unregistered trademarks on the Site are the sole property of their respective owners. Further, the content on the Site and provided during webinars and other events is subject to copyright, which is the property of its respective owners. We grant you a limited license to access and use the Site and its related content without reproducing elsewhere.</p>
<p>While presenters and sponsors retain IP rights over the content they present all webinars and videos produced by Xtalks are subject to Honeycombs copyright. For clarity, while sponsors and advertisers may deliver the same or similar content through other media channels (physical or online) it is expressly forbidden to replay or re-broadcast any Xtalks produced content on any other media, publishing or event industry website or platform without Honeycombs express written consent. Sponsors are hereby granted the permission to host the recordings of the webinars on their own website.</p>
<p>You agree that the words Honeycomb Worldwide Inc., Xtalks or any variations thereof are trade names that are owned by Honeycomb, and any related marks are trademarks owned by Honeycomb. You specifically agree that you will never, in any way, use the words Honeycomb, Xtalks or any imitation or variant thereof as part of a trade name, company name, or firm name in a manner likely to cause customer confusion with Honeycombs services.</p>
<p><strong>Indemnification</strong></p>
<p>By using the Site, you accept to indemnify, defend and hold harmless Honeycomb, its directors, officers, employees and its affiliates from any claims, damages, liabilities and expenses, including legal fees, arising from your use of the Site and its related content, such as, but not limited to, hosted webinars and discussion forums. We reserve the right, at your expense, to assume the exclusive defense and control of any matter for which you are required to indemnify Honeycomb, and you agree to cooperate with our defense of these claims. You agree not to settle any matter without the prior consent of Honeycomb. We will use reasonable efforts to notify you of any such claim, action or proceeding upon becoming aware of it.</p>
<p><strong>Minors</strong></p>
<p>The Site is a business/industry professional website and is not targeted towards children or intended for use by children. Minors should not use the Site or register any information on the Site.</p>
<p><strong>Unauthorized Use</strong></p>
<p>When you register for access to the Site, or any elements of the Site such as webinars or discussion forums that may require additional or different registration criteria, you agree to only enter information about yourself that is both true and complete. You explicitly agree not to impersonate another person, such as one of our employees, hosts, editors or moderators. Similarly, you agree not to represent yourself as an employee or agent of any organization other than that which is true.</p>
<p>You agree not to post any information on the Site unless you have the legal right to post such content and by posting such content you are not infringing the legal rights of others. You agree that any content or comments you post on the Site will not be unlawful, threatening, abusive, libelous, defamatory, pornographic, or obscene.</p>
<p>You agree not to share unauthorized commercial communications on the Site and agree to adhere to all applicable anti-spam rules and regulations. You also agree not to collect any user content or information by any automated means.</p>
<p><strong>Unauthorized Access</strong></p>
<p>You will not share your account information with any other individual. You agree to keep confidential all account information that permit access to and enable use of the Site. You must notify us immediately of any breach of security or unauthorized use of your account. We will not be liable for any losses caused by any unauthorized use of your account.</p>
<p><strong>Content and Contact Information</strong></p>
<p>You are solely responsible for keeping your contact information current, accurate, complete and secure. We will not be held liable for your failure to do so. Further, we reserve the right to remove any content at any time.</p>
<p><strong>Termination</strong></p>
<p>We reserve the right, at any time, without notice and without reason, to cancel or terminate the account of any individual or refuse their current or future access. We may also terminate the account of any individual for violation of the Terms of Use. Upon termination, all rights granted to you will also terminate.</p>
<p><strong>Access</strong></p>
<p>Access to certain of the events, documents, articles or forums on the Site may be restricted. Registration does not guarantee your access to those items. This may be particularly true for certain webinars where the audience profile is defined by our partners. Webinar registrations should therefore be viewed as an application and not a guarantee of access to the content.</p>
<p><strong>No Warranty</strong></p>
<p>We do not warrant that the Site will be secure, error-free or function without disruption.</p>
<p><strong>Controlling Law and Severability</strong></p>
<p>The Terms of Use are governed by and construed in accordance with the laws of Ontario and the federal laws of Canada applicable therein. If for any reason a court of competent jurisdiction finds any provision, or portion thereof, to be unenforceable, the remainder of the Terms of Use shall continue to be in full force and effect.</p>
											</div>
											<div class="buttons">
												<button class="xtk_btn blue agree">Agree</button>
												<button class="disagree">Disagree</button>
											</div>
										</div>
									</div>
								</div>
							</div>
						</div>
					</div>
				</div>
						<div class="popup-register-success">
				<div class="close-popup">
					<i class="fa fa-times close"></i>
				</div>
				<div class="row scrollable">
					<div class="columns small-12 medium-8 medium-centered text-center">
						<h3>Registration Successful</h3>
						<p><b>Success! You&#039;re almost there. Check your email to access your Xtalks account password and instructions to reset it.</b></p>
						<p class="join-message">Got your password? <span class="login"><a href="#">Login Here</a></span></p>
					</div>
				</div>
			</div>
			<div class="popup-peer-circle-notifications">
				<div class="close-popup">
					<i class="fa fa-times close"></i>
				</div>
				<div class="row scrollable">
					<div class="columns small-12 medium-8 medium-centered text-center">
						<p><strong></strong></p>
					</div>
				</div>
			</div>
			<div class="popup-webinar-message-presenter">
				<div class="close-popup">
					<i class="fa fa-times close"></i>
				</div>
				<div class="row scrollable">
					<div class="columns small-12 medium-8 medium-centered text-center">
						<p><strong>You must register for this webinar before messaging the presenter!</strong></p>
						<div class="columns section-padding">
														<a class="xtk_btn orange join" href="https://xtalks.com/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709/#webinar-form-outer">Register</a>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="bottombar">
			<div class="row">
				<div class="small-12 medium-6 columns">
					<p class="copyright">
						Copyright 2026 Honeycomb Worldwide Inc. All Rights Reserved. Site by <a href="http://trewknowledge.com" rel="nofollow noopener noreferrer" target="_blank">Trew Knowledge</a>.					</p>
				</div>
				<div class="small-12 medium-6 columns">
					<ul class="social-media">
																			<li><a href="https://www.youtube.com/user/XtalksWebinars?sub_confirmation=1" target="_blank" rel="nofollow noopener noreferrer" class="youtube"></a></li>
																			<li><a href="https://www.facebook.com/Xtalks.Webinars" target="_blank" rel="nofollow noopener noreferrer" class="facebook"></a></li>
																			<li><a href="https://twitter.com/xtalks" target="_blank" rel="nofollow noopener noreferrer" class="twitter"></a></li>
																			<li><a href="https://www.linkedin.com/company/1845094/" target="_blank" rel="nofollow noopener noreferrer" class="linkedin"></a></li>
											</ul>
				</div>
			</div>
		</div>
	</footer><!-- #colophon -->

	
	
</div><!-- #page -->

<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="speculationrules">
{"prefetch":[{"source":"document","where":{"and":[{"href_matches":"\/*"},{"not":{"href_matches":["\/wp-*.php","\/wp-admin\/*","\/wp-content\/uploads\/*","\/wp-content\/*","\/wp-content\/plugins\/*","\/wp-content\/themes\/xtalks\/*","\/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]}
</script>
<div  class="gdpr gdpr-overlay"></div>
<div  class="gdpr gdpr-general-confirmation">
	<div  class="gdpr-wrapper">
		<header>
			<div class="gdpr-box-title">
				<h3></h3>
				<span class="gdpr-close"></span>
			</div>
		</header>
		<div  class="gdpr-content">
			<p></p>
		</div>
		<footer >
			<button class="gdpr-ok" data-callback="closeNotification">OK</button>
		</footer>
	</div>
</div>
	<script type="text/javascript"> _linkedin_partner_id = "2175730"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); </script><script type="text/javascript"> (function(){var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(); </script> <noscript> <img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2175730&fmt=gif" /> </noscript>
	    <!-- Meta Pixel Event Code -->
    <script type='text/javascript'>
        document.addEventListener( 'wpcf7mailsent', function( event ) {
        if( "fb_pxl_code" in event.detail.apiResponse){
            eval(event.detail.apiResponse.fb_pxl_code);
        }
        }, false );
    </script>
    <!-- End Meta Pixel Event Code -->
        <div id='fb-pxl-ajax-code'></div><script type="text/javascript">var algolia = {"debug":false,"application_id":"QQ7ZRY2TC2","search_api_key":"717a7413020cd701648a0f31f9123df5","powered_by_enabled":false,"search_hits_per_page":"16","query":"","indices":{"searchable_posts":{"name":"wp_searchable_posts","id":"searchable_posts","enabled":true,"replicas":[]},"posts_post":{"name":"wp_posts_post","id":"posts_post","enabled":true,"replicas":[]},"posts_webinars":{"name":"wp_posts_webinars","id":"posts_webinars","enabled":true,"replicas":[]},"posts_job":{"name":"wp_posts_job","id":"posts_job","enabled":true,"replicas":[]},"posts_peer-circle":{"name":"wp_posts_peer-circle","id":"posts_peer-circle","enabled":true,"replicas":[]}},"autocomplete":{"sources":[{"index_id":"posts_webinars","index_name":"wp_posts_webinars","label":"Webinars","admin_name":"Webinars","position":1,"max_suggestions":5,"tmpl_suggestion":"autocomplete-post-suggestion","enabled":true},{"index_id":"posts_post","index_name":"wp_posts_post","label":"Posts","admin_name":"Posts","position":2,"max_suggestions":5,"tmpl_suggestion":"autocomplete-post-suggestion","enabled":true},{"index_id":"posts_peer-circle","index_name":"wp_posts_peer-circle","label":"Peer Circles","admin_name":"Peer Circles","position":3,"max_suggestions":5,"tmpl_suggestion":"autocomplete-post-suggestion","enabled":true},{"index_id":"posts_job","index_name":"wp_posts_job","label":"Jobs","admin_name":"Jobs","position":4,"max_suggestions":5,"tmpl_suggestion":"autocomplete-post-suggestion","enabled":true}],"input_selector":"input[name='s']:not(.no-autocomplete):not(#adminbar-search)"}};</script>
<script type="text/html" id="tmpl-autocomplete-header">
	<div class="autocomplete-header">
		<div class="autocomplete-header-title">{{{ data.label }}}</div>
		<div class="clear"></div>
	</div>
</script>

<script type="text/html" id="tmpl-autocomplete-post-suggestion">
	<a class="suggestion-link" href="{{ data.permalink }}" title="{{ data.post_title }}">
		<# if ( data.images.thumbnail ) { #>
			<img class="suggestion-post-thumbnail" src="{{ data.images.thumbnail.url }}" alt="{{ data.post_title }}">
		<# } #>
		<div class="suggestion-post-attributes">
			<span class="suggestion-post-title">{{{ data._highlightResult.post_title.value }}}</span>
			<# if ( data._snippetResult['content'] ) { #>
				<span class="suggestion-post-content">{{{ data._snippetResult['content'].value }}}</span>
			<# } #>
		</div>
			</a>
</script>

<script type="text/html" id="tmpl-autocomplete-term-suggestion">
	<a class="suggestion-link" href="{{ data.permalink }}" title="{{ data.name }}">
		<svg viewBox="0 0 21 21" width="21" height="21">
			<svg width="21" height="21" viewBox="0 0 21 21">
				<path
					d="M4.662 8.72l-1.23 1.23c-.682.682-.68 1.792.004 2.477l5.135 5.135c.7.693 1.8.688 2.48.005l1.23-1.23 5.35-5.346c.31-.31.54-.92.51-1.36l-.32-4.29c-.09-1.09-1.05-2.06-2.15-2.14l-4.3-.33c-.43-.03-1.05.2-1.36.51l-.79.8-2.27 2.28-2.28 2.27zm9.826-.98c.69 0 1.25-.56 1.25-1.25s-.56-1.25-1.25-1.25-1.25.56-1.25 1.25.56 1.25 1.25 1.25z"
					fill-rule="evenodd"></path>
			</svg>
		</svg>
		<span class="suggestion-post-title">{{{ data._highlightResult.name.value }}}</span>
	</a>
</script>

<script type="text/html" id="tmpl-autocomplete-user-suggestion">
	<a class="suggestion-link user-suggestion-link" href="{{ data.posts_url }}" title="{{ data.display_name }}">
		<# if ( data.avatar_url ) { #>
			<img class="suggestion-user-thumbnail" src="{{ data.avatar_url }}" alt="{{ data.display_name }}">
		<# } #>
		<span class="suggestion-post-title">{{{ data._highlightResult.display_name.value }}}</span>
	</a>
</script>

<script type="text/html" id="tmpl-autocomplete-footer">
	<div class="autocomplete-footer">
		<div class="autocomplete-footer-branding">
			<a href="#" class="algolia-powered-by-link" title="Algolia">
				<svg width="150px" height="25px" viewBox="0 0 572 64"><path fill="#36395A" d="M16 48.3c-3.4 0-6.3-.6-8.7-1.7A12.4 12.4 0 0 1 1.9 42C.6 40 0 38 0 35.4h6.5a6.7 6.7 0 0 0 3.9 6c1.4.7 3.3 1.1 5.6 1.1 2.2 0 4-.3 5.4-1a7 7 0 0 0 3-2.4 6 6 0 0 0 1-3.4c0-1.5-.6-2.8-1.9-3.7-1.3-1-3.3-1.6-5.9-1.8l-4-.4c-3.7-.3-6.6-1.4-8.8-3.4a10 10 0 0 1-3.3-7.9c0-2.4.6-4.6 1.8-6.4a12 12 0 0 1 5-4.3c2.2-1 4.7-1.6 7.5-1.6s5.5.5 7.6 1.6a12 12 0 0 1 5 4.4c1.2 1.8 1.8 4 1.8 6.7h-6.5a6.4 6.4 0 0 0-3.5-5.9c-1-.6-2.6-1-4.4-1s-3.2.3-4.4 1c-1.1.6-2 1.4-2.6 2.4-.5 1-.8 2-.8 3.1a5 5 0 0 0 1.5 3.6c1 1 2.6 1.7 4.7 1.9l4 .3c2.8.2 5.2.8 7.2 1.8 2.1 1 3.7 2.2 4.9 3.8a9.7 9.7 0 0 1 1.7 5.8c0 2.5-.7 4.7-2 6.6a13 13 0 0 1-5.6 4.4c-2.4 1-5.2 1.6-8.4 1.6Zm35.6 0c-2.6 0-4.8-.4-6.7-1.3a13 13 0 0 1-4.7-3.5 17.1 17.1 0 0 1-3.6-10.4v-1c0-2 .3-3.8 1-5.6a13 13 0 0 1 7.3-8.3 15 15 0 0 1 6.3-1.4A13.2 13.2 0 0 1 64 24.3c1 2.2 1.6 4.6 1.6 7.2V34H39.4v-4.3h21.8l-1.8 2.2c0-2-.3-3.7-.9-5.1a7.3 7.3 0 0 0-2.7-3.4c-1.2-.7-2.7-1.1-4.6-1.1s-3.4.4-4.7 1.3a8 8 0 0 0-2.9 3.6c-.6 1.5-.9 3.3-.9 5.4 0 2 .3 3.7 1 5.3a7.9 7.9 0 0 0 2.8 3.7c1.3.8 3 1.3 5 1.3s3.8-.5 5.1-1.3c1.3-1 2.1-2 2.4-3.2h6a11.8 11.8 0 0 1-7 8.7 16 16 0 0 1-6.4 1.2ZM80 48c-2.2 0-4-.3-5.7-1a8.4 8.4 0 0 1-3.7-3.3 9.7 9.7 0 0 1-1.3-5.2c0-2 .5-3.8 1.5-5.2a9 9 0 0 1 4.3-3.1c1.8-.7 4-1 6.7-1H89v4.1h-7.5c-2 0-3.4.5-4.4 1.4-1 1-1.6 2.1-1.6 3.6s.5 2.7 1.6 3.6c1 1 2.5 1.4 4.4 1.4 1.1 0 2.2-.2 3.2-.7 1-.4 1.9-1 2.6-2 .6-1 1-2.4 1-4.2l1.7 2.1c-.2 2-.7 3.8-1.5 5.2a9 9 0 0 1-3.4 3.3 12 12 0 0 1-5.3 1Zm9.5-.7v-8.8h-1v-10c0-1.8-.5-3.2-1.4-4.1-1-1-2.4-1.4-4.2-1.4a142.9 142.9 0 0 0-10.2.4v-5.6a74.8 74.8 0 0 1 8.6-.4c3 0 5.5.4 7.5 1.2s3.4 2 4.4 3.6c1 1.7 1.4 4 1.4 6.7v18.4h-5Zm12.9 0V17.8h5v12.3h-.2c0-4.2 1-7.4 2.8-9.5a11 11 0 0 1 8.3-3.1h1v5.6h-2a9 9 0 0 0-6.3 2.2c-1.5 1.5-2.2 3.6-2.2 6.4v15.6h-6.4Zm34.4 1a15 15 0 0 1-6.6-1.3c-1.9-.9-3.4-2-4.7-3.5a15.5 15.5 0 0 1-2.7-5c-.6-1.7-1-3.6-1-5.4v-1c0-2 .4-3.8 1-5.6a15 15 0 0 1 2.8-4.9c1.3-1.5 2.8-2.6 4.6-3.5a16.4 16.4 0 0 1 13.3.2c2 1 3.5 2.3 4.8 4a12 12 0 0 1 2 6H144c-.2-1.6-1-3-2.2-4.1a7.5 7.5 0 0 0-5.2-1.7 8 8 0 0 0-4.7 1.3 8 8 0 0 0-2.8 3.6 13.8 13.8 0 0 0 0 10.3c.6 1.5 1.5 2.7 2.8 3.6s2.8 1.3 4.8 1.3c1.5 0 2.7-.2 3.8-.8a7 7 0 0 0 2.6-2c.7-1 1-2 1.2-3.2h6.2a11 11 0 0 1-2 6.2 15.1 15.1 0 0 1-11.8 5.5Zm19.7-1v-40h6.4V31h-1.3c0-3 .4-5.5 1.1-7.6a9.7 9.7 0 0 1 3.5-4.8A9.9 9.9 0 0 1 172 17h.3c3.5 0 6 1.1 7.9 3.5 1.7 2.3 2.6 5.7 2.6 10v16.8h-6.4V29.6c0-2.1-.6-3.8-1.8-5a6.4 6.4 0 0 0-4.8-1.8c-2 0-3.7.7-5 2a7.8 7.8 0 0 0-1.9 5.5v17h-6.4Zm63.8 1a12.2 12.2 0 0 1-10.9-6.2 19 19 0 0 1-1.8-7.3h1.4v12.5h-5.1v-40h6.4v19.8l-2 3.5c.2-3.1.8-5.7 1.9-7.7a11 11 0 0 1 4.4-4.5c1.8-1 3.9-1.5 6.1-1.5a13.4 13.4 0 0 1 12.8 9.1c.7 1.9 1 3.8 1 6v1c0 2.2-.3 4.1-1 6a13.6 13.6 0 0 1-13.2 9.4Zm-1.2-5.5a8.4 8.4 0 0 0 7.9-5c.7-1.5 1.1-3.3 1.1-5.3s-.4-3.8-1.1-5.3a8.7 8.7 0 0 0-3.2-3.6 9.6 9.6 0 0 0-9.2-.2 8.5 8.5 0 0 0-3.3 3.2c-.8 1.4-1.3 3-1.3 5v2.3a9 9 0 0 0 1.3 4.8 9 9 0 0 0 3.4 3c1.4.7 2.8 1 4.4 1Zm27.3 3.9-10-28.9h6.5l9.5 28.9h-6Zm-7.5 12.2v-5.7h4.9c1 0 2-.1 2.9-.4a4 4 0 0 0 2-1.4c.4-.7.9-1.6 1.2-2.7l8.6-30.9h6.2l-9.3 32.4a14 14 0 0 1-2.5 5 8.9 8.9 0 0 1-4 2.8c-1.5.6-3.4.9-5.6.9h-4.4Zm9-12.2v-5.2h6.4v5.2H248Z"></path><path fill="#003DFF" d="M534.4 9.1H528a.8.8 0 0 1-.7-.7V1.8c0-.4.2-.7.6-.8l6.5-1c.4 0 .8.2.9.6v7.8c0 .4-.4.7-.8.7zM428 35.2V.8c0-.5-.3-.8-.7-.8h-.2l-6.4 1c-.4 0-.7.4-.7.8v35c0 1.6 0 11.8 12.3 12.2.5 0 .8-.4.8-.8V43c0-.4-.3-.7-.6-.8-4.5-.5-4.5-6-4.5-7zm106.5-21.8H528c-.4 0-.7.4-.7.8v34c0 .4.3.8.7.8h6.5c.4 0 .8-.4.8-.8v-34c0-.5-.4-.8-.8-.8zm-17.7 21.8V.8c0-.5-.3-.8-.8-.8l-6.5 1c-.4 0-.7.4-.7.8v35c0 1.6 0 11.8 12.3 12.2.4 0 .8-.4.8-.8V43c0-.4-.3-.7-.7-.8-4.4-.5-4.4-6-4.4-7zm-22.2-20.6a16.5 16.5 0 0 1 8.6 9.3c.8 2.2 1.3 4.8 1.3 7.5a19.4 19.4 0 0 1-4.6 12.6 14.8 14.8 0 0 1-5.2 3.6c-2 .9-5.2 1.4-6.8 1.4a21 21 0 0 1-6.7-1.4 15.4 15.4 0 0 1-8.6-9.3 21.3 21.3 0 0 1 0-14.4 15.2 15.2 0 0 1 8.6-9.3c2-.8 4.3-1.2 6.7-1.2s4.6.4 6.7 1.2zm-6.7 27.6c2.7 0 4.7-1 6.2-3s2.2-4.3 2.2-7.8-.7-6.3-2.2-8.3-3.5-3-6.2-3-4.7 1-6.1 3c-1.5 2-2.2 4.8-2.2 8.3s.7 5.8 2.2 7.8 3.5 3 6.2 3zm-88.8-28.8c-6.2 0-11.7 3.3-14.8 8.2a18.6 18.6 0 0 0 4.8 25.2c1.8 1.2 4 1.8 6.2 1.7s.1 0 .1 0h.9c4.2-.7 8-4 9.1-8.1v7.4c0 .4.3.7.8.7h6.4a.7.7 0 0 0 .7-.7V14.2c0-.5-.3-.8-.7-.8h-13.5zm6.3 26.5a9.8 9.8 0 0 1-5.7 2h-.5a10 10 0 0 1-9.2-14c1.4-3.7 5-6.3 9-6.3h6.4v18.3zm152.3-26.5h13.5c.5 0 .8.3.8.7v33.7c0 .4-.3.7-.8.7h-6.4a.7.7 0 0 1-.8-.7v-7.4c-1.2 4-4.8 7.4-9 8h-.1a4.2 4.2 0 0 1-.5.1h-.9a10.3 10.3 0 0 1-7-2.6c-4-3.3-6.5-8.4-6.5-14.2 0-3.7 1-7.2 3-10 3-5 8.5-8.3 14.7-8.3zm.6 28.4c2.2-.1 4.2-.6 5.7-2V21.7h-6.3a9.8 9.8 0 0 0-9 6.4 10.2 10.2 0 0 0 9.1 13.9h.5zM452.8 13.4c-6.2 0-11.7 3.3-14.8 8.2a18.5 18.5 0 0 0 3.6 24.3 10.4 10.4 0 0 0 13 .6c2.2-1.5 3.8-3.7 4.5-6.1v7.8c0 2.8-.8 5-2.2 6.3-1.5 1.5-4 2.2-7.5 2.2l-6-.3c-.3 0-.7.2-.8.5l-1.6 5.5c-.1.4.1.8.5 1h.1c2.8.4 5.5.6 7 .6 6.3 0 11-1.4 14-4.1 2.7-2.5 4.2-6.3 4.5-11.4V14.2c0-.5-.4-.8-.8-.8h-13.5zm6.3 8.2v18.3a9.6 9.6 0 0 1-5.6 2h-1a10.3 10.3 0 0 1-8.8-14c1.4-3.7 5-6.3 9-6.3h6.4zM291 31.5A32 32 0 0 1 322.8 0h30.8c.6 0 1.2.5 1.2 1.2v61.5c0 1.1-1.3 1.7-2.2 1l-19.2-17a18 18 0 0 1-11 3.4 18.1 18.1 0 1 1 18.2-14.8c-.1.4-.5.7-.9.6-.1 0-.3 0-.4-.2l-3.8-3.4c-.4-.3-.6-.8-.7-1.4a12 12 0 1 0-2.4 8.3c.4-.4 1-.5 1.6-.2l14.7 13.1v-46H323a26 26 0 1 0 10 49.7c.8-.4 1.6-.2 2.3.3l3 2.7c.3.2.3.7 0 1l-.2.2a32 32 0 0 1-47.2-28.6z"></path></svg>
			</a>
		</div>
	</div>
</script>

<script type="text/html" id="tmpl-autocomplete-empty">
	<div class="autocomplete-empty">
		No results matched your query 		<span class="empty-query">"{{ data.query }}"</span>
	</div>
</script>

<script type="text/javascript">
	window.addEventListener('load', function () {

		/* Initialize Algolia client */
		var client = algoliasearch( algolia.application_id, algolia.search_api_key );

		/**
		 * Algolia hits source method.
		 *
		 * This method defines a custom source to use with autocomplete.js.
		 *
		 * @param object $index Algolia index object.
		 * @param object $params Options object to use in search.
		 */
		var algoliaHitsSource = function( index, params ) {
			return function( query, callback ) {
				index
					.search( query, params )
					.then( function( response ) {
						callback( response.hits, response );
					})
					.catch( function( error ) {
						callback( [] );
					});
			}
		}

		/* Setup autocomplete.js sources */
		var sources = [];
		algolia.autocomplete.sources.forEach( function( config, i ) {
			var suggestion_template = wp.template( config[ 'tmpl_suggestion' ] );
			sources.push( {
				source: algoliaHitsSource( client.initIndex( config[ 'index_name' ] ), {
					hitsPerPage: config[ 'max_suggestions' ],
					attributesToSnippet: [
						'content:10'
					],
					highlightPreTag: '__ais-highlight__',
					highlightPostTag: '__/ais-highlight__'
				} ),
				debounce: config['debounce'],
				templates: {
					header: function () {
						return wp.template( 'autocomplete-header' )( {
							label: _.escape( config[ 'label' ] )
						} );
					},
					suggestion: function ( hit ) {
						if ( hit.escaped === true ) {
							return suggestion_template( hit );
						}
						hit.escaped = true;

						for ( var key in hit._highlightResult ) {
							/* We do not deal with arrays. */
							if ( typeof hit._highlightResult[ key ].value !== 'string' ) {
								continue;
							}
							hit._highlightResult[ key ].value = _.escape( hit._highlightResult[ key ].value );
							hit._highlightResult[ key ].value = hit._highlightResult[ key ].value.replace( /__ais-highlight__/g, '<em>' ).replace( /__\/ais-highlight__/g, '</em>' );
						}

						for ( var key in hit._snippetResult ) {
							/* We do not deal with arrays. */
							if ( typeof hit._snippetResult[ key ].value !== 'string' ) {
								continue;
							}

							hit._snippetResult[ key ].value = _.escape( hit._snippetResult[ key ].value );
							hit._snippetResult[ key ].value = hit._snippetResult[ key ].value.replace( /__ais-highlight__/g, '<em>' ).replace( /__\/ais-highlight__/g, '</em>' );
						}

						return suggestion_template( hit );
					}
				}
			} );

		} );

		/* Setup dropdown menus */
		document.querySelectorAll( algolia.autocomplete.input_selector ).forEach( function( element ) {

			var config = {
				debug: algolia.debug,
				hint: false,
				openOnFocus: true,
				appendTo: 'body',
				templates: {
					empty: wp.template( 'autocomplete-empty' )
				}
			};

			if ( algolia.powered_by_enabled ) {
				config.templates.footer = wp.template( 'autocomplete-footer' );
			}

			/* Instantiate autocomplete.js */
			var autocomplete = algoliaAutocomplete( element, config, sources )
				.on( 'autocomplete:selected', function ( e, suggestion ) {
					/* Redirect the user when we detect a suggestion selection. */
					window.location.href = suggestion.permalink ?? suggestion.posts_url; // Users use the `posts_url` property instead of `permalink`.
				} );

			/* Force the dropdown to be re-drawn on scroll to handle fixed containers. */
			window.addEventListener( 'scroll', function() {
				if ( autocomplete.autocomplete.getWrapper().style.display === "block" ) {
					autocomplete.autocomplete.close();
					autocomplete.autocomplete.open();
				}
			} );
		} );

		var algoliaPoweredLink = document.querySelector( '.algolia-powered-by-link' );
		if ( algoliaPoweredLink ) {
			algoliaPoweredLink.addEventListener( 'click', function( e ) {
				e.preventDefault();
				window.location = "https://www.algolia.com/?utm_source=WordPress&utm_medium=extension&utm_content=" + window.location.hostname + "&utm_campaign=poweredby";
			} );
		}
	});
</script>
<!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Join Page Pop-up 2 -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,100711,'fubyxwpk4oopvqhwrsby');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Why Transmission Electron Microscopy Is Key to Cell Line Characterization -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,100711,'w7kj5kqiiqeajpaa3f10');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Exploring Polycystic Kidney Disease Clinical Trials and New Treatments -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,100711,'xwrah1i4bjuvesesfpv3');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Profiling Biology at Scale with DRUG-seq: From Mechanisms to Safety -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,100711,'pblgldtmuwjnvhn0j8rx');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Maximum Fair Price Strategies for IPAY2027 Readiness -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,100711,'mskkaz3ry8wmw9zhyyl8');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Product Pages - Exit Popup -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,100711,'fsbuuhzpkou4tahw23xb');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Abandon Job Site - Full List -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,100711,'ztcdnovyu5c7l82j2et5');</script>
<!-- / OptinMonster --><!-- This site is converting visitors into subscribers and customers with OptinMonster - https://optinmonster.com :: Campaign Title: Abandon News -->
<script>(function(d,u,ac){var s=d.createElement('script');s.type='text/javascript';s.src='https://a.omappapi.com/app/js/api.min.js';s.async=true;s.dataset.user=u;s.dataset.campaign=ac;d.getElementsByTagName('head')[0].appendChild(s);})(document,100711,'snnftrequdjbpbhzmuts');</script>
<!-- / OptinMonster -->	<script type='text/javascript'>
		(function () {
			var c = document.body.className;
			c = c.replace(/woocommerce-no-js/, 'woocommerce-js');
			document.body.className = c;
		})();
	</script>
	
	<script type="text/javascript">
		window.WPCOM_sharing_counts = {"https:\/\/xtalks.com\/biotech-ipos-in-2024-navigating-the-new-wave-of-innovation-3709\/":130798};
	</script>
						<script type="text/javascript">
		var fubyxwpk4oopvqhwrsby_shortcode = true;var w7kj5kqiiqeajpaa3f10_shortcode = true;var xwrah1i4bjuvesesfpv3_shortcode = true;var pblgldtmuwjnvhn0j8rx_shortcode = true;var mskkaz3ry8wmw9zhyyl8_shortcode = true;var fsbuuhzpkou4tahw23xb_shortcode = true;var ztcdnovyu5c7l82j2et5_shortcode = true;var snnftrequdjbpbhzmuts_shortcode = true;		</script>
		<link rel='stylesheet' id='wc-stripe-blocks-checkout-style-css' href='https://xtalks.com/wp-content/plugins/woocommerce-gateway-stripe/build/upe-blocks.css?ver=a7aab132721a0ef865695d5cfdc746fb' type='text/css' media='all' />
<link rel='stylesheet' id='wc-blocks-style-css' href='https://xtalks.com/wp-content/plugins/woocommerce/assets/client/blocks/wc-blocks.css?ver=wc-9.9.5' type='text/css' media='all' />
<link rel='stylesheet' id='jetpack-responsive-videos-css' href='https://xtalks.com/wp-content/plugins/jetpack/jetpack_vendor/automattic/jetpack-classic-theme-helper/dist/responsive-videos/responsive-videos.css?minify=false&#038;ver=11ee3dcea6c676a3fed7' type='text/css' media='all' />
<link rel='stylesheet' id='gforms_reset_css-css' href='https://xtalks.com/wp-content/plugins/gravityforms/legacy/css/formreset.min.css?ver=2.9.11' type='text/css' media='all' />
<link rel='stylesheet' id='gforms_formsmain_css-css' href='https://xtalks.com/wp-content/plugins/gravityforms/legacy/css/formsmain.min.css?ver=2.9.11' type='text/css' media='all' />
<link rel='stylesheet' id='gforms_ready_class_css-css' href='https://xtalks.com/wp-content/plugins/gravityforms/legacy/css/readyclass.min.css?ver=2.9.11' type='text/css' media='all' />
<link rel='stylesheet' id='gforms_browsers_css-css' href='https://xtalks.com/wp-content/plugins/gravityforms/legacy/css/browsers.min.css?ver=2.9.11' type='text/css' media='all' />
<link rel='stylesheet' id='gform_basic-css' href='https://xtalks.com/wp-content/plugins/gravityforms/assets/css/dist/basic.min.css?ver=2.9.11' type='text/css' media='all' />
<link rel='stylesheet' id='gform_theme_components-css' href='https://xtalks.com/wp-content/plugins/gravityforms/assets/css/dist/theme-components.min.css?ver=2.9.11' type='text/css' media='all' />
<link rel='stylesheet' id='gform_theme-css' href='https://xtalks.com/wp-content/plugins/gravityforms/assets/css/dist/theme.min.css?ver=2.9.11' type='text/css' media='all' />
<script type="text/javascript" src="https://xtalks.com/wp-includes/js/jquery/ui/core.min.js?ver=1.13.3" id="jquery-ui-core-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/custom-start-date-for-woocommerce-subscriptions/js/js.js?ver=1770573771" id="wscsd_script-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-includes/js/jquery/ui/datepicker.min.js?ver=1.13.3" id="jquery-ui-datepicker-js"></script>
<script type="text/javascript" id="jquery-ui-datepicker-js-after">
/* <![CDATA[ */
jQuery(function(jQuery){jQuery.datepicker.setDefaults({"closeText":"Close","currentText":"Today","monthNames":["January","February","March","April","May","June","July","August","September","October","November","December"],"monthNamesShort":["Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"nextText":"Next","prevText":"Previous","dayNames":["Sunday","Monday","Tuesday","Wednesday","Thursday","Friday","Saturday"],"dayNamesShort":["Sun","Mon","Tue","Wed","Thu","Fri","Sat"],"dayNamesMin":["S","M","T","W","T","F","S"],"dateFormat":"MM d, yy","firstDay":1,"isRTL":false});});
/* ]]> */
</script>
<script type="text/javascript" src="https://widget.tagembed.com/embed.min.js?ver=6.5" id="__tagembed__embbedJs-js"></script>
<script type="text/javascript" id="tk-favorites-js-extra">
/* <![CDATA[ */
var TKF = {"nonce":"8c2a6c2e1c","admin_url":"https:\/\/xtalks.com\/wp-admin\/admin-ajax.php"};
/* ]]> */
</script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/tk-favorites/assets/js/public.js?ver=6.8.3" id="tk-favorites-js"></script>
<script type="text/javascript" id="citrix-integration-js-js-extra">
/* <![CDATA[ */
var CITRIX = {"ajaxurl":"https:\/\/xtalks.com\/wp-admin\/admin-ajax.php","nonce":"e2c978a576","current_screen":null,"post_id":"130798"};
/* ]]> */
</script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/wp-citrix-api/includes/assets/js/tk-citrix-integration.js?ver=1768247156" id="citrix-integration-js-js"></script>
<script type="text/javascript" id="xtk-appjs-js-extra">
/* <![CDATA[ */
var XTK = {"ajax_url":"https:\/\/xtalks.com\/wp-admin\/admin-ajax.php","current_user_id":"0","job_form_id":"20","sector_field_id":"36"};
/* ]]> */
</script>
<script type="text/javascript" src="https://xtalks.com/wp-content/themes/xtalks/assets/js/app.min.js?ver=1768247156" id="xtk-appjs-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/woocommerce/assets/js/sourcebuster/sourcebuster.min.js?ver=9.9.5" id="sourcebuster-js-js"></script>
<script type="text/javascript" id="wc-order-attribution-js-extra">
/* <![CDATA[ */
var wc_order_attribution = {"params":{"lifetime":1.0e-5,"session":30,"base64":false,"ajaxurl":"https:\/\/xtalks.com\/wp-admin\/admin-ajax.php","prefix":"wc_order_attribution_","allowTracking":true},"fields":{"source_type":"current.typ","referrer":"current_add.rf","utm_campaign":"current.cmp","utm_source":"current.src","utm_medium":"current.mdm","utm_content":"current.cnt","utm_id":"current.id","utm_term":"current.trm","utm_source_platform":"current.plt","utm_creative_format":"current.fmt","utm_marketing_tactic":"current.tct","session_entry":"current_add.ep","session_start_time":"current_add.fd","session_pages":"session.pgs","session_count":"udata.vst","user_agent":"udata.uag"}};
/* ]]> */
</script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/woocommerce/assets/js/frontend/order-attribution.min.js?ver=9.9.5" id="wc-order-attribution-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-includes/js/underscore.min.js?ver=1.13.7" id="underscore-js"></script>
<script type="text/javascript" id="wp-util-js-extra">
/* <![CDATA[ */
var _wpUtilSettings = {"ajax":{"url":"\/wp-admin\/admin-ajax.php"}};
/* ]]> */
</script>
<script type="text/javascript" src="https://xtalks.com/wp-includes/js/wp-util.min.js?ver=6.8.3" id="wp-util-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/wp-search-with-algolia/js/algoliasearch/dist/algoliasearch-lite.umd.js?ver=2.10.1" id="algolia-search-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/wp-search-with-algolia/js/autocomplete.js/dist/autocomplete.min.js?ver=2.10.1" id="algolia-autocomplete-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/wp-search-with-algolia/js/autocomplete-noconflict.js?ver=2.10.1" id="algolia-autocomplete-noconflict-js"></script>
<script>(function(d){var s=d.createElement("script");s.type="text/javascript";s.src="https://a.omappapi.com/app/js/api.min.js";s.async=true;s.id="omapi-script";d.getElementsByTagName("head")[0].appendChild(s);})(document);</script><script type="text/javascript" id="jetpack-stats-js-before">
/* <![CDATA[ */
_stq = window._stq || [];
_stq.push([ "view", JSON.parse("{\"v\":\"ext\",\"blog\":\"193900434\",\"post\":\"130798\",\"tz\":\"-5\",\"srv\":\"xtalks.com\",\"j\":\"1:14.8\"}") ]);
_stq.push([ "clickTrackerInit", "193900434", "130798" ]);
/* ]]> */
</script>
<script type="text/javascript" src="https://stats.wp.com/e-202606.js" id="jetpack-stats-js" defer="defer" data-wp-strategy="defer"></script>
<script type="text/javascript" src="https://xtalks.com/wp-includes/js/dist/vendor/wp-polyfill.min.js?ver=3.15.0" id="wp-polyfill-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-includes/js/dist/hooks.min.js?ver=4d63a3d491d11ffd8ac6" id="wp-hooks-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-includes/js/dist/i18n.min.js?ver=5e580eb46a90c2b997e6" id="wp-i18n-js"></script>
<script type="text/javascript" id="wp-i18n-js-after">
/* <![CDATA[ */
wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } );
/* ]]> */
</script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/jetpack/jetpack_vendor/automattic/jetpack-classic-theme-helper/dist/responsive-videos/responsive-videos.js?minify=false&amp;ver=11ee3dcea6c676a3fed7" id="jetpack-responsive-videos-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-includes/js/dist/dom-ready.min.js?ver=f77871ff7694fffea381" id="wp-dom-ready-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-includes/js/dist/a11y.min.js?ver=3156534cc54473497e14" id="wp-a11y-js"></script>
<script type="text/javascript" defer='defer' src="https://xtalks.com/wp-content/plugins/gravityforms/js/jquery.json.min.js?ver=2.9.11" id="gform_json-js"></script>
<script type="text/javascript" id="gform_gravityforms-js-extra">
/* <![CDATA[ */
var gform_i18n = {"datepicker":{"days":{"monday":"Mo","tuesday":"Tu","wednesday":"We","thursday":"Th","friday":"Fr","saturday":"Sa","sunday":"Su"},"months":{"january":"January","february":"February","march":"March","april":"April","may":"May","june":"June","july":"July","august":"August","september":"September","october":"October","november":"November","december":"December"},"firstDay":1,"iconText":"Select date"}};
var gf_legacy_multi = [];
var gform_gravityforms = {"strings":{"invalid_file_extension":"This type of file is not allowed. Must be one of the following:","delete_file":"Delete this file","in_progress":"in progress","file_exceeds_limit":"File exceeds size limit","illegal_extension":"This type of file is not allowed.","max_reached":"Maximum number of files reached","unknown_error":"There was a problem while saving the file on the server","currently_uploading":"Please wait for the uploading to complete","cancel":"Cancel","cancel_upload":"Cancel this upload","cancelled":"Cancelled"},"vars":{"images_url":"https:\/\/xtalks.com\/wp-content\/plugins\/gravityforms\/images"}};
var gf_global = {"gf_currency_config":{"name":"U.S. Dollar","symbol_left":"$","symbol_right":"","symbol_padding":"","thousand_separator":",","decimal_separator":".","decimals":2,"code":"USD"},"base_url":"https:\/\/xtalks.com\/wp-content\/plugins\/gravityforms","number_formats":[],"spinnerUrl":"https:\/\/xtalks.com\/wp-content\/plugins\/gravityforms\/images\/spinner.svg","version_hash":"e11576e0caefd9c5045644c6eaa8f0ea","strings":{"newRowAdded":"New row added.","rowRemoved":"Row removed","formSaved":"The form has been saved.  The content contains the link to return and complete the form."}};
var gf_global = {"gf_currency_config":{"name":"U.S. Dollar","symbol_left":"$","symbol_right":"","symbol_padding":"","thousand_separator":",","decimal_separator":".","decimals":2,"code":"USD"},"base_url":"https:\/\/xtalks.com\/wp-content\/plugins\/gravityforms","number_formats":[],"spinnerUrl":"https:\/\/xtalks.com\/wp-content\/plugins\/gravityforms\/images\/spinner.svg","version_hash":"e11576e0caefd9c5045644c6eaa8f0ea","strings":{"newRowAdded":"New row added.","rowRemoved":"Row removed","formSaved":"The form has been saved.  The content contains the link to return and complete the form."}};
/* ]]> */
</script>
<script type="text/javascript" defer='defer' src="https://xtalks.com/wp-content/plugins/gravityforms/js/gravityforms.min.js?ver=2.9.11" id="gform_gravityforms-js"></script>
<script type="text/javascript" defer='defer' src="https://www.google.com/recaptcha/api.js?hl=en&amp;ver=6.8.3#038;render=explicit" id="gform_recaptcha-js"></script>
<script type="text/javascript" defer='defer' src="https://xtalks.com/wp-content/plugins/gravityforms/js/placeholders.jquery.min.js?ver=2.9.11" id="gform_placeholder-js"></script>
<script type="text/javascript" defer='defer' src="https://xtalks.com/wp-content/plugins/gravityforms/assets/js/dist/utils.min.js?ver=eb348d779889cc6b85811dcec814f513" id="gform_gravityforms_utils-js"></script>
<script type="text/javascript" defer='defer' src="https://xtalks.com/wp-content/plugins/gravityforms/assets/js/dist/vendor-theme.min.js?ver=21e5a4db1670166692ac5745329bfc80" id="gform_gravityforms_theme_vendors-js"></script>
<script type="text/javascript" id="gform_gravityforms_theme-js-extra">
/* <![CDATA[ */
var gform_theme_config = {"common":{"form":{"honeypot":{"version_hash":"e11576e0caefd9c5045644c6eaa8f0ea"},"ajax":{"ajaxurl":"https:\/\/xtalks.com\/wp-admin\/admin-ajax.php","ajax_submission_nonce":"acae2afc38","i18n":{"step_announcement":"Step %1$s of %2$s, %3$s","unknown_error":"There was an unknown error processing your request. Please try again."}}}},"hmr_dev":"","public_path":"https:\/\/xtalks.com\/wp-content\/plugins\/gravityforms\/assets\/js\/dist\/","config_nonce":"1231749e64"};
/* ]]> */
</script>
<script type="text/javascript" defer='defer' src="https://xtalks.com/wp-content/plugins/gravityforms/assets/js/dist/scripts-theme.min.js?ver=66383ead18820aa88d13caee790853b0" id="gform_gravityforms_theme-js"></script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/optinmonster/assets/dist/js/helper.min.js?ver=2.16.19" id="optinmonster-wp-helper-js"></script>
<script type="text/javascript" id="sharing-js-js-extra">
/* <![CDATA[ */
var sharing_js_options = {"lang":"en","counts":"1","is_stats_active":"1"};
/* ]]> */
</script>
<script type="text/javascript" src="https://xtalks.com/wp-content/plugins/jetpack/_inc/build/sharedaddy/sharing.min.js?ver=14.8" id="sharing-js-js"></script>
<script type="text/javascript" id="sharing-js-js-after">
/* <![CDATA[ */
var windowOpen;
			( function () {
				function matches( el, sel ) {
					return !! (
						el.matches && el.matches( sel ) ||
						el.msMatchesSelector && el.msMatchesSelector( sel )
					);
				}

				document.body.addEventListener( 'click', function ( event ) {
					if ( ! event.target ) {
						return;
					}

					var el;
					if ( matches( event.target, 'a.share-linkedin' ) ) {
						el = event.target;
					} else if ( event.target.parentNode && matches( event.target.parentNode, 'a.share-linkedin' ) ) {
						el = event.target.parentNode;
					}

					if ( el ) {
						event.preventDefault();

						// If there's another sharing window open, close it.
						if ( typeof windowOpen !== 'undefined' ) {
							windowOpen.close();
						}
						windowOpen = window.open( el.getAttribute( 'href' ), 'wpcomlinkedin', 'menubar=1,resizable=1,width=580,height=450' );
						return false;
					}
				} );
			} )();
var windowOpen;
			( function () {
				function matches( el, sel ) {
					return !! (
						el.matches && el.matches( sel ) ||
						el.msMatchesSelector && el.msMatchesSelector( sel )
					);
				}

				document.body.addEventListener( 'click', function ( event ) {
					if ( ! event.target ) {
						return;
					}

					var el;
					if ( matches( event.target, 'a.share-facebook' ) ) {
						el = event.target;
					} else if ( event.target.parentNode && matches( event.target.parentNode, 'a.share-facebook' ) ) {
						el = event.target.parentNode;
					}

					if ( el ) {
						event.preventDefault();

						// If there's another sharing window open, close it.
						if ( typeof windowOpen !== 'undefined' ) {
							windowOpen.close();
						}
						windowOpen = window.open( el.getAttribute( 'href' ), 'wpcomfacebook', 'menubar=1,resizable=1,width=600,height=400' );
						return false;
					}
				} );
			} )();
var windowOpen;
			( function () {
				function matches( el, sel ) {
					return !! (
						el.matches && el.matches( sel ) ||
						el.msMatchesSelector && el.msMatchesSelector( sel )
					);
				}

				document.body.addEventListener( 'click', function ( event ) {
					if ( ! event.target ) {
						return;
					}

					var el;
					if ( matches( event.target, 'a.share-x' ) ) {
						el = event.target;
					} else if ( event.target.parentNode && matches( event.target.parentNode, 'a.share-x' ) ) {
						el = event.target.parentNode;
					}

					if ( el ) {
						event.preventDefault();

						// If there's another sharing window open, close it.
						if ( typeof windowOpen !== 'undefined' ) {
							windowOpen.close();
						}
						windowOpen = window.open( el.getAttribute( 'href' ), 'wpcomx', 'menubar=1,resizable=1,width=600,height=350' );
						return false;
					}
				} );
			} )();
/* ]]> */
</script>
<script type="text/javascript">
/* <![CDATA[ */
 gform.initializeOnLoaded( function() { jQuery(document).on('gform_post_render', function(event, formId, currentPage){if(formId == 15) {if(typeof Placeholders != 'undefined'){
                        Placeholders.enable();
                    }} } );jQuery(document).on('gform_post_conditional_logic', function(event, formId, fields, isInit){} ) } ); 
/* ]]> */
</script>
<script type="text/javascript">
/* <![CDATA[ */
 gform.initializeOnLoaded( function() {jQuery(document).trigger("gform_pre_post_render", [{ formId: "15", currentPage: "1", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( "gform_wrapper_15" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( "span" );            visibilitySpan.id = "gform_visibility_test_15";            gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( "gform_visibility_test_15" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 15, 1 );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } ); 
/* ]]> */
</script>
<script type="text/javascript">
/* <![CDATA[ */
 gform.initializeOnLoaded( function() { jQuery(document).on('gform_post_render', function(event, formId, currentPage){if(formId == 11) {if(typeof Placeholders != 'undefined'){
                        Placeholders.enable();
                    }} } );jQuery(document).on('gform_post_conditional_logic', function(event, formId, fields, isInit){} ) } ); 
/* ]]> */
</script>
<script type="text/javascript">
/* <![CDATA[ */
 gform.initializeOnLoaded( function() {jQuery(document).trigger("gform_pre_post_render", [{ formId: "11", currentPage: "1", abort: function() { this.preventDefault(); } }]);        if (event && event.defaultPrevented) {                return;        }        const gformWrapperDiv = document.getElementById( "gform_wrapper_11" );        if ( gformWrapperDiv ) {            const visibilitySpan = document.createElement( "span" );            visibilitySpan.id = "gform_visibility_test_11";            gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan );        }        const visibilityTestDiv = document.getElementById( "gform_visibility_test_11" );        let postRenderFired = false;        function triggerPostRender() {            if ( postRenderFired ) {                return;            }            postRenderFired = true;            gform.core.triggerPostRenderEvents( 11, 1 );            if ( visibilityTestDiv ) {                visibilityTestDiv.parentNode.removeChild( visibilityTestDiv );            }        }        function debounce( func, wait, immediate ) {            var timeout;            return function() {                var context = this, args = arguments;                var later = function() {                    timeout = null;                    if ( !immediate ) func.apply( context, args );                };                var callNow = immediate && !timeout;                clearTimeout( timeout );                timeout = setTimeout( later, wait );                if ( callNow ) func.apply( context, args );            };        }        const debouncedTriggerPostRender = debounce( function() {            triggerPostRender();        }, 200 );        if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) {            const observer = new MutationObserver( ( mutations ) => {                mutations.forEach( ( mutation ) => {                    if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) {                        debouncedTriggerPostRender();                        observer.disconnect();                    }                });            });            observer.observe( document.body, {                attributes: true,                childList: false,                subtree: true,                attributeFilter: [ 'style', 'class' ],            });        } else {            triggerPostRender();        }    } ); 
/* ]]> */
</script>
		<script type="text/javascript">var omapi_localized = {
			ajax: 'https://xtalks.com/wp-admin/admin-ajax.php?optin-monster-ajax-route=1',
			nonce: 'a5af991f04',
			slugs:
			{"fubyxwpk4oopvqhwrsby":{"slug":"fubyxwpk4oopvqhwrsby","mailpoet":false},"w7kj5kqiiqeajpaa3f10":{"slug":"w7kj5kqiiqeajpaa3f10","mailpoet":false},"xwrah1i4bjuvesesfpv3":{"slug":"xwrah1i4bjuvesesfpv3","mailpoet":false},"pblgldtmuwjnvhn0j8rx":{"slug":"pblgldtmuwjnvhn0j8rx","mailpoet":false},"mskkaz3ry8wmw9zhyyl8":{"slug":"mskkaz3ry8wmw9zhyyl8","mailpoet":false},"fsbuuhzpkou4tahw23xb":{"slug":"fsbuuhzpkou4tahw23xb","mailpoet":false},"ztcdnovyu5c7l82j2et5":{"slug":"ztcdnovyu5c7l82j2et5","mailpoet":false},"snnftrequdjbpbhzmuts":{"slug":"snnftrequdjbpbhzmuts","mailpoet":false}}		};</script>
				<script type="text/javascript">var omapi_data = {"object_id":130798,"object_key":"post","object_type":"post","term_ids":[32438,967,32445,969,970,962,6866,961,32437,32444,1783,473,9,10601,347,26047,1012],"wp_json":"https:\/\/xtalks.com\/wp-json","wc_active":true,"edd_active":false,"nonce":"21bc429df7"};</script>
		
</body>
</html>

<!-- This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me -->